
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            5′-Phosphorothioester Linked Cyclic Dinucleotides, Endo-S-CDNs, Displaying Impressive Antitumor Activities In Vivo when Dosed Subcutaneously - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E482AF8AEEDF530582AF0039A6A4D7.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="acsbmcau">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371493/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="ACS Bio &amp; Med Chem Au">
<meta name="citation_title" content="5′-Phosphorothioester Linked Cyclic Dinucleotides, Endo-S-CDNs, Displaying Impressive Antitumor Activities In Vivo when Dosed Subcutaneously">
<meta name="citation_author" content="Simpa K Yeboah">
<meta name="citation_author_institution" content="James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, United States">
<meta name="citation_author" content="Sagarika Meher">
<meta name="citation_author_institution" content="Department of Chemistry and Biochemistry, University of Notre Dame, 305A McCourtney Hall, Notre Dame, Indiana 46556, United States">
<meta name="citation_author" content="Haley Anne Harper">
<meta name="citation_author_institution" content="Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States">
<meta name="citation_author" content="Carli McMahan">
<meta name="citation_author_institution" content="Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States">
<meta name="citation_author" content="Bennett D Elzey">
<meta name="citation_author_institution" content="Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States">
<meta name="citation_author_institution" content="Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana 47907, United States">
<meta name="citation_author" content="Herman O Sintim">
<meta name="citation_author_institution" content="James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, United States">
<meta name="citation_author_institution" content="Department of Chemistry and Biochemistry, University of Notre Dame, 305A McCourtney Hall, Notre Dame, Indiana 46556, United States">
<meta name="citation_author_institution" content="Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States">
<meta name="citation_author_institution" content="Mike and Josie Harper Cancer Research Institute, 1234 N. Notre Dame Avenue, South Bend, Indiana 46617, United States">
<meta name="citation_publication_date" content="2025 Jun 6">
<meta name="citation_volume" content="5">
<meta name="citation_issue" content="4">
<meta name="citation_firstpage" content="665">
<meta name="citation_doi" content="10.1021/acsbiomedchemau.5c00070">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371493/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371493/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371493/pdf/bg5c00070.pdf">
<meta name="description" content="Cyclic dinucleotides (CDNs) have become popular as immunotherapies triggering an immune response achieved via their activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. Many analogs of 2′3′-cGAMP, c-di-GMP, ...">
<meta name="og:title" content="5′-Phosphorothioester Linked Cyclic Dinucleotides, Endo-S-CDNs, Displaying Impressive Antitumor Activities In Vivo when Dosed Subcutaneously">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Cyclic dinucleotides (CDNs) have become popular as immunotherapies triggering an immune response achieved via their activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. Many analogs of 2′3′-cGAMP, c-di-GMP, ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371493/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12371493">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1021/acsbiomedchemau.5c00070"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/bg5c00070.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12371493%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12371493/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12371493/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371493/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-acsbmcau.png" alt="ACS Bio &amp; Med Chem Au logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to ACS Bio &amp; Med Chem Au" title="Link to ACS Bio &amp; Med Chem Au" shape="default" href="https://pubs.acs.org/journal/abmcb8" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">ACS Bio Med Chem Au</button></div>. 2025 Jun 6;5(4):665–693. doi: <a href="https://doi.org/10.1021/acsbiomedchemau.5c00070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1021/acsbiomedchemau.5c00070</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22ACS%20Bio%20Med%20Chem%20Au%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22ACS%20Bio%20Med%20Chem%20Au%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22ACS%20Bio%20Med%20Chem%20Au%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22ACS%20Bio%20Med%20Chem%20Au%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>5′-Phosphorothioester
Linked Cyclic Dinucleotides,
Endo-S-CDNs, Displaying Impressive Antitumor Activities In Vivo when
Dosed Subcutaneously</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yeboah%20SK%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Simpa K Yeboah</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Simpa K Yeboah</span></h3>
<div class="p">
<sup>†</sup>
James
Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, 560
Oval Drive, West Lafayette, Indiana
47907, United States
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yeboah%20SK%22%5BAuthor%5D" class="usa-link"><span class="name western">Simpa K Yeboah</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Meher%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Sagarika Meher</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Sagarika Meher</span></h3>
<div class="p">
<sup>‡</sup>
Department
of Chemistry and Biochemistry, University
of Notre Dame, 305A McCourtney Hall, Notre Dame, Indiana
46556, United States
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Meher%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sagarika Meher</span></a>
</div>
</div>
<sup>‡</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Harper%20HA%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Haley Anne Harper</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Haley Anne Harper</span></h3>
<div class="p">
<sup>§</sup>
Purdue
University Center for Cancer Research, Purdue
University, West Lafayette, Indiana
47907, United States
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Harper%20HA%22%5BAuthor%5D" class="usa-link"><span class="name western">Haley Anne Harper</span></a>
</div>
</div>
<sup>§</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22McMahan%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Carli McMahan</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Carli McMahan</span></h3>
<div class="p">
<sup>§</sup>
Purdue
University Center for Cancer Research, Purdue
University, West Lafayette, Indiana
47907, United States
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22McMahan%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Carli McMahan</span></a>
</div>
</div>
<sup>§</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elzey%20BD%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Bennett D Elzey</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Bennett D Elzey</span></h3>
<div class="p">
<sup>§</sup>
Purdue
University Center for Cancer Research, Purdue
University, West Lafayette, Indiana
47907, United States
</div>
<div class="p">
<sup>∥</sup>
Department
of Comparative Pathobiology, Purdue University, West Lafayette, Indiana
47907, United States
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elzey%20BD%22%5BAuthor%5D" class="usa-link"><span class="name western">Bennett D Elzey</span></a>
</div>
</div>
<sup>§,</sup><sup>∥</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sintim%20HO%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Herman O Sintim</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Herman O Sintim</span></h3>
<div class="p">
<sup>†</sup>
James
Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, 560
Oval Drive, West Lafayette, Indiana
47907, United States
</div>
<div class="p">
<sup>‡</sup>
Department
of Chemistry and Biochemistry, University
of Notre Dame, 305A McCourtney Hall, Notre Dame, Indiana
46556, United States
</div>
<div class="p">
<sup>§</sup>
Purdue
University Center for Cancer Research, Purdue
University, West Lafayette, Indiana
47907, United States
</div>
<div class="p">
<sup>⊥</sup>
Mike
and Josie Harper Cancer Research Institute, 1234 N. Notre Dame Avenue, South Bend, Indiana
46617, United States
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sintim%20HO%22%5BAuthor%5D" class="usa-link"><span class="name western">Herman O Sintim</span></a>
</div>
</div>
<sup>†,</sup><sup>‡,</sup><sup>§,</sup><sup>⊥,</sup><sup>*</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>†</sup>
James
Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, 560
Oval Drive, West Lafayette, Indiana
47907, United States
</div>
<div id="aff2">
<sup>‡</sup>
Department
of Chemistry and Biochemistry, University
of Notre Dame, 305A McCourtney Hall, Notre Dame, Indiana
46556, United States
</div>
<div id="aff3">
<sup>§</sup>
Purdue
University Center for Cancer Research, Purdue
University, West Lafayette, Indiana
47907, United States
</div>
<div id="aff4">
<sup>∥</sup>
Department
of Comparative Pathobiology, Purdue University, West Lafayette, Indiana
47907, United States
</div>
<div id="aff5">
<sup>⊥</sup>
Mike
and Josie Harper Cancer Research Institute, 1234 N. Notre Dame Avenue, South Bend, Indiana
46617, United States
</div>
<div class="author-notes p"><div class="fn" id="cor1">
<sup>*</sup><p class="display-inline">
Email: <span>hsintim@nd.edu</span>.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 5; Accepted 2025 Jun 2; Revised 2025 May 30; Collection date 2025 Aug 20.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Authors. Published by American Chemical Society</div>
<p>This article is licensed under CC-BY-NC-ND 4.0</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12371493</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Cyclic dinucleotides (CDNs) have become popular as immunotherapies
triggering an immune response achieved via their activation of the
cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING)
pathway. Many analogs of 2′3′-cGAMP, c-di-GMP, and c-di-AMP
have been developed and shown as effective cancer vaccines and immuno-stimulators
for the induction of both the adaptive and innate immune systems.
Unfortunately, these CDNs have been dosed via intratumor route, which
is not convenient, especially for tumors that are difficult to reach.
We recently introduced endo-S-CDNs as potent STING agonists but in
our prior report we did not evaluate the in vivo efficacies of these
novel STING agonists. Herein, we conduct a more extensive structure
activity relationship study as well as in vivo evaluation of our best
endo-S-CDNs. We demonstrate that endo-S-CDNs can be dosed via subcutaneous
route to provide robust protection against MC38 and B16–F10
tumor models.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> STING, immunotherapy, cyclic dinucleotide analog, 5′-phosphorothioester linkage, PDE-stable, cancer</p></section></section><section class="abstract" id="abstract2"><hr class="headless">
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0020.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/9e28e49651cb/bg5c00070_0020.jpg" loading="lazy" height="276" width="651" alt="graphic file with name bg5c00070_0020.jpg"></a></p></section><section class="abstract" id="abstract3"><hr class="headless">
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0018.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/9e28e49651cb/bg5c00070_0018.jpg" loading="lazy" id="tgr1" height="276" width="651" alt="graphic file with name bg5c00070_0018.jpg"></a></p></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Immunotherapies are promising agents for
tackling cancer and they
can be used as standalone treatment, antitumor vaccines and vaccine
adjuvants.<em>
,
</em> Although immune-checkpoint blockade inhibitors
have revolutionized cancer treatment and boosted patient survival
across broad range of cancers, only a minority of patients respond
to these therapies.<em>
−

</em> Also, both primary and secondary resistance of these
blockade inhibitors pose a major clinical challenge.<em>
−

</em> For this reason, recent immunotherapy strategies have aimed at utilizing
pathways that can alter T-cell suppressed tumor microenvironments
(TME) into T-cell-infiltrated tumors, which are more susceptible to
checkpoint blockades. The cyclic GMP-AMP
synthase (cGAS)-stimulator of interferon genes (STING) pathway has
emerged as an exciting target for anticancer immunity; this pathway,
when activated, could turn ‘cold tumors’ into ‘hot
tumors’ by activating the tumor’s immunogenicity.</p>
<p>The cGAS-STING pathway plays an important role in sensing pathogen-associated
and damage-associated molecular patterns (PAMPs and DAMPs, respectively).<em>
−


</em> Following double-stranded DNA (dsDNA) detection in the cytoplasm,
cGAS synthesizes a cyclic dinucleotide known as 2′3′-cGAMP
(structure shown in <a href="#fig1" class="usa-link">Figure 
</a>) using ATP and GTP as substrates. 2′3′-cGAMP
has a unique 2′-5′ phosphodiester linkage mixed with
a conventional 3′–5′ phosphodiester linkage.<em>
,
</em> Binding of 2′3′-cGAMP to STING in the endoplasmic
reticulum (ER) leads to a conformational change, where the C-terminal
CDN binding domain (CTD) revolves relative to the N-terminal transmembrane
domain (NTD) subsequently engulfing 2′3′-cGAMP. This conformational change triggers STING’s
polymerization and eventual translocation from the ER to the Golgi
apparatus where it recruits other downstream effectors via the tank
binding kinase 1 (TBK1) and inhibitor of nuclear factor-κB kinase
(IKK). This leads to the production of
type I interferons (IFNs) as well as other pro-inflammatory cytokines
via activation of interferon regulatory factor 3 (IRF3) and nuclear
factor-κB (NF-κB).
</p>
<figure class="fig xbox font-sm" id="fig1"><h3 class="obj_head">1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/db135060fe13/bg5c00070_0001.jpg" loading="lazy" id="gr1" height="262" width="690" alt="1"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>CDN-based STING
agonist previously reported.</p></figcaption></figure><p>Type I IFNs are well established for promoting
robust antitumor,
antibacterial, and antiviral immunity. There is enormous evidence
that suggest innate immune cells such as dendritic cells (DCs) produce
type I IFNs and play a pivotal role in cancer immunosurveillance.
Also, type I IFN-controlled antitumor immunity is dependent on an
intact STING signaling pathway within the DC population. Therefore, STING agonism provides a platform
in developing immunotherapies, which could elicit robust and durable
antitumor immunity. In collaboration with Gravekamp’s group,
we were among the first to demonstrate that c-di-GMP, the bacterial-derived
CDN, activated STING in vivo to reduce 4T1 proliferation as well as
improving vaccination against a model of metastatic breast cancer.
</p>
<p>Indeed, CDN administered on its own or
in combination with other
therapies, such as checkpoint blockade, chimera antigen receptor T
cells (CAR-T cells) and radiation, has shown efficacious and synergistic
antitumor immunity.<em>
−


</em> However, poor cell permeability and rapid hydrolysis by plasma phosphodiesterases
(PDEs) drastically hinders 2′3′-cGAMP’s in vivo
utility. Hence, many synthetic 2′3′-cGAMP
analogs, which harbor PDE-resistant linkages, have been developed
with improved ADME properties.<em>
,−




</em> Although these analogs have shown in vivo efficacy, majority of
them are administered by intratumor injection, where these STING agonists
are delivered directly to the tumor site.<em>
,−




</em> Drawbacks of intratumor administration include: (i) its limitation
to patient population, (ii) excessive
leakage of CDNs from tumors into systemic circulation demonstrating
off-target hyperinflammation, and (iii)
the risk of overdosing a particular area where it was administered,
leading to an ablative effect in immune cells. In order to address these challenges we became interested
in developing CDN-based STING agonists that could be systemically
administered. This could alleviate the burden of cost, technical expertise
needed, and risk of infection during administration. We previously
reported endo-S-cGA<sub>F</sub>MP (<strong>3</strong>) and endo-S-cGA<sub>L</sub>MP (<strong>4</strong>) as potent STING agonists, which are stable to
clinically relevant phosphodiesterases like ectonucleotide phosphodiesterase
I (ENPP1) and poxvirus immune nucleases (poxin). Herein, we explore
a more thorough structural activity relationship (SAR) of the first-generation
endo-S-CDNs, focusing on both 2′3′-CDNs and 3′3′-CDNs,
and evaluate the best analogs activity and in vivo efficacy in MC-38
and B16–F10 tumor models.</p></section><section id="sec2"><h2 class="pmc_sec_title">Result and Discussion</h2>
<p>Interestingly, most CDN-based
STING agonists in clinical development
as immuno-oncology agents (for example ADU-S100, E7766, MK-1454, and
BI 7446 shown in <a href="#fig1" class="usa-link">Figure 
</a>) contain an exophosphorothioate modification, where a nonbridging
oxygen is replaced with sulfur. Notwithstanding
their effectiveness, this strategy produces a new P-chiral center
that is difficult to set and hence pose significant challenges in
purifying the synthesized diastereomers, leading to low synthetic
yields. Also, desulfurization of exophosphorothioate oligonucleotides
is prevalent during the cleavage and deprotection step using either
solid phase or solution phase synthesis (under aqueous ammonia in
the presence of trace amounts of Fe<sup>2+</sup>, Ni<sup>2+</sup>,
or Cr<sup>3+</sup>), and occurs readily in aqueous solution.<em>
,
</em> Hence, novel CDNs that are easier to synthesize with better synthetic
yields and retaining potency are highly desirable. Our group has previously
explored the synthesis of endo-S-CDN analogs where a 5′-bridging
oxygen of a phosphodiester is replaced with sulfur.<em>
,,,
</em> The phosphorus
on these endo-S-CDNs lacks chirality, hence alleviate the purification
and yield concerns posed by exophosphorothiate CDNs. We have shown
that such atomic editing confers cleavage resistance to phosphodiesterases
that degrade phosphodiester-containing cyclic dinucleotides.<em>
,
</em> We previously reported compound <strong>3</strong> as a STING agonist,
with in vitro activities against THP1 monocyte that were comparable
to ADU-S100 (a CDN that was evaluated in the clinic). In our earlier study, we did not evaluate the in vivo efficacy
of compound <strong>3</strong>. Here, we synthesized and tested various
analogs of compound <strong>3</strong> and we now show that compound <strong>3</strong> and another analog <strong>4</strong> show excellent efficacy
in MC38 and B16–F10 mouse tumor model when administered via
subcutaneous route.</p>
<section id="sec2.1"><h3 class="pmc_sec_title">Biological Methods and Assays</h3>
<p>In order to profile the
potency of our synthesized endo-S-CDNs, both biochemical and cellular
assays were used. To evaluate the binding affinity of hSTING (human
STING), we used the differential scanning fluorimetry (DSF) assay,
which measures the thermal shift (Δ<em>T</em>m shift)
upon binding of CDNs to hSTING. This assay assumes that the thermal
stability of CDN-hSTING complex corresponds with its binding affinity.
We confirmed the preliminary thermal shift binding results with a
hSTING fluorescence polarization (STING FP) assay previously reported
by us. This assay uses fluorescein labeled
c-di-GMP, which in the presence of strong STING binders is readily
displaced and exhibits low anisotropy but with poor binders it leads
to increased anisotropy. The effectiveness of CDNs to activate IRF
induction in THP1 monocytes and RAW macrophages was determined using
the QUANTI-Luc luminescence assay.</p></section><section id="sec2.2"><h3 class="pmc_sec_title">SAR Exploration</h3>
<p>For our SAR correlation we compared
the activities of all analogs synthesized (<strong>5–33</strong>) to 2′3′-cGAMP, ADU-S100, <strong>3</strong> and <strong>4</strong>. To account for the variation in activity that may arise
as a result of the increased ring size from changing a bridging oxygen
to a bridging sulfur, we decided to focus on both endo-S-2′3′-CDNs
and endo-S-3′3′-CDNs. A change of 3′–OH
in <strong>3</strong> to a hydrogen in <strong>5</strong> leads to a loss
in potency as evident from the STING binding and EC<sub>50</sub> determination
assays (see <a href="#tbl1" class="usa-link">Table 
</a>). Also, stemming from the effectiveness of <strong>3</strong>, we opted
to change the adenine moiety to cytidine, uridine and inosine as is
shown in <a href="#tbl1" class="usa-link">Table 
</a> for <strong>6</strong>, <strong>7</strong>, and <strong>8</strong> respectively. The DSF
result show that this change leads to a loss in binding affinity for
the pyrimidines as evident for <strong>6</strong> and <strong>7</strong> but
inosine retains binding potency as shown by <strong>8</strong> (endo-S-cGI<sub>F</sub>MP) having similar Δ<em>T</em>m value to ADU-S100
and <strong>3</strong> (see <a href="#tbl1" class="usa-link">Table 
</a>). <strong>8</strong> also exhibited better STING FP (IC<sub>50</sub> = 7.37 μM) than <strong>3</strong> (IC<sub>50</sub> = 13.97 μM)
and ADU-S100 (IC<sub>50</sub> = 12.8 μM) as well as approximately
4-fold lower EC<sub>50</sub> in the THP1 wildtype (WT) cellular assay
compared to 2′3′-cGAMP. <strong>8</strong> maintains potency
in THP1 KI STING R232 and RAW dual WT cells unlike 2′3′-cGAMP,
with comparable results to <strong>3</strong> and ADU-S100. A change of
the fluorine in <strong>8</strong> to hydrogen in <strong>9</strong> leads
to approximately 8-fold loss of EC<sub>50</sub> in THP1 monocytes.
In addition, modifying the adenine nucleobase in <strong>3</strong> to
an ethenoadenine base for <strong>10</strong>, results in reduced binding
and IRF induction in THP1 cells. Interestingly, altering the adenine
of <strong>3</strong> to a guanine in <strong>12</strong>, maintains potency
as well as STING binding. This shows all 2′-fluoro modified
endo-S-CDN analogs with natural purines as in <strong>3</strong> (adenosine), <strong>8</strong> (inosine), and <strong>12</strong> (guanosine) are all potent
STING agonists. This may be due to the ability of the purines to form
key hydrogen bonds as well as pi–pi interactions, which are
not accessible to pyrimidines. We attempted to improve cellular penetration
of our endo-S-CDNs by making an analog, <strong>13</strong>, where a charged
oxygen is replaced with a neutral methyl group. While this modification
leads to chirality at phosphorus, we could only isolate one isomer
out of the potential two diastereomers. In addition to the poor yield
of <strong>13</strong> (4%), initial evaluation of <strong>13</strong> indicated
it did not bind to STING and no THP1 activity was observed, thus there
was little impetus to continue spending resources to figuring out
which isomer (R or S at phosphorus) was obtained in <strong>13</strong>.</p>
<section class="tw xbox font-sm" id="tbl1"><h4 class="obj_head">1. Structure–Activity Relationship
of Endo-S-CDNs Varying Right-Hand Nucleobase With Ribose Substitution.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/b818eec6fb1d/bg5c00070_0009.jpg" loading="lazy" id="GRAPHIC-d14e497-autogenerated" height="272" width="498" alt="graphic file with name bg5c00070_0009.jpg"></p>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/ba05a502ef1d/bg5c00070_0010.jpg" loading="lazy" id="gr9" height="3888" width="3553" alt="graphic file with name bg5c00070_0010.jpg"></p>
<div class="p text-right font-secondary"><a href="table/tbl1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="t1fn1">
<sup>a</sup><p class="display-inline">Thermal shift assay to determine
STING binding.</p>
</div>
<div class="fn" id="t1fn2">
<sup>b</sup><p class="display-inline">Fluorescence
polarization assay
to determine binding affinity for analogs to STING.</p>
</div>
<div class="fn" id="t1fn3">
<sup>c</sup><p class="display-inline">Reporter assay in THP1 cells to
determine EC<sub>50</sub> values.</p>
</div>
<div class="fn" id="t1fn4">
<sup>d</sup><p class="display-inline">Reporter assay in RAW cells to determine
EC<sub>50</sub> values.</p>
</div>
</div></section><p>Next, we investigated changing the nucleobase of <strong>3</strong> from guanine to adenine and uridine while altering the right-hand
nucleobase (see <a href="#tbl2" class="usa-link">Table 
</a>). Though <strong>14</strong> is a close analog to ADU-S100, there is
a complete drop in efficacy as evident from thermal shift assay, STING
FP and cellular assays. Unfortunately, changing the adenine in <strong>14</strong> to guanine (<strong>15</strong>) and 2’–OH to
fluorine as in <strong>16</strong> only leads to a partial rescue of binding
as seen in <a href="#tbl2" class="usa-link">Table 
</a>.
We then explored changing the guanine in <strong>3</strong> to a uridine
moiety as in <strong>17</strong> and this substitution leads to loss in
activity. Interestingly, flipping the two bases of <strong>3</strong> as
in <strong>18</strong> rescues or retains some activity as shown by both
the STING binding assays and EC<sub>50</sub> determination (see <a href="#tbl2" class="usa-link">Table 
</a>). This shows that
the nature of the purine relative to 2′ and 3′ linkage
positions is pivotal for STING binding and activation. Next, we investigated
if substituting a charged oxygen for a methyl group can impact activity.
Just like <strong>13</strong>, this modification adds chirality at phosphorus,
and we could only isolate one of the isomers, <strong>19</strong>, in
a poor yield (3%). Unfortunately, this isomer was inactive, like results
for <strong>13</strong>, and hence no efforts were put into determining
the absolute chirality at phosphorus in <strong>19</strong>.</p>
<section class="tw xbox font-sm" id="tbl2"><h4 class="obj_head">2. Structure–Activity Relationship
of Endo-S-2′3′-CDNs Varying Both Nucleobases and Ribose
Substitution.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/995c1dd9df99/bg5c00070_0011.jpg" loading="lazy" id="GRAPHIC-d14e566-autogenerated" height="304" width="415" alt="graphic file with name bg5c00070_0011.jpg"></p>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/435024c2202f/bg5c00070_0012.jpg" loading="lazy" id="gr10" height="3051" width="3553" alt="graphic file with name bg5c00070_0012.jpg"></p>
<div class="p text-right font-secondary"><a href="table/tbl2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="t2fn1">
<sup>a</sup><p class="display-inline">Thermal shift assay to determine
STING binding.</p>
</div>
<div class="fn" id="t2fn2">
<sup>b</sup><p class="display-inline">Fluorescence
polarization assay
to determine binding affinity for analogs to STING.</p>
</div>
<div class="fn" id="t2fn3">
<sup>c</sup><p class="display-inline">Reporter assay in THP1 cells to
determine EC<sub>50</sub> values.</p>
</div>
<div class="fn" id="t2fn4">
<sup>d</sup><p class="display-inline">Reporter assay in RAW cells to determine
EC<sub>50</sub> values.</p>
</div>
</div></section><p>We have shown in a previous publication that locked
nucleic acid
(LNA) endo-S compound <strong>4</strong> is a potent STING agonist. Replacing the 3′–OH of <strong>4</strong> to hydrogen is detrimental to STING binding as shown for <strong>20</strong> (<a href="#tbl3" class="usa-link">Table 
</a>). Substituting
the guanine group in <strong>4</strong> to adenine, as in <strong>21</strong>, leads to a loss in STING binding and IRF activation in THP1. Also,
replacing the guanine in <strong>4</strong> to uridine, as in <strong>22</strong>, leads to a loss in activity, which suggests that for LNA endo-S-CDN,
the guanine moiety on the ribose unit bearing the noncanonical 2′-phosphorothioate
linkage might be essential for activity.</p>
<section class="tw xbox font-sm" id="tbl3"><h4 class="obj_head">3. Structure–Activity Relationship
of Analogs of <strong>4</strong>, Varying the Left Nucleobase or Ribose
Substitution.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/32706192ece3/bg5c00070_0013.jpg" loading="lazy" id="GRAPHIC-d14e617-autogenerated" height="324" width="498" alt="graphic file with name bg5c00070_0013.jpg"></p>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0014.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/f43bc60c43b6/bg5c00070_0014.jpg" loading="lazy" id="gr11" height="551" width="790" alt="graphic file with name bg5c00070_0014.jpg"></a></p>
<div class="p text-right font-secondary"><a href="table/tbl3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="t3fn1">
<sup>a</sup><p class="display-inline">Thermal shift assay to determine
STING binding.</p>
</div>
<div class="fn" id="t3fn2">
<sup>b</sup><p class="display-inline">Fluorescence
polarization assay
to determine binding affinity for analogs to STING.</p>
</div>
<div class="fn" id="t3fn3">
<sup>c</sup><p class="display-inline">Reporter assay in THP1 cells to
determine EC<sub>50</sub> values.</p>
</div>
<div class="fn" id="t3fn4">
<sup>d</sup><p class="display-inline">Reporter assay in RAW cells to determine
EC<sub>50</sub> values.</p>
</div>
</div></section><p>Next, we wanted to synthesize various sugar conformers
of <strong>3</strong> (changing the ribose group to either xylose or arabinose)
and probe activity with respect to STING binding and cellular activity.
Replacing the adenosine ribose group of <strong>3</strong> to a xylose
group in <strong>23</strong> completely alters and kills its potency as
shown in <a href="#tbl4" class="usa-link">Table 
</a>. Altering
the guanosine ribose of <strong>3</strong> to an arabinose sugar as in <strong>24</strong> improves the cellular profiles as evident from its performance
in THP1 and RAW cells (see <a href="#tbl4" class="usa-link">Table 
</a>). This result differs to what was observed in arabinose
and xylose modified 2′3′-cGAMP containing natural phosphodiester
linkages, where the xylose derivative still retains some of its binding
and cellular potency and arabinose 2′3′-cGAMP shows
a slightly better IRF activation compared to 2′3′-cGAMP. In our case the arabinose endo-S analog (<strong>24</strong>) shows STING binding and excellent cellular potency but
xylose modified endo-S analog (<strong>23</strong>) is a poor STING binder
and inactive in the THP1 IRF induction assay (<a href="#tbl4" class="usa-link">Table 
</a>). It appears that the properties of CDNs
containing the natural phosphodiester linkages cannot be readily extrapolated
to the endo-S CDNs, albeit the conservative change from 5′-phosphodiester
to a 5-phosphorothioester.</p>
<section class="tw xbox font-sm" id="tbl4"><h4 class="obj_head">4. Structure–Activity Relationship
of Analogs of <strong>3</strong> Containing Xylose and Arabinose-Substituted
Sugars.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0015.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/6beae6c4b8fb/bg5c00070_0015.jpg" loading="lazy" id="GRAPHIC-d14e676-autogenerated" height="128" width="682" alt="graphic file with name bg5c00070_0015.jpg"></a></p>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
</colgroup>
<thead>
<tr>
<th rowspan="2" align="center" colspan="1">CDN</th>
<th rowspan="2" align="center" colspan="1">DSF<sup></sup>Δ<em>T</em>m [K]</th>
<th rowspan="2" align="center" colspan="1">FP STING<sup></sup> IC<sub>50</sub> (<strong>μ</strong>M)</th>
<th colspan="2" align="center" rowspan="1">THP1 EC<sub>50</sub> (<strong>μ</strong>M) IRF
induction<sup></sup>
<hr>
</th>
<th rowspan="2" align="center" colspan="1">RAW dual
WT EC<sub>50</sub> (<strong>μ</strong>M)<sup></sup>
</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1">WT</th>
<th align="center" colspan="1" rowspan="1">KI STING
R232</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">2′3′cGAMP
(<strong>1)</strong>
</td>
<td align="center" colspan="1" rowspan="1">15.0</td>
<td align="center" colspan="1" rowspan="1">18.25 ± 0.98</td>
<td align="center" colspan="1" rowspan="1">15.47 ± 2.30</td>
<td align="center" colspan="1" rowspan="1">19.79 ± 0.88</td>
<td align="center" colspan="1" rowspan="1">70.067 ± 0.002</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ADU-S100 (<strong>2</strong>)</td>
<td align="center" colspan="1" rowspan="1">10.0</td>
<td align="center" colspan="1" rowspan="1">12.80 ± 0.26</td>
<td align="center" colspan="1" rowspan="1">4.08 ± 0.20</td>
<td align="center" colspan="1" rowspan="1">3.83 ± 0.65</td>
<td align="center" colspan="1" rowspan="1">13.646 ± 0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>3</strong> (endo-S-cGA<sub>F</sub>MP)</td>
<td align="center" colspan="1" rowspan="1">11.3</td>
<td align="center" colspan="1" rowspan="1">13.97 ± 1.68</td>
<td align="center" colspan="1" rowspan="1">2.45 ± 0.01</td>
<td align="center" colspan="1" rowspan="1">3.29 ± 0.21</td>
<td align="center" colspan="1" rowspan="1">5.54 ± 0.01</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>23</strong>
</td>
<td align="center" colspan="1" rowspan="1">2.0</td>
<td align="center" colspan="1" rowspan="1">&gt;25</td>
<td align="center" colspan="1" rowspan="1">&gt;50</td>
<td align="center" colspan="1" rowspan="1">N.D</td>
<td align="center" colspan="1" rowspan="1">N.D</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>24</strong>
</td>
<td align="center" colspan="1" rowspan="1">7.0</td>
<td align="center" colspan="1" rowspan="1">10.53 ± 1.99</td>
<td align="center" colspan="1" rowspan="1">1.57 ± 0.01</td>
<td align="center" colspan="1" rowspan="1">1.418 ± 0.001</td>
<td align="center" colspan="1" rowspan="1">0.886 ± 0.001</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="t4fn1">
<sup>a</sup><p class="display-inline">Thermal shift assay to determine
STING binding.</p>
</div>
<div class="fn" id="t4fn2">
<sup>b</sup><p class="display-inline">Fluorescence
polarization assay
to determine binding affinity for analogs to STING.</p>
</div>
<div class="fn" id="t4fn3">
<sup>c</sup><p class="display-inline">Reporter assay in THP1 cells to
determine EC<sub>50</sub> values.</p>
</div>
<div class="fn" id="t4fn4">
<sup>d</sup><p class="display-inline">Reporter assay in RAW cells to determine
EC<sub>50</sub> values.</p>
</div>
</div></section><p>Motivated by the activity of previously reported fluorinated
3′3′-CDNs,<em>
,,
</em> we sought to synthesize a library
of endo-S-3′3′CDNs and evaluate their activity in both
biochemical and cellular assays. Stemming from the activities of <strong>3</strong>, <strong>4</strong>, <strong>8</strong>, and <strong>12</strong> we
decided to focus on 3′–5′ phosphodiester CDNs
only having purines, 2′-fluorinated and 2′,4′-LNAs.
It is noteworthy that <strong>26</strong>, a 2′2′-difluorinated
endo-S-CDN bearing both guanine and adenine, had comparable STING
binding and low EC<sub>50</sub> as demonstrated by <strong>3</strong>, <strong>4</strong>, and <strong>8</strong>, with about 4-fold improvement over
2′3′-cGAMP in THP1 cells (see <a href="#tbl5" class="usa-link">Table 
</a>). Interestingly, flipping the position of
the nucleobases in <strong>26</strong>, as in <strong>27</strong>, leads to
a 2.5-fold reduction in THP1 WT activity although both compounds have
similar EC<sub>50</sub> values in RAW dual WT cells. 3′3′-cAIMPF<sub>2</sub>, shown in <a href="#fig1" class="usa-link">Figure 
</a>, is an ultrapotent STING agonist, which was previously developed
by Lioux et al. (invivogen). We made
the endo-S-CDN analogs of 3′3′-cAIMPF<sub>2</sub> (<strong>29</strong> and <strong>31</strong>) and evaluated their in vitro activity.
Unexpectedly, <strong>29</strong> and <strong>31</strong> completely lost
activity in both STING binding and THP1 assays (see <a href="#tbl5" class="usa-link">Table 
</a>), one more showing that the
replacement of a 5′-O bridging phosphodiester with a sulfur,
though a minimal change, is significant enough to completely abrogate
activity. Also, the endo-S-3′3′-CDN analogs of <strong>8</strong> (<strong>28</strong> and <strong>30</strong>) were inactive compounds.
Compound <strong>32</strong>, an endo-S difluorinated c-di-GMP show modest
binding as seen from its DSF and STING FP data (see <a href="#tbl5" class="usa-link">Table 
</a>). <strong>32</strong> also show
modest IRF induction in THP1 and RAW cells. In addition, <strong>33</strong> bearing two guanine bases with a fluoro group and locked nucleic
ribose could stabilize STING (Δ<em>T</em>m = 8°)
but did not show binding to the CDN site in STING (inferred from inability
to displace FAM-labeled c-di-GMP from STING, <a href="#tbl5" class="usa-link">Table 
</a>). In agreement with the STING FP assay, <strong>33</strong> had no activity in the THP IRF induction assay. We note
that while DSF is a good proxy for binding affinity, a positive thermal
shift does not always mean tighter binding and that a secondary confirmatory
assay (in this case the STING FP assay) is needed to confirm binding.
In summary, <strong>26</strong> showed the best STING binding and cellular
activity of all the endo-S-3′3′-CDNs we synthesized
and analyzed. Although fluorinated canonical 3′3′-CDNs
especially 3′3′-cAIMPF<sub>2</sub> (shown in <a href="#fig1" class="usa-link">Figure 
</a>) have good binding
and cellular activities their corresponding endo-S analogs lose that
potency as displayed in <a href="#tbl5" class="usa-link">Table 
</a>.</p>
<section class="tw xbox font-sm" id="tbl5"><h4 class="obj_head">5. Structure–activity Relationship
of endo-S-3′3′-CD ns With LNA and 2′-Fluorinated Ribose<sup></sup>
.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/c03f382065a3/bg5c00070_0016.jpg" loading="lazy" id="GRAPHIC-d14e957-autogenerated" height="246" width="643" alt="graphic file with name bg5c00070_0016.jpg"></p>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/18b390cba8c1/bg5c00070_0017.jpg" loading="lazy" id="gr12" height="3701" width="3554" alt="graphic file with name bg5c00070_0017.jpg"></p>
<div class="p text-right font-secondary"><a href="table/tbl5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="t5fn1">
<sup>a</sup><p class="display-inline">Thermal shift assay to determine
STING binding. Fluorescence polarization assay to determine binding
affinity for analogs to STING. Reporter assay in THP1 and RAW cells
to determine EC<sub>50</sub> values.</p>
</div></div></section></section><section id="sec2.3"><h3 class="pmc_sec_title">Docking <strong>3</strong>, <strong>23</strong>, and <strong>24</strong> to hSTING</h3>
<p>Encouraged by the improvement in binding (determined
by the FP assay) and cellular activity exhibited by arabinose-substituted
(<strong>24</strong>) over xylose-analog (<strong>23</strong>) and ribose-epimer
(<strong>3</strong>), we conducted a docking study to deduce if interactions
in the binding pocket of STING could explain this experimental trend.
Interestingly, our docking predicts the preferred binding pose of <strong>23</strong> (xylose derivative) is an open conformation as shown in <a href="#fig2" class="usa-link">Figure 
</a>B, while <strong>24</strong> and <strong>3</strong> adopts preferentially a closed conformation in
the binding pocket of STING (see <a href="#fig2" class="usa-link">Figure 
</a>) similar to the pose exhibited by MK-1454
bound to hSTING (PDB: <a href="https://www.rcsb.org/structure/7MHC" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">7MHC</a>). This conformation facilitates
binding to key amino acid residues with fewer steric clashes in STING’s
binding pocket. Also, noteworthy is that the best binding pose for <strong>23</strong> is flipped compared to that for <strong>3</strong> and <strong>24</strong> with its adenine portion binding in the pocket where the
guanine binds for both <strong>3</strong> and <strong>24</strong> (see <a href="#fig2" class="usa-link">Figure 
</a>D). Docking shows
these analogs all form key interactions with Tyr167, Arg238, Ser162,
and Thr263 (see <a href="#fig2" class="usa-link">Figure 
</a>), while Only <strong>3</strong> and <strong>24</strong> forms hydrogen bonding
with Thr269. Also, the 3′–OH of <strong>24</strong> is predicted
to form an additional hydrogen bond with the backbone amide of Leu159.
Docking was done with flare using PDB: <a href="https://www.rcsb.org/structure/7MHC" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">7MHC</a>. It is important to note that the activities
of <strong>3</strong>, <strong>23</strong>, and <strong>24</strong> may not be
solely based on binding to STING but also interaction with CDN-based
importers,<em>
−

</em> which traffic CDNs into mammalian cells.</p>
<figure class="fig xbox font-sm" id="fig2"><h4 class="obj_head">2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/6737bfdd16d5/bg5c00070_0002.jpg" loading="lazy" id="gr2" height="704" width="643" alt="2"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Docking of
close endo-S-CDN analogs showing key interaction with
amino acids in STING’s binding pocket (A) docking of <strong>3</strong> to STING’s binding pocket, (B) docking of <strong>23</strong> to STING’s binding pocket, (C) docking of <strong>24</strong> to STING’s binding pocket. Docking was performed using Flare
from PDB: <a href="https://www.rcsb.org/structure/7MHC" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">7MHC</a>. (D) Overlap of the best pose of <strong>3</strong>, <strong>23</strong>, and <strong>24</strong> in the binding pocket of STING.</p></figcaption></figure><p>STING activation results in downstream signaling
leading to the
transcription and expression of type I interferons and proinflammatory
cytokines like CXCL10, TNFα, and IFNβ.<em>
,−




</em> CXCL10 is highly inducted by interferons and NF-κB, and is
the major chemokine that recruits CD8+ T lymphocytes to clear and
regress expanding tumors.<em>
,
</em> Hence, we sought to
evaluate these three tumor-associated cytokines in THP1 cells. Real-time
quantitative PCR (RT-qPCR) analysis after treatment with CDNs shows
that <strong>3</strong> (approximately 100-fold upregulation as compared
to nontreated control) and <strong>8</strong> (roughly showing 400-fold
induction vs nontreated control) induce the mRNA expression of CXCL10
at 10 μM (see <a href="#fig3" class="usa-link">Figure 
</a>A) while marginally upregulating the transcription of both
TNFα and IFNβ (see <a href="#fig3" class="usa-link">Figure 
</a>B,C). However, it still performed better than 2′3′-cGAMP
in upregulating TNFα and IFNβ as shown in <a href="#fig3" class="usa-link">Figure 
</a>B,C. Also, <strong>3</strong> and <strong>8</strong> after treatment in PBMCs at 40 μM induce the expression
of TNFα compared to 2′3′-cGAMP (see <a href="#fig3" class="usa-link">Figure 
</a>D).</p>
<figure class="fig xbox font-sm" id="fig3"><h4 class="obj_head">3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/7578c9042ae2/bg5c00070_0003.jpg" loading="lazy" id="gr3" height="556" width="693" alt="3"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Comparison of induction
of some proinflammatory cytokines in either
THP1 cells or PMBC. (A) mRNA expression levels of CXCL10 in THP1 cells.
(B) mRNA expression levels of TNFα in THP1 cells. (C) mRNA expression
levels of IFNβ in THP1 cells. (D) Expression of TNFα in
PMBCs after treatment with endo-S-CDNs as quantified using an ELISA
assay. The mRNA expression levels were determined by real-time quantitative
PCR (RT-qPCR). Statistical significance was performed using Students <em>t</em>-test (paired, one-tailed) with significant differences
as * <em>P</em> ≤ 0.05.</p></figcaption></figure></section><section id="sec2.4"><h3 class="pmc_sec_title">In Vivo Efficacy of <strong>3</strong>, <strong>4</strong>, and <strong>8</strong> in Mice Tumor Models</h3>
<p>CDNs may induce ablative effect
depending on cell-type and intratumor (IT) injection provides these
CDNs at high concentration within the tumor microenvironment (TME)
and this could induce a cytotoxic effect on T cells within this region. Also, intratumor administration of CDN-based
STING agonist may not have an effect on metastasized tumors that have
moved to distal regions of the body where the CDN was not injected.
Hence, intravenous (IV) and subcutaneous (SubQ or SC) dosing could
be adequate administration routes for STING agonist with the caveat
of having a good therapeutic profile with no safety concerns. To develop
these CDN-based STING agonist for systemic administration, these compounds
should show little or no systemic hyperinflammation and should not
overstimulate the immune machinery in normal cells but also be able
to recruit and modulate different players that could elicit tumor
suppression as well as reach distal tumors. We sought to investigate
the antitumor activity of our potent STING agonist in vivo and chose
MC38 and B16–F10 mouse tumor models. While the majority of
in vivo studies with STING agonists utilized IT dosing, ALG-031048,
a CDN-based compound with a north-methanocarba sugar modification,
when dosed SubQ could reduce MC38-hPD-L1tumor, albeit modestly. Another carbocyclic containing STING agonist,
developed by Takeda scientists, displayed in vivo efficacy when dosed
via intravenous route. Thus, we wanted
to investigate and compare the efficacy when endo-S-CDNs were dosed
via SubQ and IT. For systemic administration, we preferred SubQ over
IV dosing because SubQ is easier to implement than IV. Pleasingly,
in the MC38 mice model, SubQ dosing of <strong>3</strong> provides robust
protection against MC38 tumor growth (see <a href="#fig4" class="usa-link">Figure 
</a>). Dosing was done every three days for four
times within the study period. <strong>3</strong> was dosed at 10 mg/kg
for SubQ while IT dosing was at 100 μg initially and then 50
μg for the last three regimen. IT dosing of <strong>4</strong> and <strong>8</strong> was also at 100 μg for first administration and then
changed to 50 μg for subsequent dosing. These compounds and
the respective mode of administration did not affect the body weight
of mice as can be seen in <a href="https://pubs.acs.org/doi/suppl/10.1021/acsbiomedchemau.5c00070/suppl_file/bg5c00070_si_001.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Figure S2</a>A (see <a href="https://pubs.acs.org/doi/suppl/10.1021/acsbiomedchemau.5c00070/suppl_file/bg5c00070_si_001.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supporting Information</a>). Indeed, in the clinical
setting, most CDN-based STING agonists, such as E7766, ADU-S100 (MIW815),
have been reported to be reasonably tolerated (fever and fatigue being
most adverse events) at concentrations that provided stable disease
or tumor reduction.<em>
,
</em> Even in the case of ADU-S100,
a maximum tolerated dose could not be reached in patients with metastatic
disease.<em>
,
</em>
</p>
<figure class="fig xbox font-sm" id="fig4"><h4 class="obj_head">4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0004.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/637c4df2e035/bg5c00070_0004.jpg" loading="lazy" id="gr4" height="837" width="693" alt="4"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>In vivo efficacy of endo-S-CDNs in MC38 mouse
model. (A) Chemical
structures of compounds <strong>3</strong>, <strong>4</strong>, and <strong>8</strong>. (B) Plot of tumor volume against days after treatment of
CDN regimen began. (C) Image of tumors at the end of the study. (D)
Tumor growth curves of individual animals: in vehicle (blue), <strong>3</strong> IT dosed (red), <strong>3</strong> SubQ dosed (green), <strong>4</strong> IT dosed (purple) and <strong>8</strong> IT dosed (orange).
Statistical significance was performed using Students <em>t</em>-test (paired, one-tailed) with nonsignificant and significant differences
as follows: ns <em>P</em> &gt; 0.05, *** <em>P</em> ≤
0.001, and **** <em>P</em> ≤ 0.0001. The significance
on each group is in relationship with vehicle unless otherwise stated
in <a href="#fig4" class="usa-link">Figure 
</a>A.</p></figcaption></figure><p>Pleasingly, the endo-S CDNs displayed good antitumor
activities.
The image of tumor after the end of the study is shown in <a href="#fig4" class="usa-link">Figure 
</a>C, and analysis of
respective tumor growth of each animal during the study is shown in <a href="#fig4" class="usa-link">Figure 
</a>D. Due to the encouraging
initial in vivo results obtained with the endo-S analogs, we wanted
to investigate if <strong>3</strong>, <strong>4</strong>, and <strong>8</strong> were efficacious when dosed via SubQ in a B16–F10 mouse model.
This time around we decided to compare only <strong>3</strong> via IT.
Pleasingly, all three analogs dosed subcutaneously show antitumor
efficacy with <strong>4</strong> outperforming <strong>3</strong> and <strong>8</strong> (see <a href="#fig5" class="usa-link">Figure 
</a>B–D). <strong>3</strong> showed better antitumor immunity when
dosed subcutaneously than when administered via IT. Also, the treatment
of all endo-S-CDNs did not significantly affect the body weight of
mice in this study (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsbiomedchemau.5c00070/suppl_file/bg5c00070_si_001.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Figure S2</a>B, Supporting
Information). We currently do not know why in the case of the B16–F10
model, the SubQ dosing led to a better tumor reduction than IT dosing
but we speculate that the mode of administration may have distinctive
mechanism in activating T cells and other players to cause antitumor
immunity and hence variation in the efficacy of <strong>3</strong> when
dosed by either SubQ or IT. In fact others have shown that systemic
administration of STING agonists can adequately lead to tumor shrinkage,
probably via the activation of dendritic and T cells in spleens and/or
tumor draining lymph nodes.<em>
,
</em> Even in the case of
IT administration of STING agonists, which is predicated on local
activation of the STING pathway in TME, some leakage of the STING
agonist into systemic circulation is still possible. Thus, even for
IT administration, the contribution of systemic activation of the
immune system toward tumor reduction cannot be ignored. A potential
complication of IT administration of STING agonists is the possibility
of altered T-cell signaling or induced
T cell death at high STING agonist concentration within the TME, which
could lead to a reduction in T cell number and hence reduced efficacy.<em>
,,
</em>
</p>
<figure class="fig xbox font-sm" id="fig5"><h4 class="obj_head">5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0005.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/c1896fc9de26/bg5c00070_0005.jpg" loading="lazy" id="gr5" height="804" width="693" alt="5"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>In vivo efficacy of endo-S-CDNs in B16–F10
mouse model.
(A) Chemical structures of compounds <strong>3</strong>, <strong>4</strong>, and <strong>8</strong>. (B) Plot of tumor volume against days after
treatment of CDN regimen began. (C) Image of tumors at the end of
the study. (D) Tumor growth curves of individual animals: in vehicle
(blue), <strong>3</strong> IT dosed (red), <strong>4</strong> SubQ dosed (purple), <strong>3</strong> SubQ dosed (green), and <strong>8</strong> SubQ dosed (orange).
Statistical significance was performed using Students <em>t</em>-test (paired, one-tailed) with nonsignificant and significant differences
as follows: ns <em>P</em> &gt; 0.05, ** <em>P</em> ≤
0.01, and *** <em>P</em> ≤ 0.001. The significance
on each group in <a href="#fig5" class="usa-link">Figure 
</a>A is in relationship with vehicle unless otherwise stated.</p></figcaption></figure><p>STING activation can lead to direct cancer cell
death,<em>
,
</em> so we tested these endo-S-CDNs in vitro
against both MC38 and B16–F10
cells to determine if the in vivo efficacy data was partly due to
their ability to induce cell death in these cancer cells. Compounds <strong>3</strong>, <strong>4</strong>, and <strong>8</strong> do not kill MC38 and
B16–F10 cells in vitro (see <a href="https://pubs.acs.org/doi/suppl/10.1021/acsbiomedchemau.5c00070/suppl_file/bg5c00070_si_001.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Figure S1</a>). This suggests that the tumor shrinking ability of the compounds
in vivo is likely via extrinsic mechanism, i.e. the endo-S-CDN compounds
likely activate STING to recruit the immune machinery of the mice
to suppress the tumor growth. Future work, beyond the scope of the
current study, would aim to elucidate the mechanism by which these
endo-S-CDNs provide robust protection against tumors when dosed via
SubQ as this may provide insight into how the efficacy of STING agonists
may depend on route of administration. We note that most CDN-based
STING agonists trialed in the clinic were dosed via IT or IV; our
data suggest that the mode of compound administration in these trials
should be revisited.</p></section><section id="sec2.5"><h3 class="pmc_sec_title">Synthetic Preparation of Endo-S-CDNs</h3>
<p>Conventionally,
most CDNs are prepared via H-phosphonate chemistry, which involves
one-pot synthesis developed by Jones and co-workers. This method entails the cyclization of 5′-O deprotected
dinucleotide containing an H-phosphonate moiety using 2-chloro-5,5-dimethyl-1′3′2-dioxaposphorinane-2-oxide
(DMOCP). This cyclization step is not efficient and leads to overall
poor yields of CDNs. To make endo-S-CDNs we use an underutilized approach
initially developed by Kool and co-workers on solid phase, and later adapted by us for the preparation
of endo-S-c-di-GMP and analogs via solution phase and solid phase,
respectively.<em>
,
</em> This approach is a multistep
synthesis where the penultimate step is a reaction with ammonium hydroxide
which is both a global deprotection and macrocyclization step. This
synthesis strategy has better yield than CDNs made via the Jones’
method. To synthesize the xylose (<strong>23</strong>) and arabinose (<strong>24</strong>) modified endo-S-CDNs, we use an approach disclosed by
Xie et al., where the hydroxy group of
the protected nucleoside <strong>34a</strong> and <strong>35a</strong>, respectively,
is converted to a good leaving group via triflation using triflic
anhydride and DMAP, subsequently followed by nucleophilic attack with
sodium trifluoroacetate (NaOTFA) to invert the configuration of the
2′- (arabinose) and 3′- (xylose) hydroxy group. This
is illustrated in <a href="#sch1" class="usa-link">Schemes 
</a> and , showing the synthesis of <strong>23</strong> (xylose modification) and <strong>24</strong> (arabinose modification),
respectively. <a href="#sch3" class="usa-link">Scheme 
</a> describes the synthesis of methyl phosphonate linked endo-S-CDNs.
The synthesis of the other endo-S-CDNs is described in the <a href="https://pubs.acs.org/doi/suppl/10.1021/acsbiomedchemau.5c00070/suppl_file/bg5c00070_si_001.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supporting Information</a>.</p>
<figure class="fig xbox font-sm" id="sch1"><h4 class="obj_head">1. Synthetic Preparation
of <strong>23</strong>
.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/633c3b286a49/bg5c00070_0006.jpg" loading="lazy" id="gr6" height="3269" width="3990" alt="1"></p>
<div class="p text-right font-secondary"><a href="figure/sch1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><figure class="fig xbox font-sm" id="sch2"><h4 class="obj_head">2. Synthetic Preparation of <strong>24</strong>
.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371493_bg5c00070_0007.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/9947cae0703f/bg5c00070_0007.jpg" loading="lazy" id="gr7" height="685" width="788" alt="2"></a></p>
<div class="p text-right font-secondary"><a href="figure/sch2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><figure class="fig xbox font-sm" id="sch3"><h4 class="obj_head">3. Synthesis of Methyl Phosphonate Linked endo-S-CDN <strong>13</strong> and <strong>19</strong>
.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48e/12371493/10768cd0c430/bg5c00070_0008.jpg" loading="lazy" id="gr8" height="2329" width="3831" alt="3"></p>
<div class="p text-right font-secondary"><a href="figure/sch3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section></section><section id="sec3"><h2 class="pmc_sec_title">Conclusion</h2>
<p>To conclude, though numerous CDN-based STING
agonist have been
developed with impressive in vivo activity in mouse models, their
preferred mode of administration has been via intratumoral route.
Most clinical studies of these agonist are via intratumor (IT) injection
and as combo therapy with immune checkpoint blockades. This mode of
administration is limited for a localized population and might have
ablative effect on T cells at high concentration, hence more systemic
dosing options is needed in developing STING agonists for cancer immunotherapy.
We have identified endo-S-CDNs STING agonist, which are efficacious
when dosed via subcutaneous route. These compounds do not lead to
weight loss or abnormal animal behavior, when dosed subcutaneously
and they are efficacious as a standalone therapeutic in mouse models.
In some instances, same compound dosed subcutaneously had better efficacy
in suppressing tumor growth than when they were administered intratumorally.
These CDN analogs hold promise for cancer immunotherapy and further
preclinical studies are needed to evaluate their utility in the clinic
and if they could synergize with other modalities, such as CAR T cell,
anti-PD1 and anti-CTLA4 therapies.</p></section><section id="sec4"><h2 class="pmc_sec_title">Experimental Section</h2>
<section id="sec4.1"><h3 class="pmc_sec_title">Biological Methods and Materials</h3>
<p>For all biological
assays and in vivo experiments, CDNs were dissolved in water. Sodium
salts of the respective endo-S-CDNs were used for all in vivo studies.</p>
<section id="sec4.1.1"><h4 class="pmc_sec_title">Protein Expression and Purification</h4>
<p>STING plasmid was
received from Prof Pingwei Li’s lab. After plasmid transformation
into BL21 (DE3), the
BL21 cells where cultured in LB media (10 mL) with 50 μg/mL
of selection antibiotics (kanamycin and chloramphenicol). After overnight
culturing, the 10 mL culture was inoculated into a 1L TB culture and
supplemented with 50 μg/mL of both chloramphenicol and kanamycin.
After attaining an OD of 0.6, 1 mM IPTG was added to induce STING
expression and then the culture was incubated at 16 °C for 16
h. After incubation, the culture was collected via centrifugation
at 5000 rpm for 30 min. Lysis buffer (50 mM Na<sub>3</sub>PO<sub>4</sub>, 300 mM NaCl, 20 mM imidazole, 5 mM β-mercaptoethanol (βME),
10% glycerol, pH = 7.4, and 1 mM phenylmethylsulfonyl fluoride) was
added to the collected pellets. Lysis was achieved by sonication,
and STING mixture was collected (supernatant) via centrifugation at
22,000 rpm for 25 min at 4 °C. STING was purified using a nickel
His-trap column with a gradient of imidazole in the wash and elution
buffers. The purified protein was dialyzed overnight at 4 °C
and its concentration was estimated via UV–vis spectrometry
at 280 nm wavelength (ε for STING = 47955 M<sup>–1</sup> cm<sup>–1</sup>).</p></section><section id="sec4.1.2"><h4 class="pmc_sec_title">Differential Scanning Fluorimetry Assay or Thermal Shift Assay</h4>
<p>To a solution of 150 μM CDNs in water was added to 20 μM
of STING in a buffer (100 mM Tris–HCl, pH = 7.4, 150 mM NaCl)
and 1:500 (v/v) SYPRO orange. Denaturation was done using a real time
PCR (RT-PCR) cycler with a temperature gradient from 15 to 80 °C
(increasing 1 °C per every 15 s).</p>
<table class="disp-formula p" id="uneq1"><tr><td class="formula"><math id="d1e1463" display="block" overflow="linebreak"><mi mathvariant="normal">Δ</mi><mi>T</mi><mi mathvariant="normal">m</mi><mo>=</mo><msub><mi>T</mi><mi>y</mi></msub><mo>−</mo><msub><mi>T</mi><mi>x</mi></msub></math></td></tr></table>
<p>Δ<em>T</em>m values were
reported by subtracting the average denaturing temperature (<em>T</em>
<sub>
<em>x</em>
</sub>) determined for the untreated
STING from the temperature (<em>T</em>
<sub>
<em>y</em>
</sub>) determined for treatment with CDNs.</p></section><section id="sec4.1.3"><h4 class="pmc_sec_title">hSTING Fluorescence Polarization (FP) Assay</h4>
<p>The fluorescence
assay was adapted form Karanja et al. and as previously used by Yeboah et al.
</p></section><section id="sec4.1.4"><h4 class="pmc_sec_title">EC<sub>50</sub> Determination in THP1 Dual WT, THP1 STING KI
R232, and RAW Dual WT Cells</h4>
<p>THP1 dual WT and THP1 KI STING
R232 cells (from invivogen) were grown in RPMI media supplemented
1× penicillin/streptomycin (1× pen/strep) and 10% fetal
bovine serum (FBS) in a 37 °C incubator (5% CO2) while RAW dual
WT was cultured in DMEM media supplemented with 1x pen/strep and 10%
FBS. After passaging and allowing to grow to confluence, all cell
lines were seeded at a concentration 5 × 105 cells per ml in
96 well plates. After 24 h incubation at 37 °C cells were treated
with CDNs ranging from concentration of 50 nM to 100 μM in triplicates
to determine EC<sub>50</sub> values. After incubating for 24 h, IRF
induction was deduced using QUANTI-Luc reagent (using manufacturer
protocol), and the results were analyzed via Graph Pad Prism using
the dose–response 4-point model.</p></section><section id="sec4.1.5"><h4 class="pmc_sec_title">Docking Analysis</h4>
<p>MK-1454 bound to hSTING, PDB: <a href="https://www.rcsb.org/structure/7MHC" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">7MHC</a>, crystal structure
was obtained from RCSB Protein Data Bank and were prepared using the
Protein Preparation Wizard; Flare Cresset. Ligands <strong>3</strong>, <strong>23</strong>, and <strong>24</strong> were exported as mol2 files and then
imported to Flare, version 9.0 and prepared for docking using Ligand
Preparation protocol. Docking was run using the “Very Accurate
but Slow” method by centering at 4.0 Å on precrystallized
MK-1454. For all three analogs, the best pose was selected for comparison.
Contact maps and images were then generated with Flare, version 9.0,
Cresset, Litlington, Canbridgeshire, UK: <a href="http://www.cresser-group.com/flare/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.cresser-group.com/flare/</a>
</p></section><section id="sec4.1.6"><h4 class="pmc_sec_title">Real-Time Quantitative PCR (RT-qPCR)</h4>
<p>The mRNA levels
of some cytokines were quantified using RT-PCR (RT-qPCR). THP1 WT
cells were seeded at a concentration of 1.5 × 10<sup>6</sup> cells
per ml in 6 well plates and after 24 h, CDNs were treated at either
5 μM of <strong>3</strong> and 10 μM of all CDNs including <strong>3</strong>, with 2′3′-cGAMP used as a positive control.
After 24 h incubation, cells were collected via centrifugation and
total RNA was isolated using the trizol reagent method. After total
RNA isolation, cDNA synthesis was performed using Superscript first
strand synthesis system (per manufacturer protocol). Next, the synthesized
cDNA was used for RT-PCR using the QuantiTect SYBR Green PCR kit performed
on a CFX96 real-time system, with both forward and reverse primers
of respective cytokines. RT-PCR primers used are listed in the supplementary.
The mRNA expression levels were estimated according to the formula
(2<sup>–ΔΔCq</sup>) using GAPDH as an internal
reference gene and normalized to the water-treated cells. Technical
replicates were in triplicates and biological replicates were in duplicates. <em>p</em> &lt; 0.05 was statistically significant using <em>t</em>-test. RT-qPCR primers of target cytokine genes and internal
control gene are listed below.</p>
<section class="tw xbox font-sm" id="array1"><div class="tbl-box p" tabindex="0"><table class="content">
<tr>
<td align="left" colspan="1" rowspan="1">Primer name</td>
<td align="left" colspan="1" rowspan="1">Sequence</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IFN-β-F</td>
<td align="left" colspan="1" rowspan="1">AACAAGTGTCTCCTCCAAAT</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IFN-β-R</td>
<td align="left" colspan="1" rowspan="1">TCTCCTCAGGGATGTCAAAG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CXCL10-F</td>
<td align="left" colspan="1" rowspan="1">CATTCTGATTTGCTGCCTTAT</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CXCL10-R</td>
<td align="left" colspan="1" rowspan="1">TTGATGGCCTTCGATTCTGG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TNF-α-F</td>
<td align="left" colspan="1" rowspan="1">TGAAAGCATGATCCGGGACG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TNF-α-R</td>
<td align="left" colspan="1" rowspan="1">AGGCAGAAGAGCGTGGTGGC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GADPH-F</td>
<td align="left" colspan="1" rowspan="1">GGACCTGACCTGCCGTCTA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GAPDH-R</td>
<td align="left" colspan="1" rowspan="1">GAGTGGGTGTCGCTGTTGA</td>
</tr>
</table></div>
<div class="p text-right font-secondary"><a href="table/array1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="sec4.1.7"><h4 class="pmc_sec_title">TNFα Quantification after Peripheral Blood Mononuclear
Cells (PMBCs) Were Treated with CDNs</h4>
<p>PMBCs were purchased
from ATCC (catalog number: PCS-800-011) . After successful passaging
cells were incubated in RPMI media supplemented with 1× pen/strep
and 10% FBS. PMBC Cells were seeded at 5 × 10<sup>5</sup> cells
in 96 well plates for 24 h in previously described incubation conditions.
CDNs were treated at 40 μM, after 24 h cells were applied on
human TNF alpha ELISA research reagent kit Picokine (from Boster Bio)
per manufacturer’s instruction. Experiments were done in triplicates
and data was analyzed via GraphPad prism. CDNs were treated in triplicates
and 2′3′-cGAMP as well as ADU-S100 was used as a positive
control while water was used as negative control.</p></section><section id="sec4.1.8"><h4 class="pmc_sec_title">Cell Viability Experiment (GI<sub>50</sub> Determination)</h4>
<p>MC38 and B16–F10 cells were seeded in 96-well plates. After
24 h incubation at 37 °C under 5% CO<sub>2</sub>, CDNs were treated
varying concentration from 50 nM to 40 μM. At 72 h incubation,
10 μL of CellTiter-Blue cell viability reagent (Promega) was
added and later incubated for 3 h. MC38 and B16–F10 cells where
only treated at 10 μM, 20 μM and 40 μM of the compounds.
Fluorescence (λ<sub>ex</sub>/λ<sub>em</sub> = 560/590
nm) was read using Biotek Cytation 5 multimode reader. Experiments
were done in triplicates and the cell viability were normalized to
the water treated cells for respective cell lines.</p></section><section id="sec4.1.9"><h4 class="pmc_sec_title">Animal Experiments</h4>
<p>All the procedures related to animal
handling, care and the treatment in this study were performed according
to the guidelines approved by the Institutional Animal Care and Use
Committee (IACUC) of BioDuro (MC38 tumor model) and Purdue University
(B16–F10 tumor model) following the guidance of the Association
for Assessment and Accreditation of Laboratory Animal Care (AAALAC).</p></section><section id="sec4.1.10"><h4 class="pmc_sec_title">Efficacy of endo-S-CDN in MC38 Tumor Model</h4>
<p>The sodium
salts of the respective endo-S-CDNs were used for this study. MC38
cells were cultured in DMEM medium supplemented with 10% heat-inactivated
FBS, 1× pen/strep at 37 °C in an atmosphere of 5% CO<sub>2</sub>. 5 × 10<sup>5</sup> MC38 cells were suspended in 100
μL unsupplemented DMEM medium with 50% matrix gel and inoculated
subcutaneously into the right flank of C57BL/6 female mice. When the
tumor volume reached a size of approximately 72 mm<sup>3</sup>, mice
were randomly subgrouped according to body weight and tumor volume
and administered vehicle (PBS) and respective endo-S-CDN either intratumorally
or subcutaneously. Each subgroup had six tumor-bearing mice. The tumor
volume was measured twice a week with caliper and volume was reported
in mm<sup>3</sup> using the formula: V = 0.5 <em>a</em> x <em>b</em>
<sup>2</sup>, where a and b are the long and short diameters
of the tumor, respectively. Animals with tumor size larger than 2000
mm<sup>3</sup> were euthanized.</p></section><section id="sec4.1.11"><h4 class="pmc_sec_title">Efficacy of endo-S-CDN in B16–F10 Tumor Model</h4>
<p>The sodium salts of the endo-S-CDNs were used for this study. B16–F10
cells were cultured in DMEM medium supplemented with 10% FBS and 1×
pen/strep at 37 °C in an atmosphere of 5% CO<sub>2</sub>. 5 ×
10<sup>5</sup> cells were suspended in 100 μL unsupplemented
DMEM medium and inoculated subcutaneously into the right flank of
C57BL/6 female mice. When the tumor volume reached a size of approximately
100 mm<sup>3</sup>, mice were randomly grouped according to body weight
and tumor volume and administered vehicle (PBS) and respective endo-S-CDN
either intratumorally or subcutaneously. Each group had six tumor-bearing
mice for a total of 36 mice. The tumor volume was measured with caliper
and volume was expressed in units of mm<sup>3</sup> using the formula:
V = 0.52 <em>a</em> × <em>b</em> × c. Animals
were euthanized on day 15 postinoculation. A two-way ANOVA was performed
to compare the tumor volume was analyzed using GraphPad prism. <em>p</em> &lt; 0.05 was statistically significant.</p></section></section></section><section id="sec5"><h2 class="pmc_sec_title">Chemistry</h2>
<section id="sec5.1"><h3 class="pmc_sec_title">General Synthetic Information</h3>
<p>Unless otherwise stated,
all reagents and solvents were purchased from commercial suppliers
and used as received without purification. The <sup>1</sup>H, <sup>31</sup>P and <sup>13</sup>C NMR spectra were obtained in methanol-<em>d</em>
<sub>4</sub> or D<sub>2</sub>O as solvent using either
a 500 or 800 MHz spectrometer. Tetramethylsilane was used as an internal
standard. Flash or column chromatography using silica gel (230–400
mesh) for purification of intermediates. All final compounds were
purified via RP-HPLC. The cyclic dinucleotide synthesized were either
isolated as a triethylammonium salt or proton salt. Coupling constants
(<em>J</em> values) reported in Hz. All final compounds were
characterized by <sup>1</sup>H, <sup>31</sup>P and <sup>13</sup>C
NMR, and high-resolution mass spectrometry (HRMS) data. All intermediates
were also characterized via ESI–MS using Advion Mass Spectrometer.
HRMS was done for all final compounds (ESI).</p>
<section id="sec5.1.1"><h4 class="pmc_sec_title">Synthesis of <em>N</em>-(9-((2<em>R</em>,3<em>R</em>,4<em>S</em>,5<em>R</em>)-5-((Bis­(4-methoxyphenyl)­(phenyl)­methoxy)­methyl)-3-Fluoro-4-Hydroxytetrahydrofuran-2-yl)-9<em>H</em>-purin-6-yl)­benzamide (<strong>34b</strong>)</h4>
<p>To 2
g of 5′-DMT-2′-fluoro-<em>N</em>
<sup>6</sup>-benzoyladenosine (<strong>34a</strong>, 2.56 mmol) was added DMAP (7.69
mmol, 3 equiv) and then DCM was used to dissolve the solid mixture
(30 mL). This solution was cooled on ice before triflic anhydride
(3.84 mmol, 1.5 equiv) was slowly added and the reaction mix was left
to stir for 45 min 70 mL of diethyl ether and 30 mL of 2% acetic acid
was added and separated after extraction. Another 30 mL of 2% acetic
acid was added again to wash the organic layer. 5% NaHCO<sub>3</sub> (30 mL) and water was used to back extract the diethyl ether layer.
The organic layer was concentrated via reduced pressure and subsequently
reconcentrated with acetonitrile (10 mL, 3×). Thirty ml of DMF
was used to dissolve the crude product and then sodium trifluoroacetate
(12.8 mmol, 5 equiv) was added. After 18 h, the mixture was heated
to 55–60 °C for 3 h to ensure complete inversion to the
xylose epimer, <strong>34b</strong>. After the reaction was complete,
the mixture was slowly added to a solution of 5% NaHCO<sub>3</sub> (50 mL) and water (50 mL) to precipitate the solids and then later
filtered to isolate the product. The crude product was then purified
via column chromatography to give <strong>34b</strong> (1.3 g). ESI–MS: <em>m</em>/<em>z</em> = 678.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> δ) 8.86–8.62 (m, 2H),
8.22 (d, <em>J</em> = 6.3 Hz, 2H), 8.12–7.93 (m, 3H),
7.64–7.57 (m, 2H), 7.51 (td, <em>J</em> = 7.9, 2.4
Hz, 3H), 7.46–7.40 (m, 1H), 7.36–7.27 (m, 6H), 7.27–7.18
(m, 4H), 7.18–7.13 (m, 4H), 6.86–6.75 (m, 6H), 5.79
(dd, <em>J</em> = 3.8, 1.3 Hz, 1H), 4.75–4.69 (m, 1H),
4.40–4.31 (m, 3H), 4.13–4.04 (m, 2H), 4.00 (dd, <em>J</em> = 12.9, 2.8 Hz, 1H), 3.81–3.74 (m, 9H), 3.61 (d, <em>J</em> = 4.9 Hz, 1H), 2.16 (s, 1H), 1.33–1.27 (m, 3H),
1.27–1.22 (m, 2H), 0.96 (dd, <em>J</em> = 6.8, 1.3
Hz, 3H), 0.90 (d, <em>J</em> = 2.4 Hz, 5H), 0.89–0.84
(m, 11H), 0.08 (s, 3H), −0.12 (d, <em>J</em> = 2.3
Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126 MHz): δ 164.73,
158.63, 158.55, 152.32, 150.39, 149.97, 147.38, 144.50, 142.87, 139.51,
135.66, 133.35, 133.02, 130.07, 130.01, 129.16, 128.93, 128.12, 127.94,
127.85, 127.80, 127.07, 126.89, 123.42, 113.20, 113.16, 92.80, 91.36,
86.86, 83.14, 82.30, 81.59, 81.54, 81.46, 77.96, 77.30, 77.05, 76.79,
61.87, 55.26, 55.22, 34.68, 31.60, 25.67, 25.58, 25.29, 22.67, 17.95,
17.85, 14.14, −4.73, −5.09.</p></section><section id="sec5.1.2"><h4 class="pmc_sec_title">Synthesis of (2<em>R</em>,3<em>S</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-Purin-9-Yl)-2-((Bis­(4-methoxyphenyl)­(phenyl)­methoxy)­methyl)-4-Fluorotetrahydrofuran-3-Yl
(2-Cyanoethyl) Diisopropylphosphoramidite (<strong>35b</strong>)</h4>
<p>Two grams of 5′-DMT-3′-OTBS-isobutylguanosine (<strong>35a</strong>, 2.59 mmol) used as substrate to synthesize <strong>35b</strong> similar to the procedure used to synthesize <strong>34b</strong>. ESI–MS: <em>m</em>/<em>z</em> = 770.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> δ) 7.51–7.42 (m, 3H),
7.37 (d, <em>J</em> = 8.9 Hz, 5H), 7.16 (s, 5H), 6.83 (d, <em>J</em> = 8.9 Hz, 9H), 4.43–4.40 (m, 2H), 4.09–4.06
(m, 1H), 3.99 (td, <em>J</em> = 4.2, 2.2 Hz, 1H), 1.27 (d, <em>J</em> = 6.9 Hz, 8H), 1.24 (dd, <em>J</em> = 6.9, 5.4
Hz, 6H), 0.94 (s, 7H), 0.90–0.87 (m, 12H), 0.17 (d, <em>J</em> = 9.3 Hz, 5H), 0.12 (s, 3H), 0.06 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 126 MHz): δ 158.65, 147.34, 147.04,
139.48, 130.08, 129.15, 128.30, 127.86, 127.78, 127.09, 113.18, 86.70,
81.46, 78.97, 77.29, 77.03, 76.78, 55.26, 36.46, 31.60, 25.83, 25.63,
22.67, 19.04, 18.82, 18.73, 18.07, 18.00, 14.13, −4.55, −4.84.</p></section><section id="sec5.1.3"><h4 class="pmc_sec_title">Synthesis of (2<em>R</em>,3<em>S</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-Purin-9-Yl)-2-((Bis­(4-methoxyphenyl)­(phenyl)­methoxy)­methyl)-4-Fluorotetrahydrofuran-3-Yl
(2-Cyanoethyl) Diisopropylphosphoramidite (<strong>34c</strong>)</h4>
<p>
<strong>34b</strong> (1.10 g, 1.62 mmol) was sealed, degassed and dry
DCM (10 mL), dry DIPEA (1.21 mmol, 1.1 equiv), NMI (1.21 mmol, 1.1
equiv) and 2-cyanoethyl <em>N,N-</em>diisopropyl-chlorophosphoramidite
(3.63 mmol, 3.3 equiv) was added and then vacuumed and argon was bubbled
through solution to create an inert atmosphere. After 1 h reaction
was quenched with 5 mL methanol and the product was concentrated to
an oil and immediately purified via column chromatography (gradient
Hexane/Ethyl acetate 100%/0% to 30%/70%). ESI–MS: <em>m</em>/<em>z</em> = 876.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(500 MHz, CDCl<sub>3</sub> δ) 9.30 (s, 1H), 8.81 (dd, <em>J</em> = 11.9, 2.6 Hz, 1H), 8.15 (dt, <em>J</em> = 6.7,
1.8 Hz, 1H), 8.02 (d, <em>J</em> = 7.6 Hz, 2H), 7.61–7.57
(m, 1H), 7.51 (dd, <em>J</em> = 7.7, 2.5 Hz, 2H), 7.50–7.46
(m, 3H), 7.36 (ddd, <em>J</em> = 8.8, 6.2, 3.2 Hz, 4H), 7.29–7.26
(m, 1H), 7.25–7.20 (m, 1H), 6.83 (ddd, <em>J</em> =
13.3, 6.6, 4.9 Hz, 4H), 6.51–6.43 (m, 1H), 5.42 (d, <em>J</em> = 29.1 Hz, 1H), 4.71 (tt, <em>J</em> = 7.5, 3.6
Hz, 1H), 4.59–4.49 (m, 1H), 3.87–3.83 (m, 1H), 3.83–3.73
(m, 8H), 3.71–3.61 (m, 2H), 3.59–3.48 (m, 2H), 3.48–3.40
(m, 1H), 3.36 (dd, <em>J</em> = 10.3, 2.8 Hz, 1H), 3.31–3.17
(m, 2H), 2.54 (ddt, <em>J</em> = 6.2, 3.7, 2.0 Hz, 1H), 2.35
(q, <em>J</em> = 5.8 Hz, 2H), 1.33 (dd, <em>J</em> = 6.5, 2.1 Hz, 2H), 1.30–1.18 (m, 2H), 1.04 (ddd, <em>J</em> = 16.5, 6.8, 2.4 Hz, 6H), 0.89 (dd, <em>J</em> = 6.8, 2.5 Hz, 3H), 0.82 (dd, <em>J</em> = 7.1, 2.5 Hz,
4H). <sup>31</sup>P NMR (203 MHz, CDCl<sub>3</sub>) δ 152.21,
150.34. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 164.85,
164.76, 158.59, 152.87, 152.75, 151.16, 149.46, 144.53, 144.48, 141.30,
135.89, 135.82, 135.66, 133.67, 132.78, 130.16, 130.12, 130.09, 130.05,
130.00, 128.90, 128.83, 128.25, 128.14, 127.94, 127.90, 127.01, 126.94,
123.20, 122.91, 118.21, 117.26, 117.18, 113.19, 98.23, 96.73, 88.75,
88.46, 88.33, 88.04, 86.66, 86.59, 83.30, 75.85, 74.14, 74.04, 62.60,
62.18, 58.71, 58.55, 57.98, 57.83, 57.69, 55.28, 55.24, 46.69, 43.22,
43.12, 43.02, 24.55, 24.50, 24.35, 24.15, 21.46, 20.15, 20.09, 19.07,
19.02.</p></section><section id="sec5.1.4"><h4 class="pmc_sec_title">Synthesis of (2<em>R</em>,3<em>S</em>,4<em>R</em>,5<em>R</em>)-5-((Bis­(4-Methoxyphenyl)­(phenyl)­methoxy)­methyl)-4-((<em>tert</em>-Butyldimethylsilyl)­oxy)-2-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-Purin-9-Yl)­tetrahydrofuran-3-yl (2-cyanoethyl) Diisopropylphosphoramidite
(<strong>35c</strong>)</h4>
<p>
<strong>35c</strong> was synthesized from <strong>35b</strong> using the same procedure as the synthesis of <strong>34c</strong>. ESI–MS: <em>m</em>/<em>z</em> = 971.2 [M
+ H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> δ)
7.86 (s, 1H), 7.82 (s, 1H), 7.58 (d, <em>J</em> = 5.2 Hz,
2H), 7.51 (s, 1H), 7.45–7.39 (m, 4H), 7.32 (s, 4H), 7.29 (dd, <em>J</em> = 8.9, 2.1 Hz, 5H), 7.25–7.21 (m, 2H), 7.20–7.13
(m, 2H), 7.06 (t, <em>J</em> = 1.2 Hz, 2H), 6.88 (t, <em>J</em> = 1.4 Hz, 2H), 6.81 (ddd, <em>J</em> = 9.7, 4.9,
2.7 Hz, 5H), 6.79–6.75 (m, 3H), 6.31 (s, 1H), 6.25 (dd, <em>J</em> = 9.4, 5.2 Hz, 2H), 4.36–4.32 (m, 2H), 4.31 (s,
1H), 4.19 (td, <em>J</em> = 6.2, 2.8 Hz, 2H), 4.15–4.09
(m, 3H), 4.08–4.01 (m, 4H), 3.87 (t, <em>J</em> = 6.4
Hz, 2H), 3.55–3.46 (m, 4H), 3.36–3.29 (m, 6H), 2.77–2.73
(m, 3H), 2.69 (t, <em>J</em> = 6.4 Hz, 3H), 2.63–2.56
(m, 5H), 2.03 (s, 1H), 1.35 (dd, <em>J</em> = 6.5, 3.5 Hz,
14H), 1.26 (t, <em>J</em> = 7.1 Hz, 19H), 1.24–1.20
(m, 15H), 0.98 (dd, <em>J</em> = 9.2, 6.8 Hz, 13H), 0.92–0.88
(m, 15H), 0.82 (d, <em>J</em> = 2.9 Hz, 9H), 0.74 (d, <em>J</em> = 6.7 Hz, 3H), 0.16 (d, <em>J</em> = 3.1 Hz, 3H),
0.13 (s, 1H), 0.08 (d, <em>J</em> = 2.5 Hz, 3H), 0.06 (s,
1H), −0.02 (s, 1H), −0.04 (s, 2H). <sup>31</sup>P NMR
(203 MHz, CDCl3) δ 2.49. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 158.59, 148.00, 144.45, 139.49, 136.56, 130.08,
129.14, 128.22, 127.82, 127.77, 127.04, 123.90, 121.16, 118.47, 117.69,
113.13, 77.29, 77.04, 76.79, 58.59, 57.58, 55.23, 46.63, 34.84, 29.68,
25.72, 25.66, 21.49, 20.13, 20.08, 19.01, 17.90, −3.56, −4.92.</p></section><section id="sec5.1.5"><h4 class="pmc_sec_title">Synthesis of <em>O</em>-((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((<em>Tert</em>-Butyldimethylsilyl)­oxy)-5-(Hydroxymethyl)-2-(2-Isobutyramido-6oxo-1,6-Dihydro-9<em>H</em>-Purin-9-Yl)­tetrahydrofuran-3-yl) <em>O</em>,<em>O</em>-bis­(2-cyanoethyl) Phosphorothioate (<strong>II</strong>)</h4>
<p>Cyanolethanol (0.40 mL, 5.5 mmol) was added to guanosine (<em>n</em>-ibu) 3′-tBDSilyl CED phosphoramidite or <strong>I</strong> (from Chemgenes, 1.06 g, 1.09 mmol) in anhydrous MeCN (15 mL) under
argon. After stirring for 10 min at room temperature, dicyanoimidazole
(0.472 g, 4.0 mmol) was added to the reaction mixture and stirred
for 16 h under argon at RT. Beaucage reagent was added to the reaction
mixture and left to stir for an hour. The reaction was quenched with
Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (30 mL, 1 M solution) and
subsequently extracted 3× using DCM (30 mL). After drying under
reduced pressure, the crude product was redissolved in DCM (20 mL)
and DCA (1 mL, 12.2 mmol) was added dropwise and left to stir for
10 min. Saturated NaHCO<sub>3</sub> (30 mL) was added to quench the
reaction, and the aqueous layer was extracted 3x using DCM (30 mL).
After concentrating under reduced pressure, the crude product was
purified via column chromatography (silica gel, gradient 10–100%
ethyl acetate in hexanes) to afford 0.5 g of <strong>II</strong>. ESI–MS: <em>m</em>/<em>z</em> = 670.8 [M + H]<sup>+</sup>. 1H NMR
(500 MHz, MeOD) δ 8.34 (s, 1H), 6.23 (d, <em>J</em> =
7.6 Hz, 1H), 5.44 (ddd, <em>J</em> = 12.6, 7.6, 4.7 Hz, 1H),
4.57 (d, <em>J</em> = 4.7 Hz, 1H), 4.23 (ddt, <em>J</em> = 10.5, 8.9, 5.9 Hz, 1H), 4.18–4.12 (m, 2H), 4.12–4.05
(m, 1H), 3.94 (dddd, <em>J</em> = 10.5, 9.6, 6.7, 5.1 Hz,
1H), 3.79 (qd, <em>J</em> = 12.2, 3.1 Hz, 2H), 2.81 (td, <em>J</em> = 5.9, 0.9 Hz, 2H), 2.75–2.66 (m, 2H), 2.61 (ddd, <em>J</em> = 17.2, 7.3, 5.1 Hz, 1H), 2.15 (s, 1H), 1.21 (dd, <em>J</em> = 6.9, 4.1 Hz, 7H), 0.98 (s, 9H), 0.20 (d, <em>J</em> = 11.5 Hz, 6H). 31P NMR (203 MHz, MeOD) δ 68.18. 13C NMR (126
MHz, MeOD) δ 180.40, 156.12, 149.82, 148.81, 138.38, 119.62,
116.92, 116.76, 88.13, 84.61, 79.37, 72.64, 63.51, 63.17, 61.31, 48.12,
47.95, 47.78, 47.61, 47.44, 47.27, 47.10, 35.57, 24.91, 18.53, 18.46,
18.34, 18.27, 18.01, 17.85, 17.64, −5.64, −6.07.</p></section><section id="sec5.1.6"><h4 class="pmc_sec_title">Synthesis of <em>O</em>-((2<em>R</em>,3<em>S</em>,4<em>R</em>,5<em>R</em>)-4-((<em>Tert</em>-Butyldimethylsilyl)­oxy)-5-(Hydroxymethyl)-2-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-Purin-9-Yl)­tetrahydrofuran-3-yl) <em>O</em>,<em>O</em>-Bis­(2-cyanoethyl) Phosphorothioate (<strong>35d</strong>)</h4>
<p>
<strong>35d</strong> was synthesized from <strong>35c</strong> using the
same procedure as the synthesis of <strong>II</strong>. LRMS: <em>m</em>/<em>z</em> = 670.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD) δ 8.13 (s, 1H), 7.28 (d, <em>J</em> = 35.0 Hz, 1H), 6.44 (dd, <em>J</em> = 3.8, 1.7 Hz, 1H),
4.92 (ddd, <em>J</em> = 12.0, 3.9, 2.1 Hz, 2H), 4.62 (t, <em>J</em> = 2.4 Hz, 1H), 4.35–4.30 (m, 1H), 4.26–4.14
(m, 2H), 4.04 (td, <em>J</em> = 5.7, 2.7 Hz, 1H), 4.00–3.93
(m, 2H), 3.92–3.86 (m, 1H), 3.84 (s, 2H), 3.82–3.79
(m, 2H), 2.90 (td, <em>J</em> = 6.1, 2.7 Hz, 1H), 2.86–2.82
(m, 1H), 2.70 (dq, <em>J</em> = 10.5, 6.6 Hz, 2H), 2.65 (dd, <em>J</em> = 7.2, 4.9 Hz, 1H), 2.15 (s, 1H), 1.98 (s, 1H), 0.96 (d, <em>J</em> = 9.5 Hz, 10H), 0.92 (s, 1H), 0.90 (s, 1H), 0.22 (d, <em>J</em> = 10.5 Hz, 4H), 0.17 (s, 2H), −0.00 (s, 2H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.35. <sup>13</sup>C NMR (126
MHz, MeOD) δ 180.41, 156.13, 148.95, 148.79, 139.78, 139.13,
123.57, 119.33, 116.98, 116.76, 86.67, 86.01, 85.21, 83.70, 81.45,
77.68, 76.27, 76.18, 63.47, 63.29, 61.06, 60.90, 48.12, 47.95, 47.78,
47.60, 47.43, 47.26, 47.09, 35.54, 33.48, 31.35, 29.34, 24.97, 24.87,
24.76, 22.30, 18.52, 18.45, 18.29, 18.22, 17.93, 17.90, 17.43, 13.03,
−1.44, −5.57, −5.89, −5.97, −6.16.</p></section><section id="sec5.1.7"><h4 class="pmc_sec_title">Synthesis of <em>O</em>,<em>O</em>-Bis­(2-Cyanoethyl) <em>O</em>-((2<em>R</em>,3<em>R</em>,5<em>S</em>)-5-(Hydroxymethyl)-2-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-Purin-9-Yl)­Tetrahydrofuran-3-Yl) Phosphorothioate (<strong>III</strong>)</h4>
<p>
<strong>III</strong> was synthesized from <strong>37d</strong> using the same procedure as the synthesis of <strong>II</strong>. ESI–MS: <em>m</em>/<em>z</em> = 540.6 [M
+ H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD) δ 8.30 (s,
1H), 6.18 (d, <em>J</em> = 2.4 Hz, 1H), 5.46 (ddt, <em>J</em> = 9.0, 5.7, 2.7 Hz, 1H), 4.49 (td, <em>J</em> =
6.0, 3.0 Hz, 1H), 3.88 (dd, <em>J</em> = 12.3, 2.9 Hz, 1H),
3.69 (dd, <em>J</em> = 12.3, 3.7 Hz, 1H), 3.31 (t, <em>J</em> = 1.7 Hz, 1H), 2.92–2.83 (m, 3H), 2.76–2.70
(m, 1H), 2.70–2.63 (m, 1H), 2.41 (ddd, <em>J</em> =
14.0, 6.2, 2.9 Hz, 1H), 2.15 (s, 1H), 1.31 (d, <em>J</em> =
6.5 Hz, 1H), 1.22 (d, <em>J</em> = 6.9 Hz, 5H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 66.35. <sup>13</sup>C NMR (126 MHz,
MeOD) δ 180.41, 156.11, 148.80, 148.49, 141.65, 138.55, 120.05,
117.93, 117.11, 110.57, 89.21, 89.14, 82.25, 82.20, 81.02, 63.29,
63.26, 63.22, 62.07, 60.64, 48.13, 47.96, 47.79, 47.62, 47.45, 47.28,
47.11, 35.56, 32.41, 32.38, 31.35, 29.31, 22.30, 18.67, 18.54, 18.48,
17.98, 17.95, 13.04, −1.42.</p></section><section id="sec5.1.8"><h4 class="pmc_sec_title">Synthesis of <em>O</em>-((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-2-(6-Benzamido-9<em>H</em>-Purin-9-Yl)-4-((<em>Tert</em>-Butyldimethylsilyl)­oxy)-5-(Hydroxymethyl)­tetrahydrofuran-3-yl) <em>O</em>,<em>O</em>-Bis­(2-Cyanoethyl) Phosphorothioate
(<strong>VI</strong>)</h4>
<p>
<strong>VI</strong> was synthesized from <strong>IV</strong> using the same procedure as the synthesis of <strong>II</strong>. ESI–MS: <em>m</em>/<em>z</em> = 688.8 [M
+ H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.73 (d, <em>J</em> = 13.2 Hz, 2H), 8.22–7.91 (m, 2H), 7.68–7.63
(m, 1H), 7.57 (dd, <em>J</em> = 8.4, 7.1 Hz, 2H), 6.41 (d, <em>J</em> = 6.6 Hz, 1H), 5.66 (ddd, <em>J</em> = 12.6, 6.6,
4.6 Hz, 1H), 4.71 (dd, <em>J</em> = 4.6, 2.1 Hz, 1H), 4.23
(td, <em>J</em> = 4.0, 1.2 Hz, 2H), 4.19–4.13 (m, 1H),
4.12–4.06 (m, 1H), 4.05–3.97 (m, 1H), 3.92 (dd, <em>J</em> = 12.5, 3.1 Hz, 1H), 3.79 (dd, <em>J</em> = 12.5,
2.7 Hz, 1H), 2.84–2.78 (m, 2H), 2.77–2.71 (m, 2H), 1.00
(s, 9H), 0.93–0.83 (m, 1H), 0.23 (d, <em>J</em> = 11.5
Hz, 6H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 68.39. <sup>13</sup>C NMR (126 MHz, MeOD): δ 152.00, 151.84, 150.25, 143.60, 132.55,
128.38, 128.10, 124.38, 116.93, 87.86, 86.71, 78.48, 72.07, 63.52,
63.35, 61.27, 48.11, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 24.93,
18.46, 18.39, 18.33, 17.68, −5.61, −6.08.</p></section><section id="sec5.1.9"><h4 class="pmc_sec_title">Synthesis of <em>O</em>-((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((<em>Tert</em>-Butyldimethylsilyl)­oxy)-2-(2,4-Dioxo-3,4-Dihydropyrimidin-1­(2<em>H</em>)-yl)-5-(Hydroxymethyl)­tetrahydrofuran-3-yl) <em>O</em>,<em>O</em>-Bis­(2-cyanoethyl) Phosphorothioate (<strong>VII</strong>)</h4>
<p>
<strong>VII</strong> was synthesized from V using the same
procedure as the synthesis of <strong>II</strong>. ESI–MS: <em>m</em>/<em>z</em> = 561.7 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.02 (d, <em>J</em> = 8.1 Hz,
1H), 6.19 (d, <em>J</em> = 6.3 Hz, 1H), 5.74 (d, <em>J</em> = 8.1 Hz, 1H), 5.05 (ddd, <em>J</em> = 12.6, 6.3, 4.7 Hz,
1H), 4.47 (dd, <em>J</em> = 4.8, 2.5 Hz, 1H), 4.28 (ddd, <em>J</em> = 11.9, 5.7, 2.9 Hz, 4H), 4.08 (s, 1H), 3.76 (ddd, <em>J</em> = 46.2, 12.1, 2.6 Hz, 2H), 3.37–3.20 (m, 2H), 2.87
(td, <em>J</em> = 5.8, 4.2 Hz, 4H), 0.95 (s, 9H), 0.18 (d, <em>J</em> = 15.0 Hz, 6H). <sup>31</sup>P NMR (203 MHz, MeOD) δ
68.72. <sup>13</sup>C NMR (126 MHz, MeOD): δ 164.64, 151.10,
141.72, 141.22, 117.02, 101.92, 86.80, 86.22, 86.18, 78.76, 78.72,
71.65, 71.60, 63.44, 63.41, 63.38, 63.35, 60.72, 48.13, 47.96, 47.79,
47.62, 47.45, 47.28, 47.11, 24.92, 18.61, 18.54, 18.47, 18.41, 17.64,
−5.61, −6.15.</p></section><section id="sec5.1.10"><h4 class="pmc_sec_title">Synthesis of <em>O</em>-((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-Fluoro-2-(Hydroxymethyl)­tetrahydrofuran-3-yl) <em>O</em>,<em>O</em>-Bis­(2-cyanoethyl) Phosphorothioate
(<strong>XI</strong>)</h4>
<p>
<strong>XI</strong> was synthesized from <strong>VIII</strong> using the same procedure as the synthesis of <strong>II</strong>. ESI–MS: <em>m</em>/<em>z</em> = 576.7 [M
+ H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.69 (d, <em>J</em> = 38.8 Hz, 2H), 8.19–8.00 (m, 2H), 7.64 (d, <em>J</em> = 7.4 Hz, 1H), 7.56 (dd, <em>J</em> = 8.4, 7.1
Hz, 2H), 6.50 (dd, <em>J</em> = 16.0, 3.7 Hz, 1H), 5.87 (dt, <em>J</em> = 51.5, 4.2 Hz, 1H), 5.61 (ddd, <em>J</em> = 11.4,
8.8, 5.3 Hz, 1H), 4.44 (dd, <em>J</em> = 4.9, 2.3 Hz, 1H),
4.37 (dq, <em>J</em> = 9.2, 5.8 Hz, 4H), 3.96 (dd, <em>J</em> = 12.6, 2.5 Hz, 1H), 3.84 (dd, <em>J</em> = 12.6,
3.2 Hz, 1H), 2.93 (q, <em>J</em> = 6.3 Hz, 4H), 2.15 (s, 1H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.07. <sup>13</sup>C NMR (126
MHz, MeOD): δ 166.81, 151.98, 151.56, 150.06, 143.17, 133.52,
132.56, 128.39, 128.07, 124.09, 117.15, 117.10, 91.97, 90.42, 87.09,
86.82, 83.44, 83.39, 74.58, 74.50, 63.38, 60.17, 48.12, 47.95, 47.78,
47.61, 47.44, 47.27, 47.10, 29.29, 18.58, 18.55, 18.51, 18.49.</p></section><section id="sec5.1.11"><h4 class="pmc_sec_title">Synthesis of <em>O</em>,<em>O</em>-Bis­(2-cyanoethyl) <em>O</em>-((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(Hydroxymethyl)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphorothioate (<strong>XII</strong>)</h4>
<p>
<strong>XII</strong> was synthesized from <strong>IX</strong> using the same procedure as the synthesis of <strong>II</strong>. ESI–MS: <em>m</em>/<em>z</em> = 558.3 [M
+ H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.71 (d, <em>J</em> = 5.7 Hz, 2H), 8.28 (s, 1H), 8.08 (dd, <em>J</em> = 8.4, 1.3 Hz, 2H), 7.64 (d, <em>J</em> = 7.5 Hz, 1H), 7.56
(t, <em>J</em> = 7.7 Hz, 2H), 6.43 (dd, <em>J</em> = 16.4, 2.5 Hz, 1H), 6.30 (dd, <em>J</em> = 15.1, 3.7 Hz,
1H), 5.64 (dt, <em>J</em> = 51.5, 4.1 Hz, 1H), 5.56–5.40
(m, 1H), 5.36 (ddd, <em>J</em> = 12.2, 8.8, 5.2 Hz, 1H), 4.68
(ddd, <em>J</em> = 18.1, 6.9, 4.5 Hz, 1H), 4.41–4.31
(m, 6H), 4.16 (dd, <em>J</em> = 6.8, 3.3 Hz, 1H), 3.96 (td, <em>J</em> = 12.8, 2.5 Hz, 2H), 3.82 (ddd, <em>J</em> = 21.9,
12.5, 3.1 Hz, 2H), 2.97–2.86 (m, 5H), 2.71 (p, <em>J</em> = 6.9 Hz, 1H), 2.15 (s, 1H), 1.30–1.26 (m, 2H), 1.24–1.19
(m, 7H), 0.94–0.77 (m, 2H). <sup>31</sup>P NMR (203 MHz, MeOD)
δ 67.02. <sup>13</sup>C NMR (126 MHz, MeOD): δ 180.30,
156.00, 151.89, 148.88, 148.61, 143.00, 137.90, 133.54, 132.55, 128.39,
128.06, 120.09, 117.16, 117.08, 94.36, 92.86, 92.32, 90.77, 87.33,
87.07, 86.19, 85.93, 84.33, 83.06, 83.01, 74.10, 68.81, 68.68, 63.36,
60.29, 59.55, 48.12, 47.95, 47.78, 47.61, 47.44, 47.27, 47.10, 35.60,
18.51, 18.45, 17.94, 17.88.</p></section><section id="sec5.1.12"><h4 class="pmc_sec_title">Synthesis of <em>O</em>,<em>O</em>-Bis­(2-cyanoethyl)
O-((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(Hydroxymethyl)-5-(6-Oxo-1,6-Dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphorothioate (<strong>XIII</strong>)</h4>
<p>
<strong>XIII</strong> was synthesized from <strong>X</strong> using the same procedure as the synthesis of <strong>II</strong>. ESI–MS: <em>m</em>/<em>z</em> = 473.3 [M
+ H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.34 (s,
1H), 8.08 (s, 1H), 6.37 (dd, <em>J</em> = 16.2, 3.6 Hz, 1H),
5.74 (dt, <em>J</em> = 51.7, 4.2 Hz, 1H), 5.53 (ddd, <em>J</em> = 10.5, 7.1, 5.4 Hz, 1H), 4.43–4.39 (m, 1H), 4.36
(dq, <em>J</em> = 9.1, 5.7 Hz, 4H), 3.93 (dd, <em>J</em> = 12.6, 2.6 Hz, 1H), 3.81 (dd, <em>J</em> = 12.6, 3.3 Hz,
1H), 2.97–2.88 (m, 4H), 2.15 (s, 3H). <sup>31</sup>P NMR (203
MHz, MeOD) δ 67.01. <sup>13</sup>C NMR (126 MHz, MeOD): δ
157.40, 148.17, 145.83, 141.17, 139.53, 124.71, 117.12, 92.22, 90.67,
87.01, 86.75, 83.28, 83.23, 74.44, 74.33, 63.35, 60.08, 48.11, 47.94,
47.77, 47.60, 47.43, 47.26, 47.09, 29.27, 18.52, 18.48, 18.45.</p></section><section id="sec5.1.13"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>S</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-Purin-9-Yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-Yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>Tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-Purin-9-yl)­tetrahydrofuran-2-Yl)­methyl) (2-Cyanoethyl)
Phosphate (<strong>34d</strong>)</h4>
<p>Anhydrous MeCN was used to dissolve
phosphorothioate <strong>II</strong> (0.27 g, 0.42 mmol) and phorsphoramidite <strong>34c</strong> (0.63 mmol, 1.5 equiv) and left to stir under argon for
15 min. DCI (2 mmol, 4.76 equiv) was added and left to stir at RT
for 6 h. <sup>
<em>t</em>
</sup>BuOOH (70% aq solution, 0.5
mL, 3.9 mmol) was used to oxidize the coupled product and the reaction
was left for 10 min, then the mixture was quenched with 30 mL of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (1 M) and extracted 3x with 30
mL DCM. Then the extracted product is concentrated under reduced pressure.
After concentrating, the oil is dissolved in 20 mL DCM and then 0.5
mL of DCA is added dropwise and left to stir for 12 min. Saturated
NaHCO<sub>3</sub> (30 mL) was added to quench the reaction and extracted
3× with 30 mL DCM. The organic layer is then concentrated, and
the crude product was immediately purified via flash chromatography
(2–5% methanol in ethyl acetate). To the purified product (0.3
mmol) is then added methyltriphenoxyphosphonium iodide (3 mmol, 10
equiv) and 2,6-lutidine (10.2 mmol, 34 equiv) in anhydrous DMF (1.5
mL) in inert atmosphere. After an hour, the reaction was quenched
with 20 mL of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (1 M) and then
30 mL DCM was added to extract the aqueous layer (3x). The organic
layer was concentrated under reduced pressure and the crude product
was purified via flash chromatography (4–10% methanol in ethyl
acetate). The isolated product (0.116 g) was collected as a pale yellow
solid. ESI–MS: <em>m</em>/<em>z</em> = 1268.9
[M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.81–8.64
(m, 1H), 8.53–8.33 (m, 1H), 8.08 (d, <em>J</em> = 7.7
Hz, 2H), 8.03–7.98 (m, 1H), 7.65 (t, <em>J</em> = 7.6
Hz, 1H), 7.60–7.50 (m, 2H), 6.65–6.43 (m, 1H), 6.17
(dd, <em>J</em> = 34.2, 7.6 Hz, 1H), 5.98–5.76 (m,
1H), 5.48 (dt, <em>J</em> = 12.5, 5.9 Hz, 1H), 5.33 (ddd, <em>J</em> = 13.1, 7.8, 4.9 Hz, 1H), 5.29–5.22 (m, 1H), 4.72
(d, <em>J</em> = 5.8 Hz, 1H), 4.66–4.60 (m, 1H), 4.59
(d, <em>J</em> = 1.5 Hz, 1H), 4.49 (d, <em>J</em> =
5.0 Hz, 1H), 4.41 (d, <em>J</em> = 14.6 Hz, 1H), 4.36–4.30
(m, 1H), 4.22 (dq, <em>J</em> = 10.9, 6.0 Hz, 2H), 4.19–4.13
(m, 2H), 4.09 (q, <em>J</em> = 4.7 Hz, 1H), 4.02–3.93
(m, 1H), 3.65 (dd, <em>J</em> = 12.1, 8.1 Hz, 1H), 3.60–3.43
(m, 1H), 2.93 (td, <em>J</em> = 5.9, 1.4 Hz, 1H), 2.86–2.74
(m, 3H), 2.69 (ddt, <em>J</em> = 12.9, 9.4, 6.2 Hz, 2H), 1.28
(s, 3H), 1.23–1.15 (m, 5H), 0.95 (d, <em>J</em> = 17.5
Hz, 9H), 0.20 (d, <em>J</em> = 10.5 Hz, 3H), 0.14 (d, <em>J</em> = 18.5 Hz, 2H), −0.00 (s, 1H). <sup>31</sup>P NMR
(203 MHz, MeOD) δ 67.90, −3.27, −3.36, −3.64. <sup>13</sup>C NMR (126 MHz, MeOD): δ 210.65, 180.25, 166.84, 156.04,
151.37, 149.97, 141.54, 132.55, 128.36, 128.12, 128.01, 124.00, 117.07,
116.90, 96.67, 95.17, 88.26, 85.77, 84.77, 78.10, 63.91, 63.64, 63.31,
48.11, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 35.59, 31.34, 29.34,
24.90, 22.29, 18.58, 18.10, 17.88, 17.75, 17.60, 13.03, −1.44,
−5.59, −5.96.</p></section><section id="sec5.1.14"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-Purin-9-yl)-4-Fluoro-2-(Iodomethyl)­Tetrahydrofuran-3-Yl (((2<em>R</em>,3<em>R</em>,4<em>S</em>,5<em>R</em>)-4-((Bis­(2-Cyanoethoxy)­Phosphorothioyl)­oxy)-3-((<em>Tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-Purin-9-yl)­tetrahydrofuran-2-yl)­methyl) (2-Cyanoethyl)
Phosphate (<strong>35e</strong>)</h4>
<p>
<strong>35e</strong> was synthesized
from <strong>35d</strong> (0.42 mmol) and <strong>VIII</strong> (0.63 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d</strong>. The purified product (0.090 g) was isolated as pale yellow solid.
ESI–MS: <em>m</em>/<em>z</em> = 1268.9 [M +
H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.80–8.66
(m, 1H), 8.54 (d, <em>J</em> = 15.6 Hz, 1H), 8.08 (d, <em>J</em> = 7.7 Hz, 2H), 7.66 (t, <em>J</em> = 7.4 Hz, 1H),
7.57 (t, <em>J</em> = 7.6 Hz, 2H), 6.08 (dd, <em>J</em> = 52.9, 27.1 Hz, 3H), 5.57 (s, 2H), 4.57 (s, 2H), 4.43 (d, <em>J</em> = 6.6 Hz, 2H), 4.36 (s, 1H), 4.32–4.17 (m, 3H),
3.73–3.63 (m, 1H), 3.61–3.52 (m, 1H), 2.97 (td, <em>J</em> = 9.5, 4.4 Hz, 3H), 2.89–2.81 (m, 2H), 2.75–2.60
(m, 2H), 2.15 (s, 1H), 1.95 (s, 1H), 1.29 (s, 4H), 1.24–1.19
(m, 4H), 0.97 (t, <em>J</em> = 3.7 Hz, 8H), 0.90 (q, <em>J</em> = 6.7 Hz, 2H), 0.25 (t, <em>J</em> = 6.7 Hz, 4H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.27, −2.70. <sup>13</sup>C NMR (126 MHz, MeOD): δ 181.53, 161.70, 152.17, 151.46, 148.86,
143.67, 139.21, 132.59, 128.85, 128.39, 128.11, 117.11, 112.98, 76.92,
67.56, 63.64, 48.11, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 35.57,
29.36, 24.87, 18.54, 17.44, 2.26, −1.45, −5.97.</p></section><section id="sec5.1.15"><h4 class="pmc_sec_title">Synthesis of <em>O</em>-((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-((((((2<em>S</em>,3<em>S</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-Purin-9-yl)-2-(Iodomethyl)­tetrahydrofuran-3-yl)­oxy)­(methyl)­phosphoryl)­oxy)­methyl)-4-((<em>Tert</em>-Butyldimethylsilyl)­oxy)-2-(2-Isobutyramido-6-Oxo-1,4,5,6-Tetrahydro-9<em>H</em>-Purin-9-yl)­tetrahydrofuran-3-yl) <em>O</em>,<em>O</em>-Bis­(2-cyanoethyl) Phosphorothioate (<strong>36c</strong>)</h4>
<p>
<strong>36c</strong> was synthesized from <strong>II</strong> (0.42 mmol)
and <strong>36b</strong> (0.63 mmol, 1.5 equiv) using the same procedure
as the synthesis of <strong>34d</strong>. The product (0.06 g) was isolated
as an off-white solid. ESI–MS: <em>m</em>/<em>z</em> = 1198.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ)
8.71 (d, <em>J</em> = 26.3 Hz, 1H), 8.51 (d, <em>J</em> = 69.8 Hz, 1H), 8.20 (d, <em>J</em> = 21.1 Hz, 1H), 8.09
(t, <em>J</em> = 7.7 Hz, 2H), 7.66 (t, <em>J</em> =
7.3 Hz, 1H), 7.57 (t, <em>J</em> = 7.6 Hz, 2H), 6.53 (dt, <em>J</em> = 53.3, 7.0 Hz, 1H), 6.21 (dd, <em>J</em> = 39.0,
7.5 Hz, 1H), 5.49 (s, 1H), 5.32 (d, <em>J</em> = 70.3 Hz,
1H), 4.66 (dd, <em>J</em> = 18.9, 4.8 Hz, 2H), 4.49 (d, <em>J</em> = 14.4 Hz, 2H), 4.44 (s, 2H), 4.38 (d, <em>J</em> = 6.6 Hz, 2H), 4.32 (d, <em>J</em> = 4.7 Hz, 1H), 4.27–4.13
(m, 3H), 4.11 (d, <em>J</em> = 17.2 Hz, 1H), 4.04–3.93
(m, 1H), 3.65 (dd, <em>J</em> = 10.7, 7.1 Hz, 1H), 3.53 (dt, <em>J</em> = 11.4, 6.2 Hz, 1H), 3.45 (dd, <em>J</em> = 10.5,
5.9 Hz, 1H), 3.43–3.38 (m, 1H), 2.81 (dq, <em>J</em> = 12.3, 6.2 Hz, 4H), 2.77–2.74 (m, 1H), 2.71 (dd, <em>J</em> = 11.2, 5.3 Hz, 2H), 2.15 (s, 2H), 1.75 (dd, <em>J</em> = 17.7, 13.4 Hz, 4H), 1.29 (s, 3H), 1.21 (dd, <em>J</em> = 6.9, 2.8 Hz, 6H), 0.99 (d, <em>J</em> = 5.3 Hz, 10H),
0.92–0.85 (m, 1H), 0.24 (dd, <em>J</em> = 8.3, 5.5
Hz, 6H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 68.16, 68.04,
34.09, 33.30. <sup>13</sup>C NMR (126 MHz, MeOD): δ 180.41,
166.80, 151.88, 149.89, 143.61, 138.85, 133.55, 132.55, 128.82, 128.38,
128.11, 128.05, 124.07, 120.51, 119.89, 117.08, 116.88, 85.16, 84.99,
78.48, 77.58, 71.60, 69.28, 65.37, 63.69, 63.32, 48.11, 47.94, 47.77,
47.60, 47.43, 47.26, 47.09, 36.61, 35.59, 29.28, 24.92, 24.89, 18.57,
18.34, 18.05, 17.64, 13.02, 9.17, 3.58, 3.32, −5.59, −5.92,
−6.01.</p></section><section id="sec5.1.16"><h4 class="pmc_sec_title">Synthesis of <em>O</em>-((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-2-(6-Benzamido-4,5-dihydro-9<em>H</em>-purin-9-yl)-4-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-((((((2<em>S</em>,3<em>S</em>,5<em>R</em>)-2-(Iodomethyl)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-Purin-9-yl)­tetrahydrofuran-3-yl)­oxy)­(methyl)­phosphoryl)­oxy)­methyl)­tetrahydrofuran-3-yl) <em>O</em>,<em>O</em>-bis­(2-cyanoethyl) Phosphorothioate
(<strong>36d</strong>)</h4>
<p>
<strong>36d</strong> was synthesized from <strong>IV</strong> (0.42 mmol) and <strong>36a</strong> (0.63 mmol, 1.5 equiv)
using the same procedure as the synthesis of <strong>34d</strong>. The
product (0.065 g) was isolated as an off-white solid. ESI–MS: <em>m</em>/<em>z</em> = 1198.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.78 (d, <em>J</em> =
19.4 Hz, 1H), 8.64 (d, <em>J</em> = 11.7 Hz, 1H), 8.10 (s,
1H), 8.07–7.91 (m, 2H), 7.64 (dt, <em>J</em> = 11.2,
7.4 Hz, 1H), 7.53 (dt, <em>J</em> = 25.8, 7.6 Hz, 2H), 6.46
(d, <em>J</em> = 4.1 Hz, 1H), 6.43 (d, <em>J</em> =
4.9 Hz, 1H), 6.19 (dt, <em>J</em> = 33.2, 7.1 Hz, 1H), 5.85
(dt, <em>J</em> = 12.3, 5.9 Hz, 1H), 5.22 (s, 1H), 5.03–4.95
(m, 1H), 4.58–4.51 (m, 1H), 4.49–4.42 (m, 1H), 4.32
(s, 2H), 4.26 (dtd, <em>J</em> = 19.4, 10.1, 5.1 Hz, 2H),
4.18 (ddt, <em>J</em> = 13.7, 9.8, 4.0 Hz, 2H), 3.95 (s, 1H),
2.89–2.82 (m, 2H), 2.82–2.79 (m, 1H), 2.74 (dt, <em>J</em> = 17.8, 6.1 Hz, 2H), 2.54 (dd, <em>J</em> = 13.7,
5.2 Hz, 1H), 2.15 (s, 1H), 1.61 (d, <em>J</em> = 17.7 Hz,
3H), 1.32–1.25 (m, 3H), 1.23 (d, <em>J</em> = 6.8 Hz,
3H), 1.16 (dt, <em>J</em> = 12.3, 6.1 Hz, 4H), 1.01 (d, <em>J</em> = 11.7 Hz, 9H), 0.89 (q, <em>J</em> = 5.7 Hz,
2H), 0.33–0.26 (m, 5H), 0.25 (s, 2H). <sup>31</sup>P NMR (203
MHz, MeOD) δ 68.08, 33.13. <sup>13</sup>C NMR (126 MHz, MeOD):
δ 180.43, 166.59, 161.97, 152.00, 150.35, 148.27, 144.24, 144.00,
138.71, 132.62, 128.38, 128.15, 127.95, 124.40, 120.45, 117.02, 87.50,
85.04, 84.63, 83.69, 83.09, 78.55, 78.17, 77.66, 70.72, 70.22, 63.60,
63.43, 48.11, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 36.93, 35.58,
31.35, 29.27, 24.99, 24.95, 22.30, 18.50, 18.02, 17.89, 17.68, 13.02,
10.69, 9.55, 3.77, −5.43, −5.50, −5.96, −6.02.</p></section><section id="sec5.1.17"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl) (2-Cyanoethyl)
Phosphate (<strong>38e</strong>)</h4>
<p>
<strong>38e</strong> was synthesized
from <strong>II</strong> (1.26 mmol) and <strong>VIII</strong> (1.89 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d</strong>. The product (0.45 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1268.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.73 (d, <em>J</em> =
24.8 Hz, 1H), 8.53 (d, <em>J</em> = 37.1 Hz, 1H), 8.20 (d, <em>J</em> = 11.3 Hz, 1H), 8.11–8.06 (m, 2H), 7.68–7.63
(m, 1H), 7.57 (td, <em>J</em> = 7.6, 1.3 Hz, 2H), 6.47 (ddd, <em>J</em> = 26.9, 19.3, 2.3 Hz, 1H), 6.22 (dd, <em>J</em> = 20.0, 7.5 Hz, 1H), 6.10–5.90 (m, 1H), 5.66–5.55
(m, 1H), 5.56–5.41 (m, 1H), 4.72–4.62 (m, 1H), 4.63–4.52
(m, 2H), 4.47 (dt, <em>J</em> = 7.6, 5.8 Hz, 1H), 4.40 (dt, <em>J</em> = 7.4, 5.8 Hz, 2H), 4.33–4.25 (m, 1H), 4.25–4.20
(m, 1H), 4.16 (ddd, <em>J</em> = 19.9, 10.0, 4.9 Hz, 1H),
4.08 (tdd, <em>J</em> = 9.7, 6.9, 4.8 Hz, 1H), 4.03–3.91
(m, 1H), 3.69 (ddd, <em>J</em> = 21.9, 11.3, 4.7 Hz, 1H),
3.56 (ddd, <em>J</em> = 27.4, 11.3, 5.5 Hz, 1H), 3.00 (td, <em>J</em> = 5.8, 1.2 Hz, 1H), 2.92 (td, <em>J</em> = 5.8,
1.2 Hz, 1H), 2.81 (dt, <em>J</em> = 11.0, 5.8 Hz, 2H), 2.75
(ddd, <em>J</em> = 10.1, 6.8, 3.2 Hz, 1H), 2.73–2.65
(m, 2H), 1.25–1.17 (m, 6H), 0.97 (t, <em>J</em> = 6.0
Hz, 9H), 0.88 (ddd, <em>J</em> = 15.2, 6.9, 3.0 Hz, 1H), 0.23
(dd, <em>J</em> = 7.7, 6.2 Hz, 6H). <sup>31</sup>P NMR (203
MHz, MeOD) δ 67.93, 67.91, −3.13. <sup>13</sup>C NMR
(126 MHz, MeOD): δ 180.37, 166.82, 152.17, 151.34, 150.09, 148.63,
143.89, 143.44, 139.10, 133.52, 132.58, 128.89, 128.39, 128.12, 124.07,
120.55, 119.89, 117.08, 116.88, 91.97, 90.51, 87.30, 87.05, 85.57,
84.91, 80.16, 77.47, 77.32, 76.93, 71.51, 67.86, 63.84, 63.69, 63.33,
48.12, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 35.61, 24.91, 18.90,
18.51, 18.40, 18.34, 18.11, 17.85, 17.63, 2.54, 2.26, −5.60,
−5.94, −6.00.</p></section><section id="sec5.1.18"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(4-Benzamido-2-oxopyrimidin-1­(2<em>H</em>)-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl) (2-Cyanoethyl)
Phosphate (<strong>38f</strong>)</h4>
<p>
<strong>38f</strong> was synthesized
from <strong>II</strong> (0.48 mmol) and <strong>38a</strong> (0.63 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d</strong>. The product (0.14 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1245.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.19 (s, 1H), 8.16–8.11
(m, 1H), 8.04 (d, <em>J</em> = 7.5 Hz, 1H), 7.44 (d, <em>J</em> = 7.5 Hz, 1H), 7.36 (d, <em>J</em> = 7.6 Hz, 1H),
6.22 (d, <em>J</em> = 7.6 Hz, 1H), 6.16 (d, <em>J</em> = 7.7 Hz, 1H), 5.92 (d, <em>J</em> = 22.1 Hz, 1H), 5.80
(d, <em>J</em> = 22.1 Hz, 1H), 5.56 (d, <em>J</em> = 5.0 Hz, 1H), 5.52 (t, <em>J</em> = 6.4 Hz, 1H), 5.47 (s,
1H), 5.08 (dt, <em>J</em> = 12.6, 6.2 Hz, 1H), 4.99 (dd, <em>J</em> = 18.2, 5.5 Hz, 1H), 4.66 (d, <em>J</em> = 5.0
Hz, 1H), 4.63 (d, <em>J</em> = 4.7 Hz, 1H), 4.58 (s, 1H),
4.54–4.46 (m, 2H), 4.43 (q, <em>J</em> = 6.3 Hz, 1H),
4.39–4.32 (m, 2H), 4.22 (td, <em>J</em> = 10.2, 5.0
Hz, 1H), 4.16 (q, <em>J</em> = 7.4 Hz, 2H), 4.12–4.05
(m, 1H), 4.04–3.95 (m, 1H), 3.70 (dd, <em>J</em> =
11.3, 4.1 Hz, 1H), 3.65 (dd, <em>J</em> = 11.1, 4.2 Hz, 1H),
3.54 (dd, <em>J</em> = 11.3, 5.8 Hz, 1H), 3.49 (dd, <em>J</em> = 11.2, 5.6 Hz, 1H), 2.96 (td, <em>J</em> = 5.9,
1.2 Hz, 1H), 2.89 (t, <em>J</em> = 5.9 Hz, 1H), 2.81 (q, <em>J</em> = 6.0 Hz, 2H), 2.79–2.74 (m, 1H), 2.74–2.69
(m, 2H), 2.20 (d, <em>J</em> = 10.5 Hz, 3H), 2.15 (s, 1H),
1.22 (dd, <em>J</em> = 6.8, 3.8 Hz, 6H), 0.98 (d, <em>J</em> = 3.2 Hz, 9H), 0.23 (dd, <em>J</em> = 7.5, 6.2
Hz, 7H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.85, −3.16,
−3.19. <sup>13</sup>C NMR (126 MHz, MeOD): δ 180.41,
171.66, 163.81, 155.89, 147.09, 146.64, 139.12, 117.09, 116.90, 96.94,
92.66, 84.89, 80.02, 77.14, 71.49, 67.75, 63.67, 63.33, 63.32, 48.11,
47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 35.62, 29.28, 24.91, 23.21,
18.59, 18.41, 18.35, 18.11, 17.63, 2.03, −5.61, −5.93,
−6.01.</p></section><section id="sec5.1.19"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl (2-cyanoethyl)
((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1­(2H)-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl)
Phosphate (<strong>38g</strong>)</h4>
<p>
<strong>38g</strong> was synthesized
from <strong>II</strong> (0.48 mmol) and <strong>38b</strong> (0.63 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d</strong>. The product (0.15 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1141.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.18 (d, <em>J</em> =
11.1 Hz, 1H), 7.68 (d, <em>J</em> = 8.1 Hz, 1H), 7.61 (d, <em>J</em> = 8.1 Hz, 1H), 6.22 (dd, <em>J</em> = 9.8, 7.6
Hz, 1H), 5.81 (ddd, <em>J</em> = 35.7, 22.5, 1.9 Hz, 1H),
5.72 (d, <em>J</em> = 8.0 Hz, 1H), 5.68 (d, <em>J</em> = 8.0 Hz, 1H), 5.59–5.54 (m, 1H), 5.51 (s, 1H), 5.15–5.05
(m, 1H), 5.05–4.96 (m, 1H), 4.66 (dd, <em>J</em> =
9.3, 4.8 Hz, 1H), 4.60–4.48 (m, 2H), 4.43 (q, <em>J</em> = 6.2 Hz, 1H), 4.39–4.31 (m, 2H), 4.22 (dq, <em>J</em> = 11.0, 5.2 Hz, 1H), 4.15 (ddd, <em>J</em> = 18.9, 9.4,
4.3 Hz, 1H), 4.13–4.03 (m, 2H), 4.03–3.94 (m, 1H), 3.64
(dd, <em>J</em> = 11.2, 4.4 Hz, 1H), 3.59 (dd, <em>J</em> = 11.2, 4.4 Hz, 1H), 3.49 (dd, <em>J</em> = 11.2, 5.8 Hz,
1H), 3.42 (dd, <em>J</em> = 11.2, 5.8 Hz, 1H), 2.97 (td, <em>J</em> = 5.9, 1.2 Hz, 1H), 2.89 (t, <em>J</em> = 5.8
Hz, 1H), 2.81 (p, <em>J</em> = 5.6 Hz, 2H), 2.78–2.73
(m, 1H), 2.74–2.67 (m, 2H), 1.23 (t, <em>J</em> = 6.8
Hz, 6H), 0.99 (d, <em>J</em> = 2.2 Hz, 10H), 0.90 (s, 3H),
0.23 (dd, <em>J</em> = 7.3, 3.8 Hz, 6H). <sup>31</sup>P NMR
(203 MHz, MeOD) δ 67.86, −3.07, −3.17. <sup>13</sup>C NMR (126 MHz, MeOD): δ 208.73, 180.38, 180.37, 164.58, 164.48,
150.30, 150.16, 148.62, 143.34, 143.16, 139.19, 139.08, 128.86, 123.17,
120.58, 119.89, 117.10, 117.02, 116.90, 101.82, 92.03, 91.73, 91.43,
90.51, 85.65, 85.43, 84.88, 79.67, 77.25, 76.56, 71.53, 67.72, 67.68,
63.70, 63.33, 48.12, 47.95, 47.78, 47.61, 47.44, 47.27, 47.10, 35.64,
34.28, 31.35, 29.29, 24.92, 22.30, 19.62, 18.85, 18.78, 18.72, 18.61,
18.55, 18.42, 18.36, 18.25, 17.86, 17.64, 13.03, 10.36, 2.07, 1.84,
−5.54, −5.59, −5.93, −5.99.</p></section><section id="sec5.1.20"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-Purin-9-yl)­tetrahydrofuran-2-yl)­methyl (2-Cyanoethyl)
((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(Iodomethyl)-5-(6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>38h</strong>)</h4>
<p>
<strong>38h</strong> was synthesized from <strong>II</strong> (1.26
mmol) and <strong>XIII</strong> (1.89 mmol, 1.5 equiv) using the same
procedure as the synthesis of <strong>34d</strong>. The product (0.42
g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1165.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(500 MHz, MeOD δ) 8.24 (s, 1H), 8.23–8.17 (m, 2H), 8.10
(d, <em>J</em> = 24.3 Hz, 1H), 6.43–6.35 (m, 1H), 6.32
(s, 1H), 6.24 (d, <em>J</em> = 7.5 Hz, 1H), 6.20 (d, <em>J</em> = 7.6 Hz, 1H), 6.03–5.91 (m, 1H), 5.49 (dt, <em>J</em> = 22.5, 6.8 Hz, 2H), 5.37 (s, 1H), 4.68 (d, <em>J</em> = 4.9 Hz, 1H), 4.65 (d, <em>J</em> = 5.0 Hz, 1H), 4.57 (d, <em>J</em> = 7.7 Hz, 1H), 4.55 (d, <em>J</em> = 6.5 Hz, 2H),
4.48–4.43 (m, 1H), 4.38 (t, <em>J</em> = 6.4 Hz, 2H),
4.28–4.20 (m, 2H), 4.17 (dq, <em>J</em> = 10.5, 5.5
Hz, 1H), 4.12–4.03 (m, 1H), 4.03–3.93 (m, 1H), 3.72–3.63
(m, 1H), 3.57 (dd, <em>J</em> = 11.3, 5.5 Hz, 1H), 2.98 (t, <em>J</em> = 5.8 Hz, 1H), 2.91 (t, <em>J</em> = 5.7 Hz, 2H),
2.81 (q, <em>J</em> = 6.5 Hz, 3H), 2.75 (d, <em>J</em> = 6.5 Hz, 1H), 2.73–2.66 (m, 2H), 1.29 (s, 5H), 1.22 (dd, <em>J</em> = 6.7, 2.9 Hz, 8H), 0.98 (d, <em>J</em> = 2.9
Hz, 9H), 0.92–0.88 (m, 3H), 0.89–0.84 (m, 2H), 0.23
(dd, <em>J</em> = 7.1, 4.7 Hz, 6H). <sup>31</sup>P NMR (203
MHz, MeOD) δ 67.92, 67.90, −3.01. <sup>13</sup>C NMR
(126 MHz, MeOD): δ 157.45, 148.09, 145.98, 140.24, 138.92, 128.87,
124.89, 123.15, 119.89, 117.09, 116.88, 92.18, 90.63, 85.37, 84.89,
80.21, 77.39, 76.84, 76.82, 71.52, 67.82, 63.68, 63.32, 48.11, 47.94,
47.77, 47.60, 47.43, 47.26, 47.09, 35.64, 34.28, 31.35, 24.90, 22.30,
18.76, 18.54, 18.40, 18.34, 18.15, 17.90, 17.63, 13.03, 2.46, −5.59,
−5.96, −6.02.</p></section><section id="sec5.1.21"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl (2-Cyanoethyl)
((2<em>S</em>,3<em>S</em>,5<em>R</em>)-2-(Iodomethyl)-5-(6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>38i</strong>)</h4>
<p>
<strong>38i</strong> was synthesized from <strong>II</strong> (0.48
mmol) and <strong>38c</strong> (0.63 mmol, 1.5 equiv) using the same procedure
as the synthesis of <strong>34d</strong>. The product (0.14 g) was isolated
as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1147.7 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz,
MeOD δ) 8.23 (d, <em>J</em> = 17.5 Hz, 1H), 8.18 (d, <em>J</em> = 10.9 Hz, 1H), 8.06 (d, <em>J</em> = 18.2 Hz,
1H), 6.54–6.32 (m, 1H), 6.22 (dd, <em>J</em> = 19.3,
7.5 Hz, 1H), 5.56–5.47 (m, 1H), 5.28 (d, <em>J</em> = 67.5 Hz, 1H), 4.67 (dd, <em>J</em> = 12.5, 4.7 Hz, 1H),
4.60 (t, <em>J</em> = 5.6 Hz, 1H), 4.51 (q, <em>J</em> = 6.9 Hz, 2H), 4.44–4.38 (m, 2H), 4.37–4.32 (m, 1H),
4.23 (dd, <em>J</em> = 15.9, 7.8 Hz, 1H), 4.21–4.12
(m, 1H), 4.10 (s, 1H), 4.00 (tq, <em>J</em> = 10.4, 5.6 Hz,
1H), 3.50 (dt, <em>J</em> = 10.9, 6.0 Hz, 1H), 3.42 (dd, <em>J</em> = 10.7, 5.9 Hz, 1H), 2.97 (t, <em>J</em> = 5.8
Hz, 1H), 2.91 (t, <em>J</em> = 5.9 Hz, 1H), 2.82 (q, <em>J</em> = 5.7 Hz, 2H), 2.76 (td, <em>J</em> = 6.5, 2.5
Hz, 1H), 2.72 (q, <em>J</em> = 5.7 Hz, 2H), 1.22 (dd, <em>J</em> = 5.9, 2.9 Hz, 6H), 0.98 (dd, <em>J</em> = 5.8,
2.7 Hz, 9H), 0.23 (dt, <em>J</em> = 6.0, 3.1 Hz, 5H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 68.00, −3.06, −3.24. <sup>13</sup>C NMR (126 MHz, MeOD): δ 180.38, 157.47, 156.10, 149.48,
148.53, 148.28, 145.46, 139.80, 139.19, 138.94, 128.88, 124.80, 123.17,
120.60, 119.89, 117.17, 117.08, 116.88, 85.70, 85.01, 80.98, 77.24,
71.48, 67.55, 63.69, 63.37, 48.10, 47.93, 47.76, 47.59, 47.42, 47.25,
47.08, 36.49, 35.60, 31.33, 29.34, 25.04, 24.90, 22.29, 18.85, 18.56,
18.41, 18.34, 18.05, 17.89, 17.62, 13.02, 3.26, 3.07, −5.55,
−5.60, −6.02.</p></section><section id="sec5.1.22"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl (2-Cyanoethyl)
((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(Iodomethyl)-5-(2-Isobutyramido-6-Oxo-1,4,5,6-Tetrahydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>38k</strong>)</h4>
<p>
<strong>38k</strong> was synthesized from <strong>II</strong> (0.48
mmol) and <strong>XII</strong> (0.63 mmol, 1.5 equiv) using the same procedure
as the synthesis of <strong>34d</strong>. The product (0.165 g) was isolated
as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1253.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz,
MeOD δ) 8.21 (s, 1H), 8.13 (d, <em>J</em> = 23.6 Hz,
1H), 6.33–6.25 (m, 1H), 6.24 (s, 1H), 6.19 (d, <em>J</em> = 19.3 Hz, 1H), 5.90 (d, <em>J</em> = 52.1 Hz, 1H), 5.47
(d, <em>J</em> = 31.7 Hz, 1H), 4.71–4.61 (m, 1H), 4.57
(s, 1H), 4.54 (s, 1H), 4.46 (d, <em>J</em> = 6.7 Hz, 1H),
4.38 (dd, <em>J</em> = 13.0, 6.2 Hz, 2H), 4.26–4.16
(m, 2H), 4.09 (d, <em>J</em> = 6.8 Hz, 2H), 4.05–3.92
(m, 1H), 3.68 (dd, <em>J</em> = 11.5, 5.2 Hz, 1H), 3.57 (dd, <em>J</em> = 11.3, 5.6 Hz, 1H), 2.99 (t, <em>J</em> = 5.7
Hz, 1H), 2.92 (t, <em>J</em> = 5.9 Hz, 1H), 2.82 (t, <em>J</em> = 5.8 Hz, 2H), 2.78 (s, 2H), 2.70 (dt, <em>J</em> = 12.6, 5.8 Hz, 2H), 2.15 (s, 1H), 1.95 (s, 1H), 1.31–1.27
(m, 5H), 1.27–1.21 (m, 9H), 0.98 (d, <em>J</em> = 8.0
Hz, 9H), 0.90 (t, <em>J</em> = 6.8 Hz, 2H), 0.22 (dd, <em>J</em> = 13.1, 5.4 Hz, 6H). <sup>31</sup>P NMR (203 MHz, MeOD)
δ 67.94, 67.90, −2.99. <sup>13</sup>C NMR (126 MHz, MeOD):
δ 180.30, 148.62, 138.63, 128.72, 117.11, 116.85, 91.65, 90.11,
86.73, 85.22, 84.73, 80.26, 76.81, 71.39, 67.70, 63.68, 63.30, 54.83,
48.10, 47.93, 47.76, 47.59, 47.42, 47.25, 47.08, 35.66, 34.27, 31.33,
29.34, 28.75, 24.90, 24.88, 22.28, 18.87, 18.55, 18.42, 18.35, 18.06,
17.61, 17.59, 13.02, 10.35, 2.66, −1.45, −5.55, −5.62,
−5.95, −6.04.</p></section><section id="sec5.1.23"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-4,5-dihydro-9<em>H</em>-purin-9-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl
(((2<em>S</em>,4<em>R</em>,5<em>R</em>)-4-((bis­(2-Cyanoethoxy)­phosphorothioyl)­oxy)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl) (2-Cyanoethyl)
Phosphate (<strong>38l</strong>)</h4>
<p>
<strong>38L</strong> was synthesized
from <strong>III</strong> (0.48 mmol) and <strong>VIII</strong> (0.63 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d</strong>. The product (0.1 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1140.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.72 (d, <em>J</em> =
20.4 Hz, 1H), 8.54 (d, <em>J</em> = 12.1 Hz, 1H), 8.13–8.07
(m, 3H), 7.68–7.63 (m, 1H), 7.57 (td, <em>J</em> =
7.7, 1.6 Hz, 2H), 6.42 (ddd, <em>J</em> = 19.3, 4.9, 2.3 Hz,
1H), 6.22 (dd, <em>J</em> = 20.1, 2.4 Hz, 1H), 6.14–5.94
(m, 1H), 5.66–5.48 (m, 2H), 4.56–4.52 (m, 1H), 4.44
(ddd, <em>J</em> = 24.1, 11.5, 5.9 Hz, 2H), 4.39–4.33
(m, 2H), 4.32–4.27 (m, 2H), 4.27–4.23 (m, 2H), 4.17
(q, <em>J</em> = 6.1 Hz, 1H), 3.64 (dt, <em>J</em> = 11.3, 4.6 Hz, 1H), 3.52–3.47 (m, 1H), 2.93 (ddd, <em>J</em> = 10.7, 5.4, 1.3 Hz, 2H), 2.90 (dd, <em>J</em> = 5.7, 1.2 Hz, 1H), 2.86 (ddt, <em>J</em> = 15.5, 10.9,
4.7 Hz, 5H), 2.74 (qd, <em>J</em> = 6.9, 3.0 Hz, 1H), 2.56
(ddt, <em>J</em> = 12.5, 7.5, 3.8 Hz, 1H), 1.28 (s, 5H), 1.20
(td, <em>J</em> = 4.6, 2.2 Hz, 6H), 0.90 (t, <em>J</em> = 6.8 Hz, 2H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 66.42,
−3.07, −3.14. <sup>13</sup>C NMR (126 MHz, MeOD): δ
180.40, 166.74, 156.10, 152.07, 151.32, 150.03, 148.52, 143.74, 138.80,
133.51, 132.56, 128.38, 128.11, 124.04, 120.55, 117.14, 117.06, 90.30,
89.75, 87.26, 86.98, 81.19, 80.13, 78.44, 76.83, 69.06, 63.35, 48.10,
47.93, 47.76, 47.59, 47.42, 47.25, 47.08, 35.53, 32.95, 31.66, 31.34,
29.34, 22.29, 18.76, 18.53, 18.02, 17.91, 13.02, 2.26, −1.45.</p></section><section id="sec5.1.24"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-((<em>tert</em>-Butyldimethylsilyl)­oxy)-2-(iodomethyl)­tetrahydrofuran-3-yl
(((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)­tetrahydrofuran-2-yl)­methyl)
(2-Cyanoethyl) Phosphate (<strong>39c</strong>)</h4>
<p>
<strong>39c</strong> was synthesized from <strong>VI</strong> (0.48 mmol) and <strong>39a</strong> (0.63 mmol, 1.5 equiv) using the same procedure as the synthesis
of <strong>34d</strong>. The product (0.195 g) was isolated as a pale
yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1399.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ)
8.80 (d, <em>J</em> = 1.8 Hz, 1H), 8.72 (d, <em>J</em> = 7.7 Hz, 1H), 8.64 (d, <em>J</em> = 9.3 Hz, 1H), 8.56 (d, <em>J</em> = 4.2 Hz, 1H), 8.08–8.02 (m, 3H), 7.98–7.95
(m, 1H), 7.66–7.62 (m, 1H), 7.62–7.58 (m, 1H), 7.55
(ddt, <em>J</em> = 9.5, 7.7, 3.8 Hz, 4H), 7.48 (t, <em>J</em> = 7.8 Hz, 1H), 6.46 (t, <em>J</em> = 5.3 Hz, 1H),
6.03 (dd, <em>J</em> = 48.3, 6.4 Hz, 1H), 5.88 (dq, <em>J</em> = 13.5, 4.6 Hz, 1H), 5.39 (dddd, <em>J</em> =
32.6, 6.4, 4.7, 1.9 Hz, 1H), 5.12 (dd, <em>J</em> = 5.6, 4.0
Hz, 1H), 5.03 (dddd, <em>J</em> = 21.1, 7.5, 4.7, 2.2 Hz,
1H), 4.94 (t, <em>J</em> = 4.3 Hz, 1H), 4.65–4.57 (m,
2H), 4.53 (dt, <em>J</em> = 11.3, 5.6 Hz, 1H), 4.41 (qt, <em>J</em> = 6.4, 3.3 Hz, 2H), 4.32 (dtd, <em>J</em> = 12.0,
5.3, 1.4 Hz, 2H), 4.29–4.26 (m, 1H), 4.23 (ddd, <em>J</em> = 7.7, 6.0, 1.8 Hz, 2H), 4.19 (ddd, <em>J</em> = 8.8, 4.8,
2.3 Hz, 1H), 4.17–4.13 (m, 1H), 4.12–4.06 (m, 1H), 3.65
(ddd, <em>J</em> = 11.3, 6.9, 4.5 Hz, 1H), 3.51 (ddd, <em>J</em> = 29.4, 10.8, 6.2 Hz, 1H), 2.93–2.86 (m, 2H), 2.84
(q, <em>J</em> = 6.1 Hz, 2H), 2.79 (ddd, <em>J</em> = 9.1, 5.1, 3.3 Hz, 2H), 2.15 (s, 3H), 1.01 (d, <em>J</em> = 0.9 Hz, 9H), 0.91–0.87 (m, 3H), 0.73 (d, <em>J</em> = 4.5 Hz, 9H), 0.28 (dd, <em>J</em> = 6.5, 3.1 Hz, 6H),
−0.04 (d, <em>J</em> = 17.9 Hz, 3H), −0.24 (d, <em>J</em> = 4.8 Hz, 3H). <sup>31</sup>P NMR (203 MHz, MeOD) δ
67.95, 67.92, −2.62, −2.79. <sup>13</sup>C NMR (126
MHz, MeOD): δ 208.68, 166.73, 166.61, 152.08, 151.94, 151.80,
151.73, 151.65, 150.23, 150.10, 150.05, 144.12, 144.01, 143.56, 133.54,
133.41, 132.56, 132.49, 128.93, 128.40, 128.35, 128.31, 128.10, 128.04,
124.37, 124.28, 124.11, 119.91, 117.13, 117.08, 116.99, 88.84, 88.74,
87.46, 87.18, 83.82, 83.76, 83.18, 83.12, 82.86, 82.63, 79.64, 79.60,
79.36, 79.31, 77.84, 77.53, 72.92, 72.48, 71.04, 70.60, 70.55, 67.53,
66.66, 63.64, 63.60, 63.48, 63.45, 63.34, 63.30, 63.26, 48.15, 47.98,
47.81, 47.64, 47.47, 47.30, 47.13, 36.04, 34.38, 34.29, 31.36, 29.33,
28.77, 25.05, 24.81, 24.72, 24.68, 22.85, 22.31, 19.65, 18.91, 18.85,
18.64, 18.57, 18.47, 17.70, 17.54, 17.46, 17.43, 13.07, 10.40, 3.26,
2.95, −5.36, −5.39, −5.83, −5.97, −6.04,
−6.53, −6.59.</p></section><section id="sec5.1.25"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-Purin-9-yl)-4-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)­tetrahydrofuran-2-yl)­methyl
((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((<em>tert</em>-Butyldimethylsilyl)­oxy)-2-(iodomethyl)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) (2-Cyanoethyl) Phosphate
(<strong>39d</strong>)</h4>
<p>
<strong>39d</strong> was synthesized from <strong>VI</strong> (0.48 mmol) and <strong>39b</strong> (0.63 mmol, 1.5 equiv)
using the same procedure as the synthesis of <strong>34d</strong>. The
product (0.18 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1380.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.88 (d, <em>J</em> =
12.7 Hz, 1H), 8.65 (d, <em>J</em> = 8.5 Hz, 1H), 8.12 (d, <em>J</em> = 8.8 Hz, 1H), 7.84 (dd, <em>J</em> = 25.2, 7.7
Hz, 2H), 7.63–7.58 (m, 1H), 7.46 (t, <em>J</em> = 7.9
Hz, 2H), 6.47 (dd, <em>J</em> = 13.4, 5.1 Hz, 1H), 5.90 (dt, <em>J</em> = 11.4, 4.6 Hz, 1H), 5.64 (dd, <em>J</em> = 15.4,
7.4 Hz, 1H), 5.26 (d, <em>J</em> = 5.3 Hz, 1H), 4.75 (d, <em>J</em> = 6.6 Hz, 1H), 4.57 (dd, <em>J</em> = 5.9, 3.1
Hz, 1H), 4.55–4.52 (m, 1H), 4.38 (s, 1H), 4.34–4.31
(m, 1H), 4.30–4.23 (m, 3H), 4.23–4.18 (m, 1H), 4.07
(d, <em>J</em> = 7.6 Hz, 1H), 3.77 (s, 1H), 3.47 (dd, <em>J</em> = 10.7, 7.5 Hz, 1H), 3.43 (d, <em>J</em> = 6.2
Hz, 1H), 3.39 (dd, <em>J</em> = 10.7, 5.6 Hz, 1H), 2.93–2.89
(m, 2H), 2.86 (t, <em>J</em> = 5.9 Hz, 2H), 2.83 (t, <em>J</em> = 6.0 Hz, 2H), 2.77–2.74 (m, 1H), 1.30–1.25
(m, 5H), 1.23 (dd, <em>J</em> = 6.8, 3.6 Hz, 5H), 1.02 (d, <em>J</em> = 4.3 Hz, 9H), 0.70 (d, <em>J</em> = 1.9 Hz, 9H),
0.31 (d, <em>J</em> = 2.0 Hz, 4H), 0.27 (d, <em>J</em> = 6.5 Hz, 2H), −0.05 (d, <em>J</em> = 7.7 Hz, 3H),
−0.28 (d, <em>J</em> = 18.7 Hz, 3H). <sup>31</sup>P
NMR (203 MHz, MeOD) δ 67.94, −2.07, −3.31. <sup>13</sup>C NMR (126 MHz, MeOD): δ 180.32, 166.29, 166.08, 155.74,
152.19, 152.08, 151.73, 151.52, 150.19, 149.15, 148.48, 144.60, 144.40,
138.48, 132.92, 132.68, 128.88, 128.40, 128.35, 127.82, 127.73, 124.34,
124.06, 123.15, 120.33, 119.92, 117.15, 117.07, 117.01, 87.81, 87.55,
86.92, 84.28, 83.13, 82.79, 82.48, 79.50, 77.94, 76.98, 73.86, 71.44,
70.34, 67.92, 66.47, 63.66, 63.47, 63.20, 63.16, 63.03, 48.13, 47.96,
47.79, 47.62, 47.45, 47.28, 47.11, 35.62, 34.28, 31.35, 29.34, 28.77,
25.04, 24.99, 24.81, 24.54, 22.31, 19.63, 18.93, 18.87, 18.64, 18.56,
18.49, 18.12, 17.87, 17.76, 17.70, 17.67, 17.41, 17.35, 13.05, 10.38,
3.89, 3.37, −5.36, −5.48, −5.82, −5.94,
−6.10, −6.84.</p></section><section id="sec5.1.26"><h4 class="pmc_sec_title">Synthesis of (2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)­tetrahydrofuran-(2-yl)­methyl
((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl)
(2-cyanoethyl) Phosphate (<strong>39e</strong>)</h4>
<p>
<strong>39e</strong> was synthesized from <strong>VI</strong> (0.48 mmol) and <strong>VIII</strong> (0.63 mmol, 1.5 equiv) using the same procedure as the synthesis
of <strong>34d</strong>. The product (0.15 g) was isolated as an off-white
solid. ESI–MS: <em>m</em>/<em>z</em> = 1287.3
[M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.77
(d, <em>J</em> = 10.7 Hz, 1H), 8.71 (d, <em>J</em> = 6.0 Hz, 1H), 8.60 (d, <em>J</em> = 4.1 Hz, 1H), 8.53 (d, <em>J</em> = 1.1 Hz, 1H), 8.05 (ddt, <em>J</em> = 10.3, 7.1,
1.5 Hz, 4H), 7.67–7.59 (m, 2H), 7.57–7.49 (m, 4H), 6.47–6.41
(m, 2H), 6.03 (dddd, <em>J</em> = 51.4, 21.0, 4.8, 2.5 Hz,
1H), 5.80 (ddt, <em>J</em> = 13.9, 11.8, 5.0 Hz, 1H), 5.50
(dq, <em>J</em> = 13.5, 6.3 Hz, 1H), 5.03 (t, <em>J</em> = 4.5 Hz, 1H), 4.96 (t, <em>J</em> = 4.4 Hz, 1H), 4.67–4.59
(m, 1H), 4.59–4.52 (m, 1H), 4.45–4.40 (m, 1H), 4.39–4.31
(m, 2H), 4.24 (td, <em>J</em> = 9.7, 4.8 Hz, 2H), 4.21–4.17
(m, 1H), 4.13 (dddd, <em>J</em> = 18.7, 14.4, 6.4, 4.1 Hz,
2H), 3.64 (dt, <em>J</em> = 11.2, 4.7 Hz, 1H), 3.50 (ddd, <em>J</em> = 11.2, 10.0, 5.7 Hz, 1H), 2.96–2.89 (m, 2H), 2.83
(q, <em>J</em> = 6.0 Hz, 2H), 2.79–2.73 (m, 2H), 2.15
(s, 1H), 1.28 (s, 1H), 1.00 (d, <em>J</em> = 6.6 Hz, 9H),
0.90 (t, <em>J</em> = 6.9 Hz, 2H), 0.28–0.23 (m, 6H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.98, 67.95, −3.03,
−3.07. <sup>13</sup>C NMR (126 MHz, MeOD): δ 166.75,
152.15, 151.93, 151.43, 150.14, 150.06, 143.84, 143.74, 133.51, 132.55,
132.50, 128.38, 128.35, 128.11, 124.31, 124.09, 117.06, 91.98, 90.19,
87.21, 86.93, 83.62, 80.23, 77.79, 76.90, 70.87, 67.18, 63.61, 63.43,
48.12, 47.95, 47.78, 47.61, 47.44, 47.27, 47.10, 31.35, 29.29, 24.97,
22.30, 18.81, 18.59, 18.48, 18.40, 17.66, 13.03, 2.24, −5.49,
−5.94, −5.99.</p></section><section id="sec5.1.27"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-Purin-9-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1­(2<em>H</em>)-yl)­tetrahydrofuran-2-yl)­methyl) (2-Cyanoethyl) Phosphate
(<strong>39f</strong>)</h4>
<p>
<strong>39f</strong> was synthesized from <strong>VII</strong> (0.48 mmol) and <strong>VIII</strong> (0.63 mmol, 1.5 equiv)
using the same procedure as the synthesis of <strong>34d</strong>. The
product (0.1 g) was isolated as an off-white solid. ESI–MS: <em>m</em>/<em>z</em> = 1159.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD) δ 8.77 (d, <em>J</em> =
6.1 Hz, 1H), 8.56 (d, <em>J</em> = 2.6 Hz, 1H), 8.11–8.06
(m, 2H), 7.67 (dd, <em>J</em> = 7.7, 4.9 Hz, 1H), 7.65–7.63
(m, 1H), 7.56 (dd, <em>J</em> = 8.4, 7.1 Hz, 2H), 6.54–6.46
(m, 1H), 6.17–6.11 (m, 1H), 6.09 (t, <em>J</em> = 5.4
Hz, 1H), 5.77 (dd, <em>J</em> = 8.0, 4.3 Hz, 1H), 5.58 (dddd, <em>J</em> = 14.9, 11.6, 7.7, 4.7 Hz, 1H), 5.12–5.05 (m, 1H),
5.05–4.97 (m, 1H), 4.59 (ddd, <em>J</em> = 14.5, 5.1,
3.6 Hz, 1H), 4.52 (s, 1H), 4.48–4.42 (m, 3H), 4.42–4.35
(m, 1H), 4.34–4.25 (m, 6H), 3.72 (ddd, <em>J</em> =
11.4, 4.8, 1.3 Hz, 1H), 3.59 (ddd, <em>J</em> = 11.3, 5.7,
1.7 Hz, 1H), 3.00–2.96 (m, 2H), 2.88 (dd, <em>J</em> = 7.9, 5.9 Hz, 3H), 1.29 (d, <em>J</em> = 4.7 Hz, 1H), 0.96
(d, <em>J</em> = 4.7 Hz, 9H), 0.90 (s, 1H), 0.20 (dd, <em>J</em> = 8.6, 6.5 Hz, 6H). <sup>31</sup>P NMR (203 MHz, MeOD)
δ 68.40, 68.37, −2.98. <sup>13</sup>C NMR (126 MHz, MeOD):
δ 166.85, 164.44, 160.11, 152.15, 151.47, 150.78, 150.07, 143.81,
143.71, 141.57, 141.41, 134.66, 133.49, 132.59, 128.72, 128.40, 128.11,
127.54, 124.07, 117.17, 102.38, 92.03, 90.51, 88.30, 88.08, 87.24,
86.97, 83.32, 80.41, 80.34, 77.69, 76.90, 70.55, 67.36, 63.82, 63.60,
63.49, 48.13, 47.96, 47.79, 47.62, 47.45, 47.27, 47.10, 24.94, 24.80,
18.91, 18.68, 18.61, 18.53, 18.46, 17.60, 2.33, −5.53, −6.06.</p></section><section id="sec5.1.28"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)­tetrahydrofuran-2-yl)­methyl
(2-Cyanoethyl) ((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(Iodomethyl)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>39g</strong>)</h4>
<p>
<strong>39g</strong> was synthesized from <strong>VI</strong> (0.48
mmol) and <strong>IX</strong> (0.63 mmol, 1.5 equiv) using the same procedure
as the synthesis of <strong>34d</strong>. The product (0.152 g) was isolated
as an off-white solid. ESI–MS: <em>m</em>/<em>z</em> = 1269.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ)
8.78 (d, <em>J</em> = 21.2 Hz, 1H), 8.60 (d, <em>J</em> = 28.4 Hz, 1H), 8.10 (s, 1H), 8.04 (d, <em>J</em> = 7.7
Hz, 1H), 7.98 (d, <em>J</em> = 8.2 Hz, 1H), 7.67–7.60
(m, 1H), 7.53 (dt, <em>J</em> = 20.1, 7.7 Hz, 2H), 7.40 (dt, <em>J</em> = 36.2, 7.9 Hz, 1H), 7.31–7.24 (m, 1H), 6.44 (dd, <em>J</em> = 17.3, 4.8 Hz, 1H), 6.22 (dd, <em>J</em> = 18.4,
2.7 Hz, 1H), 5.81 (dt, <em>J</em> = 10.5, 4.9 Hz, 1H), 5.03
(dt, <em>J</em> = 43.6, 4.6 Hz, 1H), 4.64–4.59 (m,
1H), 4.57 (s, 1H), 4.53 (dt, <em>J</em> = 11.4, 5.7 Hz, 2H),
4.40 (d, <em>J</em> = 5.1 Hz, 2H), 4.34 (q, <em>J</em> = 6.3 Hz, 2H), 4.29 (t, <em>J</em> = 6.5 Hz, 2H), 4.27–4.20
(m, 2H), 4.18–4.15 (m, 1H), 4.14 (d, <em>J</em> = 3.3
Hz, 1H), 3.97 (d, <em>J</em> = 6.0 Hz, 1H), 3.60 (dd, <em>J</em> = 11.3, 4.8 Hz, 1H), 3.55–3.51 (m, 1H), 3.52–3.46
(m, 1H), 3.46–3.39 (m, 1H), 2.99 (s, 1H), 2.94–2.88
(m, 2H), 2.85 (d, <em>J</em> = 3.0 Hz, 2H), 2.83 (t, <em>J</em> = 6.2 Hz, 2H), 2.80–2.75 (m, 2H), 2.72 (ddd, <em>J</em> = 13.9, 6.9, 2.3 Hz, 2H), 1.87 (dd, <em>J</em> = 18.0, 10.1 Hz, 1H), 1.51 (dt, <em>J</em> = 16.7, 4.9 Hz,
1H), 1.28 (d, <em>J</em> = 2.5 Hz, 2H), 1.24–1.22 (m,
4H), 1.20 (d, <em>J</em> = 7.2 Hz, 4H), 1.00 (d, <em>J</em> = 8.3 Hz, 9H), 0.30–0.22 (m, 6H). <sup>31</sup>P NMR (203
MHz, MeOD) δ 68.06, 68.01, 30.80, −2.71, −2.96. <sup>13</sup>C NMR (126 MHz, MeOD): δ 180.19, 172.85, 161.68, 152.11,
148.40, 143.79, 138.93, 132.55, 129.83, 128.32, 128.06, 127.99, 117.03,
87.09, 86.62, 79.80, 76.87, 70.47, 66.73, 63.46, 48.09, 47.92, 47.75,
47.59, 47.41, 47.24, 47.07, 35.62, 31.33, 29.34, 24.97, 24.94, 22.28,
18.79, 18.51, 17.92, 17.64, 13.01, 2.52, −1.46, −5.46.</p></section><section id="sec5.1.29"><h4 class="pmc_sec_title">Synthesis of (1<em>S</em>,3<em>R</em>,4<em>R</em>,7<em>S</em>)-3-(6-Benzamido-9<em>H</em>-purin-9-yl)-1-(Iodomethyl)-2,5-dioxabicyclo­[2.2.1]­heptan-7-yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2-Isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl) (2-Cyanoethyl)
Phosphate (<strong>40b</strong>)</h4>
<p>
<strong>40b</strong> was synthesized
from <strong>II</strong> (1.26 mmol) and <strong>40a</strong> (1.89 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d</strong>. The product (0.5 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1279.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.73 (s, 1H), 8.62 (d, <em>J</em> = 7.3 Hz, 1H), 8.17 (s, 1H), 8.14 (d, <em>J</em> = 7.7 Hz, 1H), 8.10–8.06 (m, 1H), 7.66 (t, <em>J</em> = 7.4 Hz, 1H), 7.58 (dt, <em>J</em> = 15.3, 7.6 Hz, 2H),
6.29 (s, 1H), 6.22–6.17 (m, 1H), 5.28–5.25 (m, 1H),
5.11 (d, <em>J</em> = 8.2 Hz, 1H), 4.63 (d, <em>J</em> = 4.8 Hz, 1H), 4.58 (s, 1H), 4.51 (dd, <em>J</em> = 12.6,
5.7 Hz, 2H), 4.43 (dd, <em>J</em> = 7.6, 5.7 Hz, 1H), 4.33
(dd, <em>J</em> = 13.0, 6.1 Hz, 2H), 4.22 (d, <em>J</em> = 8.5 Hz, 1H), 4.18–4.13 (m, 3H), 4.13–4.05 (m, 2H),
4.00 (dd, <em>J</em> = 13.6, 7.7 Hz, 1H), 3.72 (d, <em>J</em> = 1.9 Hz, 1H), 3.66 (s, 1H), 2.95 (t, <em>J</em> = 5.8 Hz, 1H), 2.86 (t, <em>J</em> = 5.8 Hz, 1H), 2.77 (dd, <em>J</em> = 7.4, 4.3 Hz, 2H), 2.72–2.65 (m, 2H), 2.15 (s,
2H), 1.28 (s, 1H), 1.21 (d, <em>J</em> = 6.8 Hz, 2H), 1.19–1.16
(m, 4H), 0.94 (d, <em>J</em> = 16.3 Hz, 9H), 0.18 (dd, <em>J</em> = 21.2, 9.3 Hz, 6H). <sup>31</sup>P NMR (203 MHz, MeOD)
δ 67.87, −3.69, −4.22. <sup>13</sup>C NMR (126
MHz, MeOD): δ 180.32, 166.73, 156.10, 152.08, 151.16, 149.95,
148.55, 141.86, 139.20, 133.53, 132.57, 128.87, 128.41, 128.21, 128.09,
124.06, 120.61, 119.90, 117.14, 117.06, 116.90, 86.58, 86.04, 85.96,
85.54, 84.87, 78.78, 78.45, 78.34, 76.99, 72.77, 71.53, 71.30, 67.86,
63.68, 63.31, 48.12, 47.95, 47.78, 47.61, 47.44, 47.27, 47.10, 35.60,
31.35, 29.29, 24.94, 24.91, 22.30, 18.69, 18.57, 18.43, 18.36, 18.09,
17.81, 17.63, 13.03, −4.02, −5.55, −5.69, −5.92,
−6.00.</p></section><section id="sec5.1.30"><h4 class="pmc_sec_title">Synthesis of 1<em>S</em>,3<em>R</em>,4<em>R</em>,7<em>S</em>)-3-(6-Benzamido-9<em>H</em>-purin-9-yl)-1-(Iodomethyl)-2,5-dioxabicyclo­[2.2.1]­heptan-7-yl (((2<em>S</em>,4<em>R</em>,5<em>R</em>)-4-((bis­(2-cyanoethoxy)­Phosphorothioyl)­oxy)-5-(2-Isobutyramido-6-Oxo-1,6-Dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl) (2-cyanoethyl)
Phosphate (<strong>40c</strong>
</h4>
<p>
<strong>40c</strong> was synthesized
from <strong>III</strong> (0.48 mmol) and <strong>40a</strong> (0.63 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d</strong>. The product (0.1 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1147.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.70 (d, <em>J</em> =
17.5 Hz, 1H), 8.55 (d, <em>J</em> = 32.3 Hz, 1H), 8.14–8.10
(m, 1H), 8.08 (dd, <em>J</em> = 6.8, 2.4 Hz, 2H), 7.68–7.62
(m, 1H), 7.57 (q, <em>J</em> = 7.5 Hz, 3H), 6.25 (s, 1H),
6.22–6.12 (m, 1H), 5.24–5.17 (m, 1H), 4.51–4.46
(m, 1H), 4.44 (t, <em>J</em> = 5.3 Hz, 1H), 4.40–4.35
(m, 1H), 4.35–4.30 (m, 2H), 4.30–4.25 (m, 3H), 4.25–4.23
(m, 1H), 4.19 (dd, <em>J</em> = 9.4, 5.8 Hz, 1H), 4.10 (dd, <em>J</em> = 12.7, 4.6 Hz, 2H), 3.64 (s, 1H), 3.62 (d, <em>J</em> = 7.9 Hz, 1H), 2.90 (td, <em>J</em> = 5.8, 1.1 Hz, 1H),
2.84 (dd, <em>J</em> = 11.1, 5.7 Hz, 4H), 2.80 (dd, <em>J</em> = 10.8, 4.8 Hz, 2H), 2.76–2.69 (m, 2H), 2.54–2.45
(m, 1H), 1.29 (d, <em>J</em> = 4.3 Hz, 4H), 1.20 (dt, <em>J</em> = 6.9, 2.5 Hz, 8H), 0.92–0.87 (m, 2H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 66.37, −3.81. <sup>13</sup>C
NMR (126 MHz, MeOD): δ 180.38, 166.69, 156.02, 152.02, 151.10,
149.89, 148.59, 148.45, 141.89, 141.69, 139.26, 138.85, 133.50, 132.55,
128.38, 128.17, 128.11, 123.88, 120.58, 117.11, 89.89, 86.44, 85.81,
81.04, 80.48, 78.78, 78.55, 78.20, 72.83, 72.69, 69.15, 63.47, 63.34,
48.10, 47.93, 47.76, 47.59, 47.42, 47.25, 47.08, 35.53, 32.96, 31.66,
31.34, 29.34, 22.29, 18.71, 18.51, 18.05, 17.99, 17.93, 13.02, −1.46,
−4.30.</p></section><section id="sec5.1.31"><h4 class="pmc_sec_title">Synthesis of (1<em>S</em>,3<em>R</em>,4<em>R</em>,7<em>S</em>)-3-(6-Benzamido-9<em>H</em>-purin-9-yl)-1-(Iodomethyl)-2,5-dioxabicyclo­[2.2.1]­heptan-7-yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)­tetrahydrofuran-2-yl)­methyl)
(2-Cyanoethyl) Phosphate (<strong>40d</strong>)</h4>
<p>
<strong>40d</strong> was synthesized from <strong>VI</strong> (0.48 mmol) and <strong>40a</strong> (0.63 mmol, 1.5 equiv) using the same procedure as the synthesis
of <strong>34d</strong>. The product (0.13 g) was isolated as a pale yellow
solid. ESI–MS: <em>m</em>/<em>z</em> = 1297.1
[M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.74
(d, <em>J</em> = 2.9 Hz, 1H), 8.71–8.69 (m, 2H), 8.64
(d, <em>J</em> = 2.0 Hz, 1H), 8.59 (d, <em>J</em> =
8.4 Hz, 1H), 8.07 (t, <em>J</em> = 7.0 Hz, 6H), 7.67–7.62
(m, 3H), 7.56 (dt, <em>J</em> = 8.5, 5.9 Hz, 5H), 6.40 (dd, <em>J</em> = 19.2, 5.4 Hz, 1H), 6.24 (q, <em>J</em> = 6.5
Hz, 2H), 6.19 (d, <em>J</em> = 4.4 Hz, 1H), 5.76 (ddt, <em>J</em> = 21.4, 11.4, 5.2 Hz, 1H), 5.21–5.13 (m, 4H), 5.13–5.06
(m, 1H), 4.57 (s, 1H), 4.54 (d, <em>J</em> = 6.0 Hz, 2H),
4.33 (d, <em>J</em> = 5.1 Hz, 1H), 4.30 (t, <em>J</em> = 6.8 Hz, 2H), 4.26 (dd, <em>J</em> = 9.5, 4.8 Hz, 1H),
4.24–4.19 (m, 1H), 4.14 (t, <em>J</em> = 8.2 Hz, 3H),
3.69 (s, 2H), 3.67–3.59 (m, 2H), 2.91–2.87 (m, 1H),
2.86 (d, <em>J</em> = 5.1 Hz, 2H), 2.74 (q, <em>J</em> = 5.2 Hz, 2H), 1.85 (dd, <em>J</em> = 18.0, 10.5 Hz, 4H),
1.46 (ddd, <em>J</em> = 17.2, 11.3, 6.2 Hz, 2H), 1.28 (s,
3H), 0.97 (d, <em>J</em> = 1.3 Hz, 9H), 0.90 (t, <em>J</em> = 6.8 Hz, 2H), 0.21 (dd, <em>J</em> = 12.1, 6.4 Hz, 6H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.96, 67.92, 30.34, 30.05,
−3.73, −3.80. <sup>13</sup>C NMR (126 MHz, MeOD): δ
166.74, 152.08, 149.90, 141.84, 128.38, 128.35, 128.11, 128.06, 125.53,
120.45, 120.41, 120.24, 120.21, 117.03, 86.51, 85.91, 78.72, 76.95,
72.90, 63.61, 31.35, 24.95, 22.30, 18.39, 17.64, 13.02, 10.65, 9.39,
−1.44, −4.49, −5.52, −6.01.</p></section><section id="sec5.1.32"><h4 class="pmc_sec_title">Synthesis of (1<em>S</em>,3<em>R</em>,4<em>R</em>,7<em>S</em>)-3-(6-Benzamido-9<em>H</em>-purin-9-yl)-1-(iodomethyl)-2,5-Dioxabicyclo­[2.2.1]­heptan-7-yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-3-((<em>tert</em>-Butyldimethylsilyl)­oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1­(2<em>H</em>)-yl)­tetrahydrofuran-2-yl)­methyl) (2-cyanoethyl) Phosphate
(<strong>40e</strong>)</h4>
<p>
<strong>40e</strong> was synthesized from <strong>VII</strong> (0.48 mmol) and <strong>40a</strong> (0.63 mmol, 1.5 equiv)
using the same procedure as the synthesis of <strong>34d</strong>. The
product (0.095 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1170.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.74 (d, <em>J</em> =
3.3 Hz, 1H), 8.69 (d, <em>J</em> = 11.3 Hz, 1H), 8.63–8.54
(m, 2H), 8.09 (dt, <em>J</em> = 5.4, 2.5 Hz, 2H), 7.68–7.64
(m, 2H), 7.57 (td, <em>J</em> = 5.2, 2.5 Hz, 3H), 6.28 (s,
1H), 6.22 (d, <em>J</em> = 27.5 Hz, 1H), 5.99 (dd, <em>J</em> = 31.1, 5.7 Hz, 1H), 5.73 (t, <em>J</em> = 7.9
Hz, 1H), 5.26–5.20 (m, 1H), 5.16 (dd, <em>J</em> =
9.3, 6.0 Hz, 3H), 5.05 (dt, <em>J</em> = 12.1, 5.3 Hz, 1H),
4.97 (dt, <em>J</em> = 12.3, 5.5 Hz, 2H), 4.57 (s, 1H), 4.55–4.44
(m, 2H), 4.41–4.33 (m, 4H), 4.32–4.23 (m, 4H), 4.23–4.17
(m, 2H), 4.15 (dt, <em>J</em> = 8.3, 2.8 Hz, 2H), 4.10 (d, <em>J</em> = 2.3 Hz, 1H), 3.76–3.68 (m, 3H), 2.99 (s, 2H),
2.92 (dtd, <em>J</em> = 8.9, 5.8, 1.2 Hz, 3H), 2.86 (d, <em>J</em> = 0.7 Hz, 4H), 1.85 (dd, <em>J</em> = 18.0, 10.5
Hz, 2H), 1.28 (s, 3H), 0.93 (d, <em>J</em> = 2.9 Hz, 9H),
0.91–0.88 (m, 2H), 0.20–0.11 (m, 6H). <sup>31</sup>P
NMR (203 MHz, MeOD) δ 68.51, 68.43, 30.35, 30.07, −3.39,
−3.74. <sup>13</sup>C NMR (126 MHz, MeOD): δ 166.73,
164.35, 163.45, 152.11, 152.01, 151.09, 150.72, 149.92, 141.83, 141.62,
141.52, 141.24, 133.55, 132.53, 129.75, 129.60, 128.38, 128.09, 128.05,
125.51, 125.34, 123.97, 120.41, 120.21, 117.16, 102.35, 102.27, 88.51,
87.90, 86.47, 85.87, 83.32, 83.14, 79.06, 78.93, 78.81, 78.74, 78.34,
78.19, 77.66, 77.52, 76.93, 76.74, 72.89, 72.79, 70.40, 67.16, 63.75,
63.58, 63.44, 48.10, 47.93, 47.76, 47.59, 47.42, 47.25, 47.08, 35.54,
31.33, 30.24, 24.90, 22.28, 18.79, 18.64, 18.58, 18.49, 18.43, 17.57,
13.02, 10.65, −1.45, −4.15, −4.34, −4.49,
−5.56, −6.08, −6.14.</p></section><section id="sec5.1.33"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-3-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-fluorotetrahydrofuran-2-yl)­methyl
((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl)
(2-cyanoethyl) Phosphate (<strong>41a</strong>)</h4>
<p>
<strong>41a</strong> was synthesized from <strong>XI</strong> (0.48 mmol) and <strong>VIII</strong> (0.63 mmol, 1.5 equiv) using the same procedure as the synthesis
of <strong>34d</strong>. The product (0.15 g) was isolated as a pale yellow
solid. ESI–MS: <em>m</em>/<em>z</em> = 1174.8
[M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.77
(d, <em>J</em> = 17.4 Hz, 1H), 8.69 (s, 1H), 8.54 (d, <em>J</em> = 3.0 Hz, 1H), 8.52 (d, <em>J</em> = 6.5 Hz, 1H),
8.08–8.03 (m, 3H), 8.03–7.99 (m, 1H), 7.67–7.61
(m, 1H), 7.61–7.57 (m, 1H), 7.58–7.52 (m, 3H), 7.52–7.48
(m, 1H), 6.51 (ddd, <em>J</em> = 19.6, 8.7, 1.3 Hz, 1H), 6.37
(ddd, <em>J</em> = 44.0, 18.9, 2.6 Hz, 1H), 6.06 (d, <em>J</em> = 5.0 Hz, 1H), 5.98–5.94 (m, 1H), 5.45 (ddt, <em>J</em> = 29.8, 12.5, 6.9 Hz, 1H), 4.67 (ddt, <em>J</em> = 8.8, 5.7, 2.9 Hz, 1H), 4.65–4.51 (m, 2H), 4.45–4.35
(m, 4H), 4.31 (dp, <em>J</em> = 8.8, 3.1 Hz, 1H), 4.25 (dt, <em>J</em> = 7.2, 5.9 Hz, 1H), 4.19 (d, <em>J</em> = 6.0
Hz, 1H), 4.00 (d, <em>J</em> = 5.6 Hz, 1H), 3.60 (ddd, <em>J</em> = 25.7, 11.2, 5.0 Hz, 1H), 3.44 (ddd, <em>J</em> = 38.6, 11.2, 5.8 Hz, 1H), 3.01–2.90 (m, 5H), 2.87 (td, <em>J</em> = 5.8, 1.2 Hz, 1H), 2.15 (s, 3H), 1.97 (s, 1H), 1.29 (s,
2H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.24, 67.17, −3.23,
−3.31. <sup>13</sup>C NMR (126 MHz, MeOD): δ 166.74,
152.26, 151.37, 143.78, 133.50, 132.55, 128.86, 128.37, 128.09, 124.07,
123.11, 119.92, 117.27, 117.15, 91.95, 90.42, 87.21, 80.18, 79.49,
76.83, 72.98, 66.15, 63.68, 63.51, 48.11, 47.94, 47.77, 47.60, 47.43,
47.26, 47.09, 29.28, 18.63, 13.03, 2.22.</p></section><section id="sec5.1.34"><h4 class="pmc_sec_title">Synthesis of (2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-3-(((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-fluorotetrahydrofuran-2-yl)­methyl
(2-cyanoethyl) ((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(iodomethyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>41b</strong>)</h4>
<p>
<strong>41b</strong> was synthesized from <strong>XI</strong> (0.48
mmol) and <strong>IX</strong> (0.63 mmol, 1.5 equiv) using the same procedure
as the synthesis of <strong>34d</strong>. The product (0.131 g) was isolated
as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1156.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz,
MeOD δ) 8.79 (d, <em>J</em> = 35.8 Hz, 1H), 8.55 (d, <em>J</em> = 45.6 Hz, 1H), 8.09 (d, <em>J</em> = 9.0 Hz,
1H), 8.06–7.89 (m, 2H), 7.63 (dt, <em>J</em> = 15.3,
7.5 Hz, 1H), 7.54 (t, <em>J</em> = 7.7 Hz, 1H), 7.48 (t, <em>J</em> = 7.7 Hz, 1H), 6.51 (t, <em>J</em> = 19.6 Hz,
1H), 6.29–6.10 (m, 1H), 6.10–5.94 (m, 2H), 5.80–5.59
(m, 1H), 5.32–5.10 (m, 1H), 4.70–4.48 (m, 3H), 4.40
(ddt, <em>J</em> = 16.9, 9.2, 5.8 Hz, 3H), 4.28 (dt, <em>J</em> = 7.3, 5.9 Hz, 1H), 4.26–4.20 (m, 1H), 3.57 (dd, <em>J</em> = 11.3, 4.8 Hz, 1H), 3.45 (dt, <em>J</em> = 10.8,
5.4 Hz, 1H), 3.38–3.34 (m, 1H), 3.00–2.90 (m, 4H), 2.88–2.82
(m, 1H), 2.75–2.69 (m, 1H), 2.15 (s, 2H), 1.98 (s, 1H), 1.28
(s, 1H), 1.25–1.16 (m, 6H), 0.90 (t, <em>J</em> = 6.9
Hz, 1H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.28, 67.20,
−2.81, −3.07. <sup>13</sup>C NMR (126 MHz, MeOD): δ
180.36, 152.29, 151.33, 148.50, 143.98, 143.76, 139.06, 132.63, 128.87,
128.38, 128.33, 128.09, 127.94, 123.96, 123.13, 120.50, 119.92, 117.27,
117.10, 87.95, 87.67, 76.82, 72.99, 66.17, 63.71, 63.48, 48.11, 47.95,
47.77, 47.60, 47.43, 47.26, 47.09, 35.63, 31.34, 29.28, 22.29, 18.73,
18.61, 18.01, 17.91, 13.02, 2.58, 2.17.</p></section><section id="sec5.1.35"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-3-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-Fluoro-5-(2-Isobutyramido-6-Oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl) (2-cyanoethyl)
Phosphate (<strong>41c</strong>)</h4>
<p>
<strong>41c</strong> was synthesized
from <strong>XII</strong> (0.48 mmol) and <strong>VIII</strong> (0.63 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d.</strong> The product (0.15 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1156.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.71 (d, <em>J</em> =
29.5 Hz, 1H), 8.54 (d, <em>J</em> = 14.7 Hz, 1H), 8.11 (d, <em>J</em> = 7.1 Hz, 1H), 8.08 (d, <em>J</em> = 4.2 Hz, 2H),
7.66 (t, <em>J</em> = 7.4 Hz, 1H), 7.57 (t, <em>J</em> = 7.6 Hz, 2H), 6.44 (ddd, <em>J</em> = 19.2, 7.1, 2.4 Hz,
1H), 6.33 (ddd, <em>J</em> = 17.1, 14.7, 3.0 Hz, 1H), 6.06
(dd, <em>J</em> = 51.8, 34.1 Hz, 1H), 5.81 (ddt, <em>J</em> = 51.1, 24.1, 3.5 Hz, 1H), 5.55–5.47 (m, 1H), 4.71–4.59
(m, 2H), 4.44 (d, <em>J</em> = 6.1 Hz, 1H), 4.36 (dtd, <em>J</em> = 11.0, 6.2, 2.3 Hz, 3H), 4.27–4.22 (m, 1H), 3.70–3.63
(m, 1H), 3.52 (ddd, <em>J</em> = 13.4, 11.2, 5.7 Hz, 1H),
2.96 (q, <em>J</em> = 5.1 Hz, 2H), 2.92 (q, <em>J</em> = 6.1 Hz, 3H), 2.75 (td, <em>J</em> = 6.8, 4.3 Hz, 1H),
1.29 (s, 2H), 1.24–1.17 (m, 6H), 0.90 (t, <em>J</em> = 6.8 Hz, 1H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.07,
66.97, −3.25, −3.31. <sup>13</sup>C NMR (126 MHz, MeOD):
δ 180.21, 166.79, 159.18, 151.41, 148.64, 143.78, 138.50, 132.57,
128.86, 128.38, 128.12, 119.92, 117.39, 117.20, 113.08, 87.01, 80.29,
76.93, 73.23, 63.63, 48.11, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09,
35.64, 29.37, 18.66, 18.06, 17.81, 15.88, 2.09.</p></section><section id="sec5.1.36"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-3-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-Fluoro-5-(2-Isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl (2-Cyanoethyl)
((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(iodomethyl)-5-(6-Oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>41d</strong>)</h4>
<p>
<strong>41d</strong> was synthesized from <strong>XII</strong> (0.48 mmol) and <strong>X</strong> (0.63 mmol, 1.5 equiv) using the
same procedure as the synthesis of <strong>34d</strong>. The product (0.15
g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1053.6 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(500 MHz, MeOD δ) 8.21 (d, <em>J</em> = 9.8 Hz, 1H),
8.13–8.09 (m, 1H), 8.08 (d, <em>J</em> = 8.9 Hz, 1H),
6.38–6.30 (m, 2H), 5.98 (s, 1H), 5.90–5.82 (m, 1H),
5.78 (s, 1H), 5.52 (s, 2H), 5.16 (s, 1H), 4.63 (d, <em>J</em> = 5.9 Hz, 2H), 4.57 (s, 2H), 4.43–4.31 (m, 6H), 4.20 (d, <em>J</em> = 5.6 Hz, 1H), 3.95 (s, 1H), 3.62 (dt, <em>J</em> = 11.2, 5.5 Hz, 1H), 3.50 (dt, <em>J</em> = 10.9, 5.5 Hz,
2H), 3.21 (s, 1H), 3.16 (p, <em>J</em> = 1.6 Hz, 2H), 2.92
(dq, <em>J</em> = 17.6, 5.9 Hz, 7H), 2.41 (s, 1H), 2.31 (s,
1H), 2.25 (s, 1H), 2.15 (s, 1H), 1.95 (s, 1H), 1.29 (s, 2H), 1.25–1.21
(m, 6H), 0.90 (s, 1H). <sup>31</sup>P NMR (203 MHz, MeOD) δ
67.11, 67.02, −3.29.</p></section><section id="sec5.1.37"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-3-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-fluorotetrahydrofuran-2-yl)­methyl
(2-cyanoethyl) ((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(iodomethyl)-5-(6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>40e</strong>)</h4>
<p>
<strong>41e</strong> was synthesized from <strong>XI</strong> (0.48
mmol) and <strong>X</strong> (0.63 mmol, 1.5 equiv) using the same procedure
as the synthesis of <strong>34d</strong>. The product (0.10 g) was isolated
as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1071.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (800 MHz,
D<sub>2</sub>O δ) 10.17 (s, 1H), 9.64 (s, 1H), 9.48 (s, 4H),
9.03 (d, <em>J</em> = 71.3 Hz, 3H), 8.65 (d, <em>J</em> = 48.4 Hz, 5H), 7.93 (s, 1H), 5.81 (s, 2H), 4.36 (s, 3H), 2.71 (s,
10H), 2.32 (s, 1H), 1.43 (s, 24H). <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 168.23, 163.08, 147.15, 133.96, 130.20, 129.77,
129.51, 124.38, 121.33, 118.48, 113.99, 76.23, 64.86, 30.74, 19.94,
14.41, −7.63.</p></section><section id="sec5.1.38"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-3-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-Fluoro-5-(6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl (2-Cyanoethyl)
((2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-4-Fluoro-2-(iodomethyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>41f</strong>)</h4>
<p>
<strong>41f</strong> was synthesized from <strong>XIII</strong> (0.48 mmol) and <strong>IX</strong> (0.63 mmol, 1.5 equiv) using the
same procedure as the synthesis of <strong>34d</strong>. The product (0.09
g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1053.7 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(500 MHz, MeOD δ) 8.29–8.18 (m, 1H), 8.16–8.02
(m, 2H), 6.45–6.36 (m, 1H), 6.24 (ddd, <em>J</em> =
18.3, 7.1, 2.8 Hz, 1H), 5.93–5.86 (m, 1H), 5.86–5.78
(m, 1H), 5.78–5.73 (m, 1H), 5.21 (ddt, <em>J</em> =
19.2, 13.5, 6.2 Hz, 1H), 4.66–4.58 (m, 1H), 4.53 (ddd, <em>J</em> = 17.0, 11.0, 6.4 Hz, 2H), 4.42–4.38 (m, 1H), 4.38–4.33
(m, 2H), 4.33–4.28 (m, 2H), 4.03–3.93 (m, 1H), 3.91–3.70
(m, 1H), 3.49 (ddd, <em>J</em> = 11.4, 5.5, 3.7 Hz, 1H), 2.96–2.86
(m, 6H), 2.84–2.70 (m, 2H), 2.15 (s, 1H), 1.29 (s, 2H), 1.25–1.21
(m, 6H), 0.90 (t, <em>J</em> = 6.9 Hz, 1H). <sup>31</sup>P
NMR (203 MHz, MeOD) δ 67.13, 67.05, −2.88, −3.11,
−3.12. <sup>13</sup>C NMR (126 MHz, MeOD): δ 180.62,
157.48, 148.63, 148.04, 146.05, 146.03, 140.01, 139.12, 128.87, 125.07,
120.62, 117.27, 117.17, 114.23, 92.09, 90.56, 86.63, 79.53, 76.85,
73.03, 66.39, 63.63, 56.07, 48.11, 47.94, 47.77, 47.60, 47.43, 47.26,
47.09, 35.60, 18.57, 17.97, 17.93, 15.87, 13.01, 2.35, 2.14.</p></section><section id="sec5.1.39"><h4 class="pmc_sec_title">Synthesis of (2<em>S</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-5-(6-Benzamido-9<em>H</em>-purin-9-yl)-4-Fluoro-2-(iodomethyl)­tetrahydrofuran-3-yl (((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-3-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-Fluoro-5-(6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl) (2-Cyanoethyl)
Phosphate (<strong>41g</strong>)</h4>
<p>
<strong>41g</strong> was synthesized
from <strong>XIII</strong> (0.48 mmol) and <strong>VIII</strong> (0.63 mmol,
1.5 equiv) using the same procedure as the synthesis of <strong>34d</strong>. The product (0.11 g) was isolated as a pale yellow solid. ESI–MS: <em>m</em>/<em>z</em> = 1071.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.74 (d, <em>J</em> =
6.9 Hz, 1H), 8.54 (d, <em>J</em> = 1.7 Hz, 1H), 8.21 (d, <em>J</em> = 10.1 Hz, 1H), 8.09 (d, <em>J</em> = 6.4 Hz,
2H), 7.66 (t, <em>J</em> = 7.4 Hz, 1H), 7.57 (t, <em>J</em> = 7.7 Hz, 2H), 6.47–6.36 (m, 2H), 6.03 (d, <em>J</em> = 51.4 Hz, 1H), 5.90 (d, <em>J</em> = 7.9 Hz, 1H), 5.83
(d, <em>J</em> = 12.0 Hz, 1H), 5.82–5.77 (m, 1H), 5.50
(dd, <em>J</em> = 14.9, 6.9 Hz, 1H), 4.66 (dd, <em>J</em> = 10.3, 5.0 Hz, 1H), 4.57 (dd, <em>J</em> = 14.9, 8.8 Hz,
3H), 4.42–4.31 (m, 6H), 4.23 (t, <em>J</em> = 5.8 Hz,
1H), 3.63 (ddd, <em>J</em> = 22.1, 11.2, 4.7 Hz, 1H), 3.48
(ddd, <em>J</em> = 29.0, 11.3, 5.5 Hz, 1H), 2.92 (dq, <em>J</em> = 16.0, 6.0 Hz, 6H), 2.15 (s, 2H), 1.99 (s, 1H), 1.29
(s, 6H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.07, 67.04,
−3.20, −3.24. <sup>13</sup>C NMR (126 MHz, MeOD): δ
166.87, 157.46, 152.12, 150.08, 148.00, 146.00, 143.73, 140.18, 132.58,
128.85, 128.39, 128.12, 119.94, 117.18, 101.34, 92.03, 90.54, 87.91,
86.97, 80.17, 79.59, 76.81, 73.12, 63.61, 63.59, 56.07, 48.11, 47.94,
47.77, 47.60, 47.43, 47.26, 47.09, 22.81, 18.56, 15.72, 2.17.</p></section><section id="sec5.1.40"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-3-((Bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-Fluoro-5-(2-isobutyramido-6-oxo-1,6-dihydro-<em>9H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl (2-cyanoethyl)
((2S,3R,4R,5R)-4-fluoro-2-(iodomethyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-3-yl) Phosphate (<strong>41h</strong>)</h4>
<p>
<strong>41h</strong> was synthesized from <strong>XII</strong> (0.48 mmol) and <strong>IX</strong> (0.63 mmol, 1.5 equiv) using the
same procedure as the synthesis of <strong>34d</strong>. The product (0.2
g) was isolated as a pale yellow solid. ESI-MS: <em>m</em>/<em>z</em> = 1138.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(500 MHz, MeOD δ) 8.14 (d, <em>J</em> = 12.0 Hz, 1H),
8.09 (d, <em>J</em> = 11.8 Hz, 1H), 6.33 (ddd, <em>J</em> = 25.7, 16.9, 2.8 Hz, 1H), 6.21 (dd, <em>J</em> = 18.1,
3.2 Hz, 1H), 5.98–5.90 (m, 1H), 5.88–5.78 (m, 1H), 5.75
(s, 1H), 5.50 (s, 1H), 5.27 (s, 1H), 4.65–4.58 (m, 2H), 4.57
(t, <em>J</em> = 4.9 Hz, 1H), 4.42–4.37 (m, 3H), 4.37–4.32
(m, 3H), 4.23–4.17 (m, 1H), 3.60–3.41 (m, 2H), 2.95
(q, <em>J</em> = 6.2 Hz, 4H), 2.92–2.90 (m, 2H), 2.81–2.70
(m, 2H), 2.15 (s, 4H), 1.24–1.21 (m, 6H), 0.90 (d, <em>J</em> = 6.7 Hz, 1H). <sup>31</sup>P NMR (203 MHz, MeOD) δ
67.10, 67.02, −3.06, −3.15. <sup>13</sup>C NMR (126
MHz, MeOD): δ 208.73, 180.24, 156.03, 148.63, 138.85, 138.40,
128.91, 120.53, 117.39, 117.22, 91.69, 90.14, 86.70, 86.43, 79.95,
76.84, 73.07, 66.39, 63.63, 48.12, 47.95, 47.78, 47.61, 47.44, 47.27,
47.10, 35.66, 31.35, 29.29, 22.29, 18.71, 18.63, 17.98, 17.85, 13.03,
2.32.</p></section><section id="sec5.1.41"><h4 class="pmc_sec_title">Synthesis of ((2<em>R</em>,3<em>R</em>,4<em>R</em>,5<em>R</em>)-3-((bis­(2-cyanoethoxy)­phosphorothioyl)­oxy)-4-Fluoro-5-(2-isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)­tetrahydrofuran-2-yl)­methyl (2-Cyanoethyl)
((1<em>S</em>,3<em>R</em>,4<em>R</em>,7<em>S</em>)-1-(iodomethyl)-3-(2-isobutyramido-6-oxo-1,6-dihydro-9<em>H</em>-purin-9-yl)-2,5-dioxabicyclo­[2.2.1]­heptan-7-yl) Phosphate
(<strong>42b</strong>)</h4>
<p>
<strong>42b</strong> was synthesized from <strong>XII</strong> (0.48 mmol) and <strong>42a</strong> (0.63 mmol, 1.5 equiv)
using the same procedure as the synthesis of <strong>34d</strong>. The
product (0.18 g) was isolated as a pale yellow solid. ESI-MS: <em>m</em>/<em>z</em> = 1148.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, MeOD δ) 8.71 (s, 1H), 8.05 (d, <em>J</em> = 12.0 Hz, 2H), 6.29 (dd, <em>J</em> = 16.9, 3.1
Hz, 1H), 6.04 (s, 1H), 5.85–5.67 (m, 1H), 5.44 (d, <em>J</em> = 30.9 Hz, 1H), 5.11 (d, <em>J</em> = 12.3 Hz,
2H), 4.63–4.51 (m, 4H), 4.42–4.30 (m, 5H), 4.30–4.23
(m, 2H), 4.14–4.01 (m, 3H), 3.64 (s, 2H), 3.22 (s, 2H), 3.11
(s, 2H), 2.93 (dt, <em>J</em> = 11.8, 5.9 Hz, 4H), 2.83 (s,
1H), 2.75–2.67 (m, 1H), 2.15 (d, <em>J</em> = 0.8 Hz,
2H), 1.29 (s, 3H), 1.23–1.17 (m, 6H), 0.90 (t, <em>J</em> = 6.8 Hz, 1H). <sup>31</sup>P NMR (203 MHz, MeOD) δ 67.04,
−4.05. <sup>13</sup>C NMR (126 MHz, MeOD): δ 180.19,
158.79, 157.94, 149.71, 138.52, 136.44, 128.84, 117.45, 117.25, 91.19,
87.01, 86.30, 85.73, 79.95, 78.79, 78.16, 73.36, 72.66, 66.63, 63.61,
48.11, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 40.19, 35.66, 34.05,
29.27, 18.61, 18.01, 17.84, 13.02, −4.13.</p></section></section><section id="sec5.2"><h3 class="pmc_sec_title">General Synthesis of Endo-S-CDNs</h3>
<p>For the synthesis
of <strong>3</strong>,<strong>4</strong>, <strong>6</strong>–<strong>9</strong>, <strong>12</strong>–<strong>19</strong>, and <strong>21</strong>–<strong>24</strong>: Ammonium hydroxide (5 mL, 30% ammonia in water) was added
to representative iodide intermediate (<strong>31d</strong>–<strong>40e</strong>, 0.038 mmol) and the reaction was left to stir at RT for
24 h. The cyclized product was then dried under reduced pressure and
then pyridine (1 mL) and Et<sub>3</sub>N·3HF (125 μL, 0.798
mmol) was added and left to stir at 55–60 °C for 6 h.
Ten milliliters of acetone was then added to precipitate the respective
products, and this was collected via centrifugation as an off-white
solid. The isolated product was washed 3x with 1 mL acetone before
being left to dry overnight. The product was then dissolved in 5 mL
of water and then purified via reverse phase (RP)-HPLC using either
COSMOSIL C18-PAQ or Xterra RP18 5.0 μm or Hypersil Gold PFP
packed columns with gradient comprising of 0–16 min: 99%–87%
0.1 M triethylammonium acetate (TEAA), 1–13% acetonitrile,
16–23 min: 87–10% 0.1 M TEAA, 13–90% acetonitrile
23–25 min: 10–99% 0.1 M TEAA, 90–1% acetonitrile
or 0–16 min: 99%–87% of 0.1% formic acid, 1–13%
acetonitrile, 16–23 min: 87–10% of 0.1% formic acid,
13–90% acetonitrile 23–25 min: 10–99% of 0.1%
formic acid, 90–1% acetonitrile to afford either the triethylammonium
or proton salt, respectively. Dowex 50W X8 was used for the salt exchange
to convert the triethylammonium salt to the sodium salt for <strong>3</strong>, <strong>4</strong>, and <strong>8</strong> which was used for the
in vivo studies.</p>
<p>For the synthesis of <strong>5</strong>, <strong>20</strong>, <strong>25–33</strong>: 5 mL of ammonium hydroxide
solution (30% ammonia in water) was added to dinucleotide iodide intermediate
(<strong>38l</strong>, <strong>40c</strong>, and <strong>41a</strong>–<strong>42b</strong>, 0.038 mmol) and stirred for 24 h at RT. The macrocyclized
product was then dried under reduced pressure. Five ml of water was
added to dissolve about 20 mg of crude product and this solution was
purified via RP-HPLC using same procedure as described for the synthesis
of <strong>3</strong>,<strong>4</strong>, <strong>6</strong>–<strong>9</strong>, <strong>12</strong>–<strong>19</strong>, and <strong>21</strong>–<strong>24</strong>.</p>
<section id="sec5.2.1"><h4 class="pmc_sec_title">Characterization of <strong>3</strong>
</h4>
<p>Off-white solid,
30% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.23
(d, <em>J</em> = 2.6 Hz, 1H), 8.14 (d, <em>J</em> =
2.6 Hz, 1H), 8.04 (s, 1H), 6.35 (dt, <em>J</em> = 17.5, 2.6
Hz, 1H), 5.99 (dd, <em>J</em> = 8.2, 2.6 Hz, 1H), 5.70 (dd, <em>J</em> = 5.0, 2.6 Hz, 1H), 5.64 (dd, <em>J</em> = 4.9,
2.5 Hz, 1H), 5.48 (td, <em>J</em> = 7.8, 4.2 Hz, 1H), 5.18–5.12
(m, 3H), 4.60 (t, <em>J</em> = 3.4 Hz, 1H), 4.55–4.53
(m, 1H), 4.39–4.37 (m, 1H), 4.21 (dt, <em>J</em> =
5.2, 2.6 Hz, 4H), 3.37 (dtd, <em>J</em> = 11.5, 6.1, 3.0 Hz,
2H), 3.04 (ddt, <em>J</em> = 13.9, 11.1, 2.7 Hz, 2H), 1.92
(d, <em>J</em> = 2.5 Hz, 2H). <sup>31</sup>P NMR (203 MHz,
D<sub>2</sub>O) δ 18.78, −1.24. <sup>13</sup>C NMR (201
MHz, D<sub>2</sub>O) δ 178.84, 158.85, 154.51, 153.53, 151.99,
151.33, 148.31, 140.03, 138.80, 118.82, 116.43, 91.87, 90.92, 86.80,
86.63, 85.18, 84.15, 80.34, 76.60, 72.42, 71.69, 65.83, 30.80, 21.63,
10.42. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for
C<sub>20</sub>H<sub>22</sub>FN<sub>10</sub>O<sub>11</sub>P<sub>2</sub>S [M-H]<sup>−</sup> 691.064956, found 691.06582.</p></section><section id="sec5.2.2"><h4 class="pmc_sec_title">Characterization of <strong>4</strong>
</h4>
<p>Off-white solid,
29% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.18
(s, 1H), 8.07 (d, <em>J</em> = 2.6 Hz, 1H), 7.81 (s, 1H),
6.09 (s, 1H), 5.97 (d, <em>J</em> = 8.0 Hz, 1H), 5.84 (d, <em>J</em> = 10.6 Hz, 2H), 4.66–4.58 (m, 1H), 4.35 (s, 2H),
4.12 (d, <em>J</em> = 8.3 Hz, 2H), 4.07 (td, <em>J</em> = 7.2, 3.8 Hz, 2H), 3.96 (d, <em>J</em> = 8.2 Hz, 2H), 3.40
(d, <em>J</em> = 13.4 Hz, 2H), 2.98 (t, <em>J</em> = 12.9 Hz, 2H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ
18.43, −1.00. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O)
δ 159.03, 155.62, 152.96, 152.79, 151.67, 147.84, 140.31, 138.03,
118.89, 117.02, 86.95, 86.80, 86.18, 83.70, 78.58, 74.82, 73.43, 73.24,
71.49, 64.74. HRMS (ESI-) <em>m</em>/<em>z</em> calcd
for C<sub>21</sub>H<sub>23</sub>N<sub>10</sub>O<sub>12</sub>P<sub>2</sub>S [M-H]<sup>−</sup> 701.069293, found 701.069293.</p></section><section id="sec5.2.3"><h4 class="pmc_sec_title">Characterization of <strong>5</strong>
</h4>
<p>Off-white solid,
23% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.18
(d, <em>J</em> = 29.4 Hz, 1H), 7.95 (d, <em>J</em> = 2.1 Hz, 2H), 5.93–5.79 (m, 1H), 5.78–5.73 (m, 2H),
5.41 (d, <em>J</em> = 9.1 Hz, 1H), 5.18–5.10 (m, 1H),
4.59 (s, 1H), 4.29 (d, <em>J</em> = 11.5 Hz, 1H), 4.23–4.17
(m, 2H), 4.11 (d, <em>J</em> = 14.1 Hz, 3H), 3.88 (s, 2H),
3.40 (dd, <em>J</em> = 13.6, 6.8 Hz, 1H), 2.98 (s, 1H), 2.85
(dt, <em>J</em> = 14.1, 7.4 Hz, 1H), 2.42–2.40 (m,
1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 17.33, −1.35. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 158.99, 155.62, 153.69,
152.90, 148.57, 139.79, 138.11, 118.85, 116.54, 91.08, 88.36, 86.67,
80.32, 79.18, 77.59, 72.40, 68.08, 46.65, 42.23, 33.09, 30.67, 10.50,
8.20. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for
[C<sub>20</sub>H<sub>21</sub>FN<sub>10</sub>O<sub>10</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 337.03165, found 337.03119.</p></section><section id="sec5.2.4"><h4 class="pmc_sec_title">Characterization of <strong>6</strong>
</h4>
<p>Off-white solid,
20% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.01
(s, 1H), 7.53 (dd, <em>J</em> = 7.8, 5.0 Hz, 1H), 5.95 (d, <em>J</em> = 18.2 Hz, 3H), 5.91 (d, <em>J</em> = 5.0 Hz,
1H), 5.41–5.33 (m, 2H), 5.28 (d, <em>J</em> = 5.6 Hz,
1H), 4.56 (t, <em>J</em> = 4.8 Hz, 1H), 4.44 (s, 2H), 4.39
(s, 1H), 4.18 (p, <em>J</em> = 6.4 Hz, 4H), 3.45–3.41
(m, 1H), 3.02 (td, <em>J</em> = 11.4, 6.5 Hz, 2H), 2.98 (t, <em>J</em> = 6.5 Hz, 1H), 1.94 (d, <em>J</em> = 4.9 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.60, −1.19. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 163.63, 158.77, 153.58,
142.27, 95.58, 92.12, 91.18, 90.05, 89.87, 85.46, 84.22, 79.13, 76.81,
71.38, 65.48, 42.15, 30.60, 10.41. HRMS (ESI-) <em>m</em>/<em>z</em> Calcd for [C<sub>19</sub>H<sub>21</sub>FN<sub>8</sub>O<sub>12</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 333.02475, Found 333.02432.</p></section><section id="sec5.2.5"><h4 class="pmc_sec_title">Characterization of <strong>7</strong>
</h4>
<p>Off-white solid,
21% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.14
(d, <em>J</em> = 13.4 Hz, 1H), 7.50–7.41 (m, 1H), 6.01
(t, <em>J</em> = 10.6 Hz, 1H), 5.90 (t, <em>J</em> = 17.6 Hz, 1H), 5.83–5.72 (m, 1H), 5.46–5.38 (m, 2H),
5.40–5.27 (m, 1H), 4.59–4.55 (m, 1H), 4.41–4.35
(m, 2H), 4.19 (q, <em>J</em> = 5.2 Hz, 2H), 3.34 (dd, <em>J</em> = 15.0, 8.3 Hz, 1H), 3.00 (d, <em>J</em> = 13.3
Hz, 2H), 1.99 (d, <em>J</em> = 14.0 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.96, −1.26. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 166.03, 158.53, 153.82,
151.86, 150.88, 142.53, 138.41, 102.21, 91.63, 90.68, 90.20, 85.15,
84.32, 79.43, 76.77, 71.79, 71.60, 65.70, 30.66, 20.49. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>19</sub>H<sub>20</sub>FN<sub>7</sub>O<sub>13</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 333.51695, found 333.51676.</p></section><section id="sec5.2.6"><h4 class="pmc_sec_title">Characterization of <strong>8</strong>
</h4>
<p>Off-white solid,
34% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.23–8.07
(m, 3H), 6.44–6.25 (m, 1H), 6.02 (q, <em>J</em> = 8.6
Hz, 1H), 5.73 (d, <em>J</em> = 51.3 Hz, 2H), 5.51 (s, 2H),
5.28 (d, <em>J</em> = 12.8 Hz, 1H), 4.64–4.55 (m, 2H),
4.52 (t, <em>J</em> = 8.2 Hz, 2H), 4.39 (d, <em>J</em> = 10.8 Hz, 2H), 4.26–4.11 (m, 3H), 3.32 (s, 3H), 3.02 (s,
2H), 1.90–1.79 (m, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 19.06, −1.25. <sup>13</sup>C NMR (201 MHz,
D<sub>2</sub>O) δ 158.92, 158.54, 153.65, 152.11, 148.37, 146.10,
140.28, 138.53, 124.12, 116.31, 91.88, 90.92, 87.17, 87.00, 84.78,
84.17, 80.69, 76.63, 72.74, 71.85, 66.02, 30.77. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>21</sub>FN<sub>9</sub>O<sub>12</sub>P<sub>2</sub>S]<sup>−</sup> [M-H]<sup>−</sup> 692.048972, found 692.04958.</p></section><section id="sec5.2.7"><h4 class="pmc_sec_title">Characterization of <strong>9</strong>
</h4>
<p>Off-white solid,
22% yield. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O) δ 8.17
(s, 1H), 8.12 (s, 1H), 8.09 (d, <em>J</em> = 0.9 Hz, 1H),
6.43 (t, <em>J</em> = 7.1 Hz, 1H), 6.00 (d, <em>J</em> = 8.1 Hz, 1H), 5.45 (td, <em>J</em> = 7.8, 4.1 Hz, 1H),
5.25–5.00 (m, 1H), 4.59 (d, <em>J</em> = 4.4 Hz, 2H),
4.36 (d, <em>J</em> = 3.1 Hz, 3H), 4.18 (dt, <em>J</em> = 6.4, 3.7 Hz, 3H), 3.03–2.98 (m, 2H), 2.97 (d, <em>J</em> = 6.8 Hz, 3H), 2.96–2.89 (m, 2H), 2.71 (ddd, <em>J</em> = 14.5, 6.4, 2.7 Hz, 2H), 2.13 (s, 1H), 1.88 (s, 3H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 19.50, −1.20. HRMS
(ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>21</sub>N<sub>9</sub>O<sub>12</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 336.52583, found 336.52504.</p></section><section id="sec5.2.8"><h4 class="pmc_sec_title">Characterization of <strong>12</strong>
</h4>
<p>Off-white solid,
31% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.59
(s, 1H), 8.08 (s, 1H), 6.20 (dd, <em>J</em> = 17.4, 3.0 Hz,
1H), 6.09 (d, <em>J</em> = 8.1 Hz, 1H), 5.57–5.51 (m,
1H), 5.15 (dq, <em>J</em> = 11.8, 5.9 Hz, 1H), 4.62 (d, <em>J</em> = 4.3 Hz, 1H), 4.49–4.45 (m, 1H), 4.41 (d, <em>J</em> = 2.6 Hz, 1H), 4.25–4.21 (m, 1H), 3.06–3.00
(m, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 19.10,
−1.42. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ
215.40, 157.96, 156.97, 154.54, 154.29, 114.43, 91.61, 90.66, 87.11,
86.94, 85.91, 84.68, 81.21, 76.56, 73.31, 71.93, 66.01, 64.33, 30.93.
HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>21</sub>FN<sub>10</sub>O<sub>12</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 353.02657, found 353.02584.</p></section><section id="sec5.2.9"><h4 class="pmc_sec_title">Characterization of <strong>13</strong>
</h4>
<p>Off-white solid,
4% yield. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O) δ 8.44
(s, 1H), 8.16 (s, 1H), 7.96 (s, 1H), 6.44 (t, <em>J</em> =
7.1 Hz, 1H), 6.07 (d, <em>J</em> = 8.0 Hz, 1H), 5.24 (s, 2H),
4.47 (d, <em>J</em> = 10.1 Hz, 2H), 4.29 (d, <em>J</em> = 12.2 Hz, 1H), 3.49–3.43 (m, 1H), 3.12–3.08 (m, 1H),
3.05–2.90 (m, 3H), 2.81 (d, <em>J</em> = 6.2 Hz, 2H),
2.78 (d, <em>J</em> = 6.2 Hz, 1H), 2.25 (s, 2H), 1.99 (d, <em>J</em> = 9.6 Hz, 2H), 1.79 (d, <em>J</em> = 17.1 Hz,
4H), 1.34 (s, 1H), 1.26 (s, 3H), 1.16 (dt, <em>J</em> = 15.6,
7.2 Hz, 2H), 1.08 (t, <em>J</em> = 7.1 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 34.39, 19.38. HRMS (ESI+) <em>m</em>/<em>z</em> calcd for [C<sub>21</sub>H<sub>27</sub>N<sub>10</sub>O<sub>10</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 673.110763, found 673.10951.</p></section><section id="sec5.2.10"><h4 class="pmc_sec_title">Characterization of <strong>14</strong>
</h4>
<p>Off-white solid,
29% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.66
(t, <em>J</em> = 8.8 Hz, 2H), 8.42 (t, <em>J</em> =
8.0 Hz, 1H), 8.20 (d, <em>J</em> = 3.7 Hz, 1H), 7.90 (d, <em>J</em> = 6.7 Hz, 1H), 6.26 (t, <em>J</em> = 5.7 Hz, 1H),
6.05 (t, <em>J</em> = 4.9 Hz, 1H), 5.29 (ddd, <em>J</em> = 12.1, 8.2, 4.3 Hz, 1H), 4.47–4.42 (m, 2H), 4.24 (dd, <em>J</em> = 11.8, 5.1 Hz, 1H), 4.16–4.10 (m, 1H), 4.05 (q, <em>J</em> = 7.3 Hz, 1H), 3.28 (td, <em>J</em> = 10.0, 3.5
Hz, 2H), 2.88 (q, <em>J</em> = 5.3 Hz, 2H). <sup>31</sup>P
NMR (203 MHz, D<sub>2</sub>O) δ 19.16, −1.02. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 215.33, 154.51, 154.19, 151.33,
150.94, 149.36, 148.89, 145.54, 142.19, 140.37, 126.83, 118.86, 118.23,
117.53, 87.29, 84.74, 84.15, 83.24, 78.29, 75.80, 72.18, 72.07, 66.26,
61.62, 35.16, 32.20, 30.13, 20.41, 15.66, 13.14. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>23</sub>N<sub>10</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>−</sup> [M-H]<sup>−</sup> 673.074378, found 673.07474.</p></section><section id="sec5.2.11"><h4 class="pmc_sec_title">Characterization of <strong>15</strong>
</h4>
<p>Off-white solid,
31% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.65
(d, <em>J</em> = 5.0 Hz, 1H), 8.19 (d, <em>J</em> =
5.0 Hz, 1H), 7.85 (s, 1H), 6.29–6.24 (m, 1H), 5.85 (t, <em>J</em> = 5.9 Hz, 1H), 5.33–5.26 (m, 1H), 4.47–4.42
(m, 1H), 4.39 (dt, <em>J</em> = 5.5, 2.8 Hz, 1H), 4.26–4.19
(m, 1H), 4.13 (t, <em>J</em> = 3.0 Hz, 1H), 1.89 (d, <em>J</em> = 5.2 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 19.25, −1.04. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 179.48, 158.91, 154.65, 153.71, 151.69, 151.56,
149.44, 140.18, 137.99, 118.28, 116.59, 87.24, 84.67, 84.63, 84.05,
84.02, 83.36, 78.22, 78.20, 76.09, 76.06, 72.05, 71.67, 66.25, 66.22,
42.15, 32.25, 22.03, 10.41. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>23</sub>N<sub>10</sub>O<sub>12</sub>P<sub>2</sub>S]<sup>−</sup> [M-H]<sup>−</sup> 689.069293, found 689.06932.</p></section><section id="sec5.2.12"><h4 class="pmc_sec_title">Characterization of <strong>16</strong>
</h4>
<p>Off-white solid,
12% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.61
(s, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 6.33 (dd, <em>J</em> =
17.2, 3.0 Hz, 1H), 6.26 (d, <em>J</em> = 8.0 Hz, 1H), 5.77–5.63
(m, 1H), 5.27 (td, <em>J</em> = 9.1, 3.7 Hz, 1H), 5.08 (dd, <em>J</em> = 13.4, 6.5 Hz, 1H), 4.62 (d, <em>J</em> = 4.2
Hz, 1H), 4.50 (d, <em>J</em> = 4.7 Hz, 1H), 4.45 (s, 1H),
4.26 (dd, <em>J</em> = 12.1, 5.7 Hz, 1H), 4.14 (dt, <em>J</em> = 12.0, 2.8 Hz, 1H), 3.29 (td, <em>J</em> = 12.7,
6.7 Hz, 1H), 3.06 (t, <em>J</em> = 12.5 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.76, −1.33. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 155.44, 152.72, 152.50,
148.62, 139.73, 124.59, 91.47, 90.51, 86.57, 86.40, 84.80, 84.26,
80.79, 78.51, 72.83, 72.08, 66.29, 57.33, 42.16, 31.27, 16.68, 10.41.
HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>22</sub>FN<sub>10</sub>O<sub>10</sub>P<sub>2</sub>S]<sup>−</sup> [M-H]<sup>−</sup> 675.070041, found 675.07062.</p></section><section id="sec5.2.13"><h4 class="pmc_sec_title">Characterization of <strong>17</strong>
</h4>
<p>Off-white solid,
16% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.19
(d, <em>J</em> = 4.5 Hz, 1H), 7.93 (d, <em>J</em> =
8.1 Hz, 2H), 6.33 (dd, <em>J</em> = 16.3, 3.2 Hz, 2H), 6.23
(d, <em>J</em> = 8.3 Hz, 1H), 5.76 (d, <em>J</em> =
8.1 Hz, 2H), 5.72 (t, <em>J</em> = 4.0 Hz, 1H), 5.66 (t, <em>J</em> = 4.0 Hz, 1H), 5.04 (dd, <em>J</em> = 13.1, 6.5
Hz, 2H), 4.52 (d, <em>J</em> = 4.3 Hz, 2H), 4.49 (d, <em>J</em> = 5.1 Hz, 2H), 4.32 (s, 2H), 4.24 (dd, <em>J</em> = 12.2, 6.8 Hz, 2H), 4.10–4.07 (m, 3H), 4.05 (t, <em>J</em> = 7.2 Hz, 2H), 3.29 (td, <em>J</em> = 13.1, 6.9
Hz, 3H), 3.08–3.04 (m, 3H), 1.84 (s, 2H). <sup>31</sup>P NMR
(203 MHz, D<sub>2</sub>O) δ 18.94, −1.50. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 174.63, 165.66, 155.54, 152.76,
151.91, 148.52, 141.17, 139.77, 118.91, 102.96, 91.31, 90.34, 86.43,
86.26, 84.22, 84.01, 80.92, 76.73, 73.21, 71.68, 66.58, 61.62, 31.15,
20.41, 13.14. HRMS (ESI-) <em>m</em>/<em>z</em> calcd
for [C<sub>19</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>12</sub>P<sub>2</sub>S]<sup>−</sup> [M-H]<sup>−</sup> 652.042824,
found 652.04271.</p></section><section id="sec5.2.14"><h4 class="pmc_sec_title">Characterization of <strong>18</strong>
</h4>
<p>Off-white solid,
23% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.71
(s, 1H), 8.36 (s, 1H), 8.25 (s, 1H), 6.32 (d, <em>J</em> =
8.0 Hz, 1H), 6.21 (dd, <em>J</em> = 17.2, 3.1 Hz, 1H), 5.74
(dt, <em>J</em> = 50.9, 3.6 Hz, 1H), 5.31 (ddd, <em>J</em> = 11.8, 7.9, 4.1 Hz, 1H), 5.13 (dd, <em>J</em> = 13.0, 6.4
Hz, 1H), 4.45 (s, 2H), 4.29 (dd, <em>J</em> = 12.2, 7.1 Hz,
1H), 4.16 (ddd, <em>J</em> = 12.4, 4.9, 2.4 Hz, 1H), 3.22
(td, <em>J</em> = 14.0, 6.8 Hz, 1H), 3.05 (ddd, <em>J</em> = 14.6, 10.7, 4.3 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.78, −1.52. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 165.75, 157.39, 154.51, 150.57, 149.90, 149.12,
144.71, 142.22, 137.39, 118.21, 113.22, 91.29, 90.33, 87.40, 87.23,
85.07, 85.04, 84.65, 84.63, 81.60, 78.62, 78.59, 73.68, 73.66, 73.60,
72.23, 72.21, 66.56, 66.53, 46.66, 31.22. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>21</sub>FN<sub>10</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 345.02911, found 345.02899.</p></section><section id="sec5.2.15"><h4 class="pmc_sec_title">Characterization of <strong>19</strong>
</h4>
<p>Off-white solid,
3% yield. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O) δ 8.57
(s, 1H), 8.17 (s, 1H), 7.76 (s, 1H), 6.31–6.05 (m, 2H), 5.33
(s, 1H), 5.09 (ddd, <em>J</em> = 12.6, 8.3, 4.1 Hz, 1H), 4.50
(s, 1H), 4.40 (d, <em>J</em> = 15.0 Hz, 2H), 3.01–2.90
(m, 2H), 2.69 (dd, <em>J</em> = 13.9, 5.8 Hz, 1H), 1.73 (d, <em>J</em> = 17.4 Hz, 3H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 35.75, 19.83. <sup>13</sup>C NMR (126 MHz, D<sub>2</sub>O) δ 158.99, 155.32, 153.74, 152.51, 151.42, 149.39, 139.79,
137.53, 118.73, 117.63, 116.60, 84.53, 84.51, 83.92, 78.39, 76.66,
71.07, 67.00, 36.62, 31.43, 9.69, 8.59. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>21</sub>H<sub>27</sub>N<sub>10</sub>O<sub>10</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 673.110763, found 673.10942.</p></section><section id="sec5.2.16"><h4 class="pmc_sec_title">Characterization of <strong>20</strong>
</h4>
<p>Off-white solid,
15% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 7.98
(s, 2H), 5.93 (s, 1H), 5.77 (s, 2H), 4.88 (d, <em>J</em> =
4.5 Hz, 3H), 4.57 (s, 2H), 4.34 (d, <em>J</em> = 11.0 Hz,
2H), 4.14 (s, 1H), 3.60 (d, <em>J</em> = 4.0 Hz, 1H), 3.41
(dt, <em>J</em> = 14.8, 7.5 Hz, 1H), 3.35 (d, <em>J</em> = 12.3 Hz, 1H), 3.26 (d, <em>J</em> = 13.3 Hz, 3H), 3.02
(s, 1H), 3.00–2.98 (m, 1H), 2.54–2.45 (m, 3H), 2.42–2.33
(m, 4H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.63,
−2.05. HRMS (ESI-) <em>m</em>/<em>z</em> calcd
for [C<sub>22</sub>H<sub>23</sub>N<sub>9</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 342.03382,
found 342.03400.</p></section><section id="sec5.2.17"><h4 class="pmc_sec_title">Characterization of <strong>21</strong>
</h4>
<p>Off-white solid,
24% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.57–8.49
(m, 1H), 8.41–8.35 (m, 1H), 8.33–8.32 (m, 1H), 8.27–8.23
(m, 1H), 6.32 (d, <em>J</em> = 7.7 Hz, 1H), 6.18 (d, <em>J</em> = 2.4 Hz, 1H), 5.43 (s, 1H), 4.94 (s, 2H), 4.65 (s, 2H),
4.61 (d, <em>J</em> = 4.4 Hz, 2H), 4.43 (s, 1H), 4.26 (t, <em>J</em> = 10.3 Hz, 2H), 4.19 (d, <em>J</em> = 11.9 Hz,
2H), 4.11 (d, <em>J</em> = 8.5 Hz, 2H), 4.00 (d, <em>J</em> = 8.6 Hz, 2H), 3.35 (d, <em>J</em> = 13.1 Hz, 1H), 2.95
(t, <em>J</em> = 12.2 Hz, 1H), 1.20 (t, <em>J</em> = 7.5 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ
18.47, −1.48. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O)
δ 150.42, 147.66, 145.96, 145.22, 142.43, 140.60, 119.06, 86.17,
85.06, 78.75, 77.98, 74.07, 73.65, 71.94, 66.33, 30.21, 25.91. HRMS
(ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>22</sub>H<sub>23</sub>N<sub>9</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 342.03382, found 342.03387.</p></section><section id="sec5.2.18"><h4 class="pmc_sec_title">Characterization of <strong>22</strong>
</h4>
<p>Off-white solid,
25% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.37
(s, 1H), 8.33 (s, 1H), 7.78 (d, <em>J</em> = 8.1 Hz, 2H),
6.22 (s, 1H), 6.18 (s, 2H), 5.67 (d, <em>J</em> = 8.1 Hz,
2H), 4.95 (s, 2H), 4.90–4.87 (m, 2H), 4.46 (d, <em>J</em> = 4.5 Hz, 2H), 4.31–4.28 (m, 2H), 4.25 (ddd, <em>J</em> = 12.3, 7.8, 1.9 Hz, 2H), 4.09 (d, <em>J</em> = 8.4 Hz,
2H), 4.04 (ddd, <em>J</em> = 12.1, 5.0, 2.0 Hz, 2H), 4.00
(d, <em>J</em> = 8.4 Hz, 2H), 3.40 (d, <em>J</em> =
13.6 Hz, 2H), 2.98 (dd, <em>J</em> = 13.5, 11.4 Hz, 2H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.16, −1.49. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 165.79, 151.88, 150.36,
147.49, 145.11, 141.18, 140.68, 119.06, 103.12, 86.26, 84.62, 84.29,
78.56, 76.70, 73.67, 71.61, 66.87, 26.06. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>21</sub>N<sub>7</sub>O<sub>13</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 330.52021, found 330.52025.</p></section><section id="sec5.2.19"><h4 class="pmc_sec_title">Characterization of <strong>23</strong>
</h4>
<p>Off-white solid,
21% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.26
(s, 1H), 8.04 (s, 1H), 6.32 (d, <em>J</em> = 21.0 Hz, 1H),
6.03–5.96 (m, 1H), 5.52 (d, <em>J</em> = 48.1 Hz, 1H),
5.27 (s, 1H), 4.96 (s, 2H), 4.64 (d, <em>J</em> = 4.4 Hz,
1H), 4.60–4.50 (m, 1H), 4.39 (s, 1H), 4.18 (d, <em>J</em> = 11.8 Hz, 1H), 4.11 (d, <em>J</em> = 11.9 Hz, 1H), 3.24
(s, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.07,
−0.65. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ
215.41, 159.05, 155.67, 153.87, 152.87, 152.31, 148.55, 139.86, 137.79,
118.59, 116.38, 97.76, 96.83, 86.78, 86.60, 84.22, 84.17, 83.99, 80.95,
76.78, 75.38, 71.26, 65.64, 30.21, 27.84. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>21</sub>FN<sub>10</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 345.02911, found 345.02914.</p></section><section id="sec5.2.20"><h4 class="pmc_sec_title">Characterization of <strong>24</strong>
</h4>
<p>Off-white solid,
23% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.23
(s, 1H), 8.21 (s, 1H), 8.05 (s, 1H), 6.35 (d, <em>J</em> =
18.1 Hz, 1H), 6.31 (d, <em>J</em> = 3.8 Hz, 1H), 5.06 (s,
1H), 4.54 (s, 1H), 4.18 (s, 4H), 3.39 (t, <em>J</em> = 13.2
Hz, 1H), 3.27 (d, <em>J</em> = 3.0 Hz, 3H). <sup>31</sup>P
NMR (203 MHz, D<sub>2</sub>O) δ 18.44, −1.11. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 159.04, 155.71, 154.02, 153.06,
148.67, 140.11, 138.98, 118.92, 115.48, 86.56, 84.16, 83.65, 78.65,
75.10, 63.99, 48.85, 31.86. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>21</sub>FN<sub>10</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 345.02911, found 345.02893.</p></section><section id="sec5.2.21"><h4 class="pmc_sec_title">Characterization of <strong>25</strong>
</h4>
<p>Off-white solid,
28% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.35
(s, 1H), 8.12 (s, 1H), 8.07 (s, 1H), 6.39 (d, <em>J</em> =
17.0 Hz, 2H), 6.30 (d, <em>J</em> = 19.8 Hz, 2H), 5.67 (dd, <em>J</em> = 51.5, 4.7 Hz, 2H), 5.47 (dd, <em>J</em> = 51.2,
3.9 Hz, 2H), 5.16 (dh, <em>J</em> = 19.9, 4.6 Hz, 2H), 5.05–4.94
(m, 2H), 4.57 (t, <em>J</em> = 6.6 Hz, 1H), 4.49 (d, <em>J</em> = 9.5 Hz, 2H), 4.41 (d, <em>J</em> = 12.2 Hz,
2H), 4.09 (dd, <em>J</em> = 12.2, 3.5 Hz, 2H), 3.44 (dt, <em>J</em> = 13.6, 4.1 Hz, 2H), 3.00 (t, <em>J</em> = 12.3
Hz, 3H), 2.14 (s, 2H), 1.82 (s, 2H). <sup>31</sup>P NMR (203 MHz,
D<sub>2</sub>O) δ 18.22, −1.44. <sup>13</sup>C NMR (201
MHz, D<sub>2</sub>O) δ 155.42, 152.79, 152.69, 148.29, 147.78,
139.16, 118.70, 92.55, 92.08, 91.61, 91.13, 87.42, 87.25, 86.94, 86.77,
79.37, 78.93, 71.31, 69.27, 61.91, 30.08, 23.15. HRMS (ESI+) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>23</sub>F<sub>2</sub>N<sub>10</sub>O<sub>9</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 679.081353, found 679.08209.</p></section><section id="sec5.2.22"><h4 class="pmc_sec_title">Characterization of <strong>26</strong>
</h4>
<p>Off-white solid,
30% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.36
(s, 1H), 8.13 (s, 1H), 7.83 (s, 1H), 6.39 (d, <em>J</em> =
17.3 Hz, 1H), 6.12 (d, <em>J</em> = 20.5 Hz, 1H), 5.68 (dd, <em>J</em> = 52.1, 4.9 Hz, 1H), 5.47 (dd, <em>J</em> = 51.3,
4.0 Hz, 1H), 5.23 (ddd, <em>J</em> = 17.6, 8.6, 3.6 Hz, 1H),
5.01 (ddd, <em>J</em> = 18.0, 8.8, 4.4 Hz, 1H), 4.50–4.48
(m, 2H), 4.41 (d, <em>J</em> = 12.2 Hz, 1H), 4.09 (dd, <em>J</em> = 11.8, 3.3 Hz, 1H), 3.42 (dt, <em>J</em> = 13.6,
4.5 Hz, 2H), 3.01 (t, <em>J</em> = 12.0 Hz, 2H), 1.88 (s,
1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.93, −1.41. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 158.75, 155.13, 155.08,
153.69, 152.73, 151.72, 151.09, 147.85, 140.03, 138.95, 118.85, 118.79,
116.32, 93.11, 92.26, 87.80, 87.62, 86.61, 79.13, 78.42, 69.58, 61.99.
HRMS (ESI+) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>23</sub>F<sub>2</sub>N<sub>10</sub>O<sub>10</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 695.076268, found 695.07602.</p></section><section id="sec5.2.23"><h4 class="pmc_sec_title">Characterization of <strong>27</strong>
</h4>
<p>Off-white solid,
31% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.23
(s, 1H), 8.12 (s, 1H), 7.99 (s, 1H), 6.33 (d, <em>J</em> =
19.7 Hz, 1H), 6.22 (d, <em>J</em> = 18.8 Hz, 1H), 5.65 (dd, <em>J</em> = 51.5, 4.7 Hz, 1H), 5.48 (dd, <em>J</em> = 51.5,
4.1 Hz, 1H), 5.18–5.09 (m, 1H), 5.07 (ddd, <em>J</em> = 21.2, 10.2, 5.9 Hz, 1H), 4.56 (t, <em>J</em> = 6.6 Hz,
1H), 4.40 (d, <em>J</em> = 9.5 Hz, 1H), 4.35 (d, <em>J</em> = 12.2 Hz, 1H), 4.08–4.03 (m, 1H), 3.46–3.39 (m, 1H),
3.01 (t, <em>J</em> = 12.3 Hz, 1H), 2.22–2.01 (m, 1H),
1.86 (s, 2H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ
18.56, −1.41. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O)
δ 215.33, 158.82, 155.18, 153.84, 152.41, 150.68, 148.43, 140.12,
137.14, 118.66, 116.36, 92.64, 92.05, 91.70, 91.11, 87.17, 87.00,
86.80, 86.62, 79.04, 78.95, 71.46, 71.39, 69.38, 69.30, 61.89, 30.17,
30.13, 22.58. HRMS (ESI+) <em>m</em>/<em>z</em> calcd
for [C<sub>20</sub>H<sub>23</sub>F<sub>2</sub>N<sub>10</sub>O<sub>10</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 695.076268,
found 695.07635.</p></section><section id="sec5.2.24"><h4 class="pmc_sec_title">Characterization of <strong>28</strong>
</h4>
<p>Off-white solid,
22% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.20
(s, 1H), 8.07 (d, <em>J</em> = 1.9 Hz, 1H), 8.03 (s, 1H),
6.38–6.30 (m, 1H), 6.24 (d, <em>J</em> = 18.6 Hz, 1H),
5.75–5.63 (m, 1H), 5.46 (dd, <em>J</em> = 51.5, 4.0
Hz, 1H), 5.33–5.17 (m, 1H), 5.12–4.96 (m, 1H), 4.53
(t, <em>J</em> = 6.5 Hz, 1H), 4.41 (d, <em>J</em> =
9.5 Hz, 1H), 4.35 (d, <em>J</em> = 12.3 Hz, 1H), 4.06 (d, <em>J</em> = 12.2 Hz, 1H), 3.43 (dt, <em>J</em> = 13.6, 4.4
Hz, 1H), 3.04–2.96 (m, 1H). <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 180.04, 158.89, 158.51, 153.88, 150.75, 148.32,
146.01, 140.58, 137.10, 124.03, 116.36, 92.67, 92.15, 91.73, 91.20,
87.37, 87.19, 87.06, 86.89, 78.96, 71.32, 69.33, 61.84, 30.11. HRMS
(ESI+) <em>m</em>/<em>z</em> calcd for [C<sub>20</sub>H<sub>22</sub>F<sub>2</sub>N<sub>9</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 696.060285, found 696.06024.</p></section><section id="sec5.2.25"><h4 class="pmc_sec_title">Characterization of <strong>29</strong>
</h4>
<p>Off-white solid,
24% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.40
(d, <em>J</em> = 4.1 Hz, 1H), 8.20 (d, <em>J</em> =
4.1 Hz, 1H), 8.17 (d, <em>J</em> = 4.2 Hz, 1H), 8.02 (d, <em>J</em> = 4.4 Hz, 1H), 6.43 (dd, <em>J</em> = 17.0, 4.0
Hz, 2H), 6.33 (dd, <em>J</em> = 20.6, 4.2 Hz, 2H), 5.69 (dd, <em>J</em> = 51.7, 5.3 Hz, 2H), 5.44 (dd, <em>J</em> = 51.4,
4.5 Hz, 2H), 5.26 (ddd, <em>J</em> = 18.7, 11.8, 6.3 Hz, 2H),
5.02 (dd, <em>J</em> = 20.3, 11.2 Hz, 2H), 4.54 (t, <em>J</em> = 6.6 Hz, 1H), 4.49 (d, <em>J</em> = 9.4 Hz, 1H),
4.41 (d, <em>J</em> = 12.3 Hz, 2H), 4.12–4.04 (m, 2H),
3.47–3.36 (m, 2H), 3.03–2.96 (m, 2H). <sup>13</sup>C
NMR (201 MHz, D<sub>2</sub>O) δ 181.32, 158.49, 155.55, 152.77,
148.27, 147.98, 145.93, 140.51, 139.21, 124.00, 118.80, 92.65, 92.14,
91.71, 91.20, 87.39, 87.22, 87.06, 79.20, 78.97, 71.37, 69.15, 61.89,
30.07, 23.10. HRMS (ESI+) <em>m</em>/<em>z</em> calcd
for [C<sub>20</sub>H<sub>22</sub>F<sub>2</sub>N<sub>9</sub>O<sub>10</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 680.06537, found
680.0654.</p></section><section id="sec5.2.26"><h4 class="pmc_sec_title">Characterization of <strong>30</strong>
</h4>
<p>Off-white solid,
34% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.32
(s, 1H), 8.14 (s, 1H), 7.86 (s, 1H), 6.42 (d, <em>J</em> =
17.8 Hz, 1H), 6.14 (d, <em>J</em> = 21.0 Hz, 1H), 5.67 (d, <em>J</em> = 52.2 Hz, 1H), 5.50 (d, <em>J</em> = 51.6 Hz,
1H), 5.22 (dd, <em>J</em> = 16.5, 8.4 Hz, 1H), 5.11–5.01
(m, 1H), 4.51–4.44 (m, 2H), 4.38 (d, <em>J</em> = 12.4
Hz, 1H), 4.08 (d, <em>J</em> = 12.4 Hz, 1H), 3.44–3.35
(m, 1H), 3.01 (t, <em>J</em> = 12.1 Hz, 1H). <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 180.15, 158.91, 158.52, 153.70,
151.27, 147.86, 146.12, 139.43, 138.24, 124.04, 116.35, 92.84, 91.90,
91.80, 90.86, 87.54, 87.37, 86.89, 86.71, 79.22, 78.59, 71.53, 69.16,
69.08, 61.84. HRMS (ESI+) <em>m</em>/<em>z</em> calcd
for [C<sub>20</sub>H<sub>22</sub>F<sub>2</sub>N<sub>9</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 696.060285, found
696.06054.</p></section><section id="sec5.2.27"><h4 class="pmc_sec_title">Characterization of <strong>31</strong>
</h4>
<p>Off-white solid,
22% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 8.34
(s, 1H), 8.24 (s, 1H), 8.15 (s, 1H), 8.12 (s, 1H), 6.44 (d, <em>J</em> = 18.0 Hz, 1H), 6.38–6.30 (m, 1H), 5.65 (dd, <em>J</em> = 51.5, 4.7 Hz, 1H), 5.51 (dd, <em>J</em> = 51.3,
4.0 Hz, 1H), 5.11 (dddd, <em>J</em> = 40.7, 21.9, 8.3, 4.3
Hz, 2H), 4.56 (t, <em>J</em> = 6.4 Hz, 1H), 4.46 (d, <em>J</em> = 9.6 Hz, 1H), 4.38 (d, <em>J</em> = 12.2 Hz,
1H), 4.11–4.04 (m, 1H), 3.45–3.39 (m, 1H), 3.01 (t, <em>J</em> = 12.3 Hz, 1H). <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 158.55, 152.91, 148.57, 147.87, 146.10, 140.00, 139.44,
118.68, 92.80, 92.06, 91.86, 91.11, 87.56, 87.39, 86.65, 86.47, 79.26,
78.88, 61.85. HRMS (ESI+) <em>m</em>/<em>z</em> calcd
for [C<sub>20</sub>H<sub>22</sub>F<sub>2</sub>N<sub>9</sub>O<sub>10</sub>P<sub>2</sub>S]<sup>+</sup> [M + H]<sup>+</sup> 680.06537, found
680.06515.</p></section></section><section id="sec5.3"><h3 class="pmc_sec_title">Characterization of <strong>32</strong>
</h3>
<p>Off-white solid,
35% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 7.99
(s, 1H), 7.86 (s, 1H), 6.22 (d, <em>J</em> = 18.9 Hz, 1H),
6.14 (dd, <em>J</em> = 21.1, 1.9 Hz, 1H), 5.75–5.58
(m, 1H), 5.49 (dd, <em>J</em> = 51.8, 4.1 Hz, 1H), 5.23 (ddd, <em>J</em> = 17.6, 13.3, 8.3 Hz, 1H), 5.05 (dtd, <em>J</em> = 22.5, 8.9, 4.0 Hz, 1H), 4.49 (d, <em>J</em> = 6.8 Hz,
2H), 4.40 (d, <em>J</em> = 9.5 Hz, 2H), 4.35 (d, <em>J</em> = 12.3 Hz, 2H), 4.08–4.02 (m, 2H), 3.40 (dt, <em>J</em> = 13.6, 4.6 Hz, 2H), 3.04–3.00 (m, 2H). <sup>31</sup>P NMR
(203 MHz, D<sub>2</sub>O) δ 19.07, −1.30. <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 179.58, 158.93, 158.91, 153.93,
153.75, 151.30, 150.79, 138.30, 137.21, 116.42, 116.39, 92.73, 91.88,
91.79, 90.94, 87.20, 87.03, 86.86, 79.10, 79.05, 78.99, 78.69, 78.65,
78.60, 71.60, 71.57, 71.52, 71.50, 69.40, 69.37, 69.32, 69.29, 61.94,
61.92, 42.23. HRMS (ESI-) <em>m</em>/<em>z</em> calcd
for [C<sub>20</sub>H<sub>20</sub>F<sub>2</sub>N<sub>10</sub>O<sub>11</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 354.02440, found 354.02432.</p>
<section id="sec5.3.1"><h4 class="pmc_sec_title">Characterization of <strong>33</strong>
</h4>
<p>Off-white solid,
31% yield. <sup>1</sup>H NMR (800 MHz, D<sub>2</sub>O) δ 7.88
(s, 1H), 7.85 (s, 1H), 6.20 (d, <em>J</em> = 20.6 Hz, 1H),
5.91 (s, 1H), 5.35–5.26 (m, 1H), 4.96 (d, <em>J</em> = 8.0 Hz, 1H), 4.35 (d, <em>J</em> = 9.8 Hz, 2H), 4.26 (d, <em>J</em> = 12.2 Hz, 1H), 4.07 (d, <em>J</em> = 8.5 Hz,
1H), 4.06–4.03 (m, 1H), 3.97 (d, <em>J</em> = 8.4 Hz,
1H), 3.33 (d, <em>J</em> = 13.2 Hz, 1H), 3.01 (dd, <em>J</em> = 13.3, 9.9 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 18.22, −1.44. <sup>13</sup>C NMR (201 MHz,
D<sub>2</sub>O) δ 158.98, 153.83, 153.67, 150.94, 138.13, 136.25,
116.49, 116.37, 92.62, 91.69, 87.40, 87.22, 85.98, 85.27, 79.03, 78.89,
78.83, 73.77, 73.45, 69.73, 69.65, 61.89. HRMS (ESI-) <em>m</em>/<em>z</em> calcd for [C<sub>21</sub>H<sub>21</sub>FN<sub>10</sub>O<sub>12</sub>P<sub>2</sub>S]<sup>2–</sup> [M]<sup>2–</sup> 359.02657, found 359.02647.</p></section></section></section><section id="sec95"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="sifile1"><div class="media p"><div class="caption">
<a href="/articles/instance/12371493/bin/bg5c00070_si_001.pdf" data-ga-action="click_feat_suppl" class="usa-link">bg5c00070_si_001.pdf</a><sup> (10.7MB, pdf) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>We thank Purdue University and University of Notre
Dame for funding.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Glossary</h2>
<h3>Abbreviations</h3>
<dl class="def-list" id="dl1">
<dt>CDNs</dt>
<dd><p>Cyclic
dinucleotides</p></dd>
<dt>TME</dt>
<dd><p>Tumor Microenvironments</p></dd>
<dt>PDE</dt>
<dd><p>Phosphodiesterase</p></dd>
<dt>SAR</dt>
<dd><p>Structure–Activity Relationship
Exploration</p></dd>
<dt>STING</dt>
<dd><p>Stimulator of Interferon Genes</p></dd>
<dt>DAMPs</dt>
<dd><p>Damage-Associated Molecular Patterns</p></dd>
<dt>PAMPs</dt>
<dd><p>Pathogen-Associated
Molecular
Patterns</p></dd>
</dl></section><section id="notes1"><p>The Supporting Information
is
available free of charge at <a href="https://pubs.acs.org/doi/10.1021/acsbiomedchemau.5c00070?goto=supporting-info" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://pubs.acs.org/doi/10.1021/acsbiomedchemau.5c00070</a>.</p>
<ul id="silist" class="list" style="list-style-type:none"><li><p>Synthetic schemes, <sup>1</sup>H/<sup>13</sup>C NMR
spectra of new synthetic compounds, HPLC traces of key compounds,
and biological evaluations are provided (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsbiomedchemau.5c00070/suppl_file/bg5c00070_si_001.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">PDF</a>)</p></li></ul></section><section id="notes3"><p>The manuscript
was written through contributions of all authors. All authors have
given approval to the final version of the manuscript. CRediT: <strong>Simpa K. Yeboah</strong> investigation, writing - original draft; <strong>Sagarika Meher</strong> formal analysis, writing - original draft; <strong>Haley Anne Harper</strong> investigation; <strong>Carli Jacole McMahan</strong> investigation; <strong>Bennett D Elzey</strong> supervision, writing
- review &amp; editing; <strong>Herman O. Sintim</strong> conceptualization,
project administration, supervision, writing - review &amp; editing.</p></section><section id="notes2"><p>The authors
declare no competing financial interest.</p></section><section id="spn1"><p>Published
as part of <em>ACS Bio &amp; Med Chem Au</em>
<a href="https://pubs.acs.org/curated-content?journal=abmcb8&amp;ref=feature" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">special issue</a> “Juneteenth 2025”.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ol class="ref-list font-sm">
<li id="ref1">
<cite>Ishida Y., Agata Y., Shibahara K., Honjo T.. Induced Expression
of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, upon
Programmed Cell Death. EMBO J. 1992;11(11):3887–3895. doi: 10.1002/j.1460-2075.1992.tb05481.x.</cite> [<a href="https://doi.org/10.1002/j.1460-2075.1992.tb05481.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC556898/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1396582/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EMBO%20J.&amp;title=Induced%20Expression%20of%20PD-1,%20a%20Novel%20Member%20of%20the%20Immunoglobulin%20Gene%20Superfamily,%20upon%20Programmed%20Cell%20Death&amp;author=Y.%20Ishida&amp;author=Y.%20Agata&amp;author=K.%20Shibahara&amp;author=T.%20Honjo&amp;volume=11&amp;issue=11&amp;publication_year=1992&amp;pages=3887-3895&amp;pmid=1396582&amp;doi=10.1002/j.1460-2075.1992.tb05481.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref2">
<cite>Leach D. R., Krummel M. F., Allison J. P.. Enhancement
of Antitumor Immunity
by CTLA-4 Blockade. Science. 1996;271(5256):1734–1736. doi: 10.1126/science.271.5256.1734.</cite> [<a href="https://doi.org/10.1126/science.271.5256.1734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8596936/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Enhancement%20of%20Antitumor%20Immunity%20by%20CTLA-4%20Blockade&amp;author=D.%20R.%20Leach&amp;author=M.%20F.%20Krummel&amp;author=J.%20P.%20Allison&amp;volume=271&amp;issue=5256&amp;publication_year=1996&amp;pages=1734-1736&amp;pmid=8596936&amp;doi=10.1126/science.271.5256.1734&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref3">
<cite>Walsh R. J., Soo R. A.. Resistance to Immune
Checkpoint Inhibitors in Non-Small
Cell Lung Cancer: Biomarkers and Therapeutic Strategies. Ther. Adv. Med. Oncol. 2020;12:1758835920937902. doi: 10.1177/1758835920937902.</cite> [<a href="https://doi.org/10.1177/1758835920937902" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7339077/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32670423/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ther.%20Adv.%20Med.%20Oncol.&amp;title=Resistance%20to%20Immune%20Checkpoint%20Inhibitors%20in%20Non-Small%20Cell%20Lung%20Cancer:%20Biomarkers%20and%20Therapeutic%20Strategies&amp;author=R.%20J.%20Walsh&amp;author=R.%20A.%20Soo&amp;volume=12&amp;publication_year=2020&amp;pages=1758835920937902&amp;pmid=32670423&amp;doi=10.1177/1758835920937902&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref4">
<cite>Nowicki T. S., Hu-Lieskovan S., Ribas A.. Mechanisms of Resistance to PD-1
and PD-L1 Blockade. Cancer J. 2018;24(1):47–53. doi: 10.1097/PPO.0000000000000303.</cite> [<a href="https://doi.org/10.1097/PPO.0000000000000303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5785093/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29360728/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20J.&amp;title=Mechanisms%20of%20Resistance%20to%20PD-1%20and%20PD-L1%20Blockade&amp;author=T.%20S.%20Nowicki&amp;author=S.%20Hu-Lieskovan&amp;author=A.%20Ribas&amp;volume=24&amp;issue=1&amp;publication_year=2018&amp;pages=47-53&amp;pmid=29360728&amp;doi=10.1097/PPO.0000000000000303&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref5">
<cite>Chyuan I. T., Chu C. L., Hsu P. N.. Targeting
the Tumor Microenvironment
for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing
on Immune Checkpoint Inhibitors and Combination Therapies. Cancers. 2021;13(6):1188. doi: 10.3390/cancers13061188.</cite> [<a href="https://doi.org/10.3390/cancers13061188" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7998672/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33801815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Targeting%20the%20Tumor%20Microenvironment%20for%20Improving%20Therapeutic%20Effectiveness%20in%20Cancer%20Immunotherapy:%20Focusing%20on%20Immune%20Checkpoint%20Inhibitors%20and%20Combination%20Therapies&amp;author=I.%20T.%20Chyuan&amp;author=C.%20L.%20Chu&amp;author=P.%20N.%20Hsu&amp;volume=13&amp;issue=6&amp;publication_year=2021&amp;pages=1188&amp;pmid=33801815&amp;doi=10.3390/cancers13061188&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref6">
<cite>Galon J., Bruni D.. Approaches to Treat
Immune Hot, Altered and Cold Tumours with Combination
Immunotherapies. Nat. Rev. Drug Discovery. 2019;18(3):197–218. doi: 10.1038/s41573-018-0007-y.</cite> [<a href="https://doi.org/10.1038/s41573-018-0007-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30610226/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Drug%20Discovery&amp;title=Approaches%20to%20Treat%20Immune%20Hot,%20Altered%20and%20Cold%20Tumours%20with%20Combination%20Immunotherapies&amp;author=J.%20Galon&amp;author=D.%20Bruni&amp;volume=18&amp;issue=3&amp;publication_year=2019&amp;pages=197-218&amp;pmid=30610226&amp;doi=10.1038/s41573-018-0007-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref7">
<cite>Ishikawa H., Barber G. N.. STING Is an Endoplasmic
Reticulum Adaptor That Facilitates
Innate Immune Signalling. Nature. 2008;455(7213):674–678. doi: 10.1038/nature07317.</cite> [<a href="https://doi.org/10.1038/nature07317" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2804933/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18724357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=STING%20Is%20an%20Endoplasmic%20Reticulum%20Adaptor%20That%20Facilitates%20Innate%20Immune%20Signalling&amp;author=H.%20Ishikawa&amp;author=G.%20N.%20Barber&amp;volume=455&amp;issue=7213&amp;publication_year=2008&amp;pages=674-678&amp;pmid=18724357&amp;doi=10.1038/nature07317&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref8">
<cite>Zhong B., Yang Y., Li S., Wang Y.-Y., Li Y., Diao F., Lei C., He X., Zhang L., Tien P., Shu H.-B.. The Adaptor Protein
MITA Links Virus-Sensing
Receptors to IRF3 Transcription Factor Activation. Immunity. 2008;29(4):538–550. doi: 10.1016/j.immuni.2008.09.003.</cite> [<a href="https://doi.org/10.1016/j.immuni.2008.09.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18818105/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=The%20Adaptor%20Protein%20MITA%20Links%20Virus-Sensing%20Receptors%20to%20IRF3%20Transcription%20Factor%20Activation&amp;author=B.%20Zhong&amp;author=Y.%20Yang&amp;author=S.%20Li&amp;author=Y.-Y.%20Wang&amp;author=Y.%20Li&amp;volume=29&amp;issue=4&amp;publication_year=2008&amp;pages=538-550&amp;pmid=18818105&amp;doi=10.1016/j.immuni.2008.09.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref9">
<cite>Sun L., Wu J., Du F., Chen X., Chen Z. J.. Cyclic
GMP-AMP Synthase
Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway. Science. 2013;339(6121):786–791. doi: 10.1126/science.1232458.</cite> [<a href="https://doi.org/10.1126/science.1232458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3863629/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23258413/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Cyclic%20GMP-AMP%20Synthase%20Is%20a%20Cytosolic%20DNA%20Sensor%20That%20Activates%20the%20Type%20I%20Interferon%20Pathway&amp;author=L.%20Sun&amp;author=J.%20Wu&amp;author=F.%20Du&amp;author=X.%20Chen&amp;author=Z.%20J.%20Chen&amp;volume=339&amp;issue=6121&amp;publication_year=2013&amp;pages=786-791&amp;pmid=23258413&amp;doi=10.1126/science.1232458&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref10">
<cite>Wu J., Sun L., Chen X., Du F., Shi H., Chen C., Chen Z. J.. Cyclic GMP-AMP Is an Endogenous Second Messenger in
Innate Immune Signaling by Cytosolic DNA. Science. 2013;339(6121):826–830. doi: 10.1126/science.1229963.</cite> [<a href="https://doi.org/10.1126/science.1229963" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3855410/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23258412/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Cyclic%20GMP-AMP%20Is%20an%20Endogenous%20Second%20Messenger%20in%20Innate%20Immune%20Signaling%20by%20Cytosolic%20DNA&amp;author=J.%20Wu&amp;author=L.%20Sun&amp;author=X.%20Chen&amp;author=F.%20Du&amp;author=H.%20Shi&amp;volume=339&amp;issue=6121&amp;publication_year=2013&amp;pages=826-830&amp;pmid=23258412&amp;doi=10.1126/science.1229963&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref11">
<cite>Zhang X., Shi H., Wu J., Zhang X., Sun L., Chen C., Chen Z. J.. Cyclic
GMP-AMP Containing Mixed Phosphodiester Linkages
Is An Endogenous High-Affinity Ligand for STING. Mol. Cell. 2013;51(2):226–235. doi: 10.1016/j.molcel.2013.05.022.</cite> [<a href="https://doi.org/10.1016/j.molcel.2013.05.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3808999/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23747010/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cell&amp;title=Cyclic%20GMP-AMP%20Containing%20Mixed%20Phosphodiester%20Linkages%20Is%20An%20Endogenous%20High-Affinity%20Ligand%20for%20STING&amp;author=X.%20Zhang&amp;author=H.%20Shi&amp;author=J.%20Wu&amp;author=X.%20Zhang&amp;author=L.%20Sun&amp;volume=51&amp;issue=2&amp;publication_year=2013&amp;pages=226-235&amp;pmid=23747010&amp;doi=10.1016/j.molcel.2013.05.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref12">
<cite>Ablasser A., Goldeck M., Cavlar T., Deimling T., Witte G., Röhl I., Hopfner K.-P., Ludwig J., Hornung V.. CGAS Produces
a 2′-5′-Linked Cyclic Dinucleotide Second Messenger
That Activates STING. Nature. 2013;498(7454):380–384. doi: 10.1038/nature12306.</cite> [<a href="https://doi.org/10.1038/nature12306" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4143541/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23722158/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=CGAS%20Produces%20a%202%E2%80%B2-5%E2%80%B2-Linked%20Cyclic%20Dinucleotide%20Second%20Messenger%20That%20Activates%20STING&amp;author=A.%20Ablasser&amp;author=M.%20Goldeck&amp;author=T.%20Cavlar&amp;author=T.%20Deimling&amp;author=G.%20Witte&amp;volume=498&amp;issue=7454&amp;publication_year=2013&amp;pages=380-384&amp;pmid=23722158&amp;doi=10.1038/nature12306&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref13">
<cite>

Hussain, B.
; 
Xie, Y.
; 
Jabeen, U.
; 
Lu, D.
; 
Yang, B.
; 
Wu, C.
; 
Shang, G.
. 
Activation of STING Based on Its Structural Features. Front. Immunol.
2022, 13. 10.3389/fimmu.2022.808607.</cite> [<a href="https://doi.org/10.3389/fimmu.2022.808607" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9343627/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35928815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Immunol.&amp;title=Activation%20of%20STING%20Based%20on%20Its%20Structural%20Features&amp;volume=13&amp;publication_year=2022&amp;pmid=35928815&amp;doi=10.3389/fimmu.2022.808607&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref14">
<cite>Ahn J., Barber G. N.. STING Signaling and Host Defense against Microbial
Infection. Exp. Mol. Med. 2019;51(12):1–10. doi: 10.1038/s12276-019-0333-0.</cite> [<a href="https://doi.org/10.1038/s12276-019-0333-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6906460/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31827069/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp.%20Mol.%20Med.&amp;title=STING%20Signaling%20and%20Host%20Defense%20against%20Microbial%20Infection&amp;author=J.%20Ahn&amp;author=G.%20N.%20Barber&amp;volume=51&amp;issue=12&amp;publication_year=2019&amp;pages=1-10&amp;pmid=31827069&amp;doi=10.1038/s12276-019-0333-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref15">
<cite>Fuertes M. B., Kacha A. K., Kline J., Woo S.-R., Kranz D. M., Murphy K. M., Gajewski T. F.. Host Type
I IFN Signals Are Required
for Antitumor CD8+ T Cell Responses through CD8α+ Dendritic
Cells. J. Exp. Med. 2011;208(10):2005–2016. doi: 10.1084/jem.20101159.</cite> [<a href="https://doi.org/10.1084/jem.20101159" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3182064/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21930765/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Exp.%20Med.&amp;title=Host%20Type%20I%20IFN%20Signals%20Are%20Required%20for%20Antitumor%20CD8+%20T%20Cell%20Responses%20through%20CD8%CE%B1+%20Dendritic%20Cells&amp;author=M.%20B.%20Fuertes&amp;author=A.%20K.%20Kacha&amp;author=J.%20Kline&amp;author=S.-R.%20Woo&amp;author=D.%20M.%20Kranz&amp;volume=208&amp;issue=10&amp;publication_year=2011&amp;pages=2005-2016&amp;pmid=21930765&amp;doi=10.1084/jem.20101159&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref16">
<cite>Chandra D., Quispe-Tintaya W., Jahangir A., Asafu-Adjei D., Ramos I., Sintim H. O., Zhou J., Hayakawa Y., Karaolis D. K. R., Gravekamp C.. STING Ligand C-Di-GMP Improves Cancer
Vaccination against Metastatic Breast Cancer. Cancer Immunol. Res. 2014;2(9):901–910. doi: 10.1158/2326-6066.CIR-13-0123.</cite> [<a href="https://doi.org/10.1158/2326-6066.CIR-13-0123" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4264585/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24913717/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Immunol.%20Res.&amp;title=STING%20Ligand%20C-Di-GMP%20Improves%20Cancer%20Vaccination%20against%20Metastatic%20Breast%20Cancer&amp;author=D.%20Chandra&amp;author=W.%20Quispe-Tintaya&amp;author=A.%20Jahangir&amp;author=D.%20Asafu-Adjei&amp;author=I.%20Ramos&amp;volume=2&amp;issue=9&amp;publication_year=2014&amp;pages=901-910&amp;pmid=24913717&amp;doi=10.1158/2326-6066.CIR-13-0123&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref17">
<cite>Smith T. T., Moffett H. F., Stephan S. B., Opel C. F., Dumigan A. G., Jiang X., Pillarisetty V. G., Pillai S. P. S., Wittrup K. D., Stephan M. T.. Biopolymers Codelivering
Engineered T Cells and STING
Agonists Can Eliminate Heterogeneous Tumors. J. Clin. Invest. 2017;127(6):2176–2191. doi: 10.1172/JCI87624.</cite> [<a href="https://doi.org/10.1172/JCI87624" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5451231/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28436934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Invest.&amp;title=Biopolymers%20Codelivering%20Engineered%20T%20Cells%20and%20STING%20Agonists%20Can%20Eliminate%20Heterogeneous%20Tumors&amp;author=T.%20T.%20Smith&amp;author=H.%20F.%20Moffett&amp;author=S.%20B.%20Stephan&amp;author=C.%20F.%20Opel&amp;author=A.%20G.%20Dumigan&amp;volume=127&amp;issue=6&amp;publication_year=2017&amp;pages=2176-2191&amp;pmid=28436934&amp;doi=10.1172/JCI87624&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref18">
<cite>Wang H., Hu S., Chen X., Shi H., Chen C., Sun L., Chen Z. J.. CGAS Is Essential for the Antitumor Effect of Immune
Checkpoint Blockade. Proc. Natl. Acad. Sci.
U.S.A. 2017;114(7):1637–1642. doi: 10.1073/pnas.1621363114.</cite> [<a href="https://doi.org/10.1073/pnas.1621363114" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5320994/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28137885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc.%20Natl.%20Acad.%20Sci.%20U.S.A.&amp;title=CGAS%20Is%20Essential%20for%20the%20Antitumor%20Effect%20of%20Immune%20Checkpoint%20Blockade&amp;author=H.%20Wang&amp;author=S.%20Hu&amp;author=X.%20Chen&amp;author=H.%20Shi&amp;author=C.%20Chen&amp;volume=114&amp;issue=7&amp;publication_year=2017&amp;pages=1637-1642&amp;pmid=28137885&amp;doi=10.1073/pnas.1621363114&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref19">
<cite>Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., Li X.-D., Mauceri H., Beckett M., Darga T., Huang X., Gajewski T. F., Chen Z. J., Fu Y.-X., Weichselbaum R. R.. STING-Dependent Cytosolic DNA Sensing
Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity
in Immunogenic Tumors. Immunity. 2014;41(5):843–852. doi: 10.1016/j.immuni.2014.10.019.</cite> [<a href="https://doi.org/10.1016/j.immuni.2014.10.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5155593/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25517616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=STING-Dependent%20Cytosolic%20DNA%20Sensing%20Promotes%20Radiation-Induced%20Type%20I%20Interferon-Dependent%20Antitumor%20Immunity%20in%20Immunogenic%20Tumors&amp;author=L.%20Deng&amp;author=H.%20Liang&amp;author=M.%20Xu&amp;author=X.%20Yang&amp;author=B.%20Burnette&amp;volume=41&amp;issue=5&amp;publication_year=2014&amp;pages=843-852&amp;pmid=25517616&amp;doi=10.1016/j.immuni.2014.10.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref20">
<cite>Corrales L., Glickman L. H., McWhirter S. M., Kanne D. B., Sivick K. E., Katibah G. E., Woo S.-R., Lemmens E., Banda T., Leong J. J., Metchette K., Dubensky T. W., Gajewski T. F.. Direct
Activation of STING in the Tumor Microenvironment Leads to Potent
and Systemic Tumor Regression and Immunity. Cell Rep. 2015;11(7):1018–1030. doi: 10.1016/j.celrep.2015.04.031.</cite> [<a href="https://doi.org/10.1016/j.celrep.2015.04.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4440852/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25959818/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Rep.&amp;title=Direct%20Activation%20of%20STING%20in%20the%20Tumor%20Microenvironment%20Leads%20to%20Potent%20and%20Systemic%20Tumor%20Regression%20and%20Immunity&amp;author=L.%20Corrales&amp;author=L.%20H.%20Glickman&amp;author=S.%20M.%20McWhirter&amp;author=D.%20B.%20Kanne&amp;author=K.%20E.%20Sivick&amp;volume=11&amp;issue=7&amp;publication_year=2015&amp;pages=1018-1030&amp;pmid=25959818&amp;doi=10.1016/j.celrep.2015.04.031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref21">
<cite>Kato K., Nishimasu H., Oikawa D., Hirano S., Hirano H., Kasuya G., Ishitani R., Tokunaga F., Nureki O.. Structural
Insights into CGAMP Degradation by Ecto-Nucleotide Pyrophosphatase
Phosphodiesterase 1. Nat. Commun. 2018;9(1):4424. doi: 10.1038/s41467-018-06922-7.</cite> [<a href="https://doi.org/10.1038/s41467-018-06922-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6200793/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30356045/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Structural%20Insights%20into%20CGAMP%20Degradation%20by%20Ecto-Nucleotide%20Pyrophosphatase%20Phosphodiesterase%201&amp;author=K.%20Kato&amp;author=H.%20Nishimasu&amp;author=D.%20Oikawa&amp;author=S.%20Hirano&amp;author=H.%20Hirano&amp;volume=9&amp;issue=1&amp;publication_year=2018&amp;pages=4424&amp;pmid=30356045&amp;doi=10.1038/s41467-018-06922-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref22">
<cite>Chang W., Altman M. D., Lesburg C. A., Perera S. A., Piesvaux J. A., Schroeder G. K., Wyss D. F., Cemerski S., Chen Y., DiNunzio E., Haidle A. M., Ho T., Kariv I., Knemeyer I., Kopinja J. E., Lacey B. M., Laskey J., Lim J., Long B. J., Ma Y., Maddess M. L., Pan B.-S., Presland J. P., Spooner E., Steinhuebel D., Truong Q., Zhang Z., Fu J., Addona G. H., Northrup A. B., Parmee E., Tata J. R., Bennett D. J., Cumming J. N., Siu T., Trotter B. W.. Discovery
of MK-1454:
A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist
for the Treatment of Cancer. J. Med. Chem. 2022;65(7):5675–5689. doi: 10.1021/acs.jmedchem.1c02197.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.1c02197" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35332774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Discovery%20of%20MK-1454:%20A%20Potent%20Cyclic%20Dinucleotide%20Stimulator%20of%20Interferon%20Genes%20Agonist%20for%20the%20Treatment%20of%20Cancer&amp;author=W.%20Chang&amp;author=M.%20D.%20Altman&amp;author=C.%20A.%20Lesburg&amp;author=S.%20A.%20Perera&amp;author=J.%20A.%20Piesvaux&amp;volume=65&amp;issue=7&amp;publication_year=2022&amp;pages=5675-5689&amp;pmid=35332774&amp;doi=10.1021/acs.jmedchem.1c02197&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref23">
<cite>Kuttruff C. A., Fleck M., Carotta S., Arnhof H., Bretschneider T., Dahmann G., Gremel G., Grube A., Handschuh S., Heimann A., Hofmann M. H., Impagnatiello M. A., Nar H., Rast G., Schaaf O., Schmidt E., Oost T.. Discovery
of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum
Variant Activity for the Treatment of Cancer. J. Med. Chem. 2023;66(14):9376–9400. doi: 10.1021/acs.jmedchem.3c00510.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.3c00510" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37450324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Discovery%20of%20BI%207446:%20A%20Potent%20Cyclic%20Dinucleotide%20STING%20Agonist%20with%20Broad-Spectrum%20Variant%20Activity%20for%20the%20Treatment%20of%20Cancer&amp;author=C.%20A.%20Kuttruff&amp;author=M.%20Fleck&amp;author=S.%20Carotta&amp;author=H.%20Arnhof&amp;author=T.%20Bretschneider&amp;volume=66&amp;issue=14&amp;publication_year=2023&amp;pages=9376-9400&amp;pmid=37450324&amp;doi=10.1021/acs.jmedchem.3c00510&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref24">
<cite>Dejmek M., Brazdova A., Otava T., Polidarova M. P., Klíma M., Smola M., Vavrina Z., Buděšínský M., Dračínský M., Liboska R., Boura E., Birkuš G., Nencka R.. Vinylphosphonate-Based Cyclic Dinucleotides
Enhance STING-Mediated Cancer Immunotherapy. Eur. J. Med. Chem. 2023;259:115685. doi: 10.1016/j.ejmech.2023.115685.</cite> [<a href="https://doi.org/10.1016/j.ejmech.2023.115685" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37567057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Med.%20Chem.&amp;title=Vinylphosphonate-Based%20Cyclic%20Dinucleotides%20Enhance%20STING-Mediated%20Cancer%20Immunotherapy&amp;author=M.%20Dejmek&amp;author=A.%20Brazdova&amp;author=T.%20Otava&amp;author=M.%20P.%20Polidarova&amp;author=M.%20Kl%C3%ADma&amp;volume=259&amp;publication_year=2023&amp;pages=115685&amp;pmid=37567057&amp;doi=10.1016/j.ejmech.2023.115685&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref25">
<cite>Halbritter A. L. J., Gärtner Y. V., Nabiev J., Hernichel F., Ganazzoli G., Özdemir D., Pappa A., Veth S., Stazzoni S., Müller M., Hornung V.. et al. A Phosphotriester-Masked
Dideoxy-cGAMP Derivative as a Cell-Permeable STING Agonist. Angew. Chem., Int. Ed. 2024;63(52):e202416353.  doi: 10.1002/anie.202416353.</cite> [<a href="https://doi.org/10.1002/anie.202416353" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11656140/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39531199/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Angew.%20Chem.,%20Int.%20Ed.&amp;title=A%20Phosphotriester-Masked%20Dideoxy-cGAMP%20Derivative%20as%20a%20Cell-Permeable%20STING%20Agonist&amp;author=A.%20L.%20J.%20Halbritter&amp;author=Y.%20V.%20G%C3%A4rtner&amp;author=J.%20Nabiev&amp;author=F.%20Hernichel&amp;author=G.%20Ganazzoli&amp;volume=63&amp;issue=52&amp;publication_year=2024&amp;pages=e202416353&amp;pmid=39531199&amp;doi=10.1002/anie.202416353&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref26">
<cite>Vyskocil S., Cardin D., Ciavarri J., Conlon J., Cullis C., England D., Gershman R., Gigstad K., Gipson K., Gould A., Greenspan P.. et al. Identification of novel
carbocyclic pyrimidine cyclic dinucleotide STING agonists for antitumor
immunotherapy using systemic intravenous route. J. Med. Chem. 2021;64(10):6902–6923. doi: 10.1021/acs.jmedchem.1c00374.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.1c00374" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34000802/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Identification%20of%20novel%20carbocyclic%20pyrimidine%20cyclic%20dinucleotide%20STING%20agonists%20for%20antitumor%20immunotherapy%20using%20systemic%20intravenous%20route&amp;author=S.%20Vyskocil&amp;author=D.%20Cardin&amp;author=J.%20Ciavarri&amp;author=J.%20Conlon&amp;author=C.%20Cullis&amp;volume=64&amp;issue=10&amp;publication_year=2021&amp;pages=6902-6923&amp;pmid=34000802&amp;doi=10.1021/acs.jmedchem.1c00374&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref27">
<cite>Klima M., Dejmek M., Duchoslav V., Eisenreichova A., Sala M., Chalupsky K., Chalupska D., Novotná B., Birkuš G., Nencka R., Boura E.. Fluorinated
cGAMP analogs, which act as STING agonists and are not cleavable by
poxins: Structural basis of their function. Structure. 2024;32(4):433–439. doi: 10.1016/j.str.2024.01.008.</cite> [<a href="https://doi.org/10.1016/j.str.2024.01.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38325369/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Structure&amp;title=Fluorinated%20cGAMP%20analogs,%20which%20act%20as%20STING%20agonists%20and%20are%20not%20cleavable%20by%20poxins:%20Structural%20basis%20of%20their%20function&amp;author=M.%20Klima&amp;author=M.%20Dejmek&amp;author=V.%20Duchoslav&amp;author=A.%20Eisenreichova&amp;author=M.%20Sala&amp;volume=32&amp;issue=4&amp;publication_year=2024&amp;pages=433-439&amp;pmid=38325369&amp;doi=10.1016/j.str.2024.01.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref28">
<cite>Marabelle A., Andtbacka R., Harrington K., Melero I., Leidner R., de Baere T., Robert C., Ascierto P. A., Baurain J.-F., Imperiale M., Rahimian S., Tersago D., Klumper E., Hendriks M., Kumar R., Stern M., Öhrling K., Massacesi C., Tchakov I., Tse A., Douillard J.-Y., Tabernero J., Haanen J., Brody J.. Starting the Fight
in the Tumor: Expert Recommendations for the Development of Human
Intratumoral Immunotherapy (HIT-IT) Ann. Oncol. 2018;29(11):2163–2174. doi: 10.1093/annonc/mdy423.</cite> [<a href="https://doi.org/10.1093/annonc/mdy423" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6290929/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30295695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=Starting%20the%20Fight%20in%20the%20Tumor:%20Expert%20Recommendations%20for%20the%20Development%20of%20Human%20Intratumoral%20Immunotherapy%20(HIT-IT)&amp;author=A.%20Marabelle&amp;author=R.%20Andtbacka&amp;author=K.%20Harrington&amp;author=I.%20Melero&amp;author=R.%20Leidner&amp;volume=29&amp;issue=11&amp;publication_year=2018&amp;pages=2163-2174&amp;pmid=30295695&amp;doi=10.1093/annonc/mdy423&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref29">
<cite>Sivick K. E., Desbien A. L., Glickman L. H., Reiner G. L., Corrales L., Surh N. H., Hudson T. E., Vu U. T., Francica B. J., Banda T., Katibah G. E., Kanne D. B., Leong J. J., Metchette K., Bruml J. R., Ndubaku C. O., McKenna J. M., Feng Y., Zheng L., Bender S. L., Cho C. Y., Leong M. L., van Elsas A., Dubensky T. W. Jr., McWhirter S. M.. Magnitude
of Therapeutic STING Activation Determines
CD8+ T Cell-Mediated Anti-Tumor Immunity. Cell. Rep. 2018;25(11):3074–3085e5. doi: 10.1016/j.celrep.2018.11.047.</cite> [<a href="https://doi.org/10.1016/j.celrep.2018.11.047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30540940/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell.%20Rep.&amp;title=Magnitude%20of%20Therapeutic%20STING%20Activation%20Determines%20CD8+%20T%20Cell-Mediated%20Anti-Tumor%20Immunity&amp;author=K.%20E.%20Sivick&amp;author=A.%20L.%20Desbien&amp;author=L.%20H.%20Glickman&amp;author=G.%20L.%20Reiner&amp;author=L.%20Corrales&amp;volume=25&amp;issue=11&amp;publication_year=2018&amp;pages=3074-3085e5&amp;pmid=30540940&amp;doi=10.1016/j.celrep.2018.11.047&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref30">
<cite>Yeboah S. K., Sintim H. O.. PDE-Stable 2′3′-CGAMP
Analogues, Containing
5′-S-Phosphorothioester Linkage, as STING Agonists. RSC Med. Chem. 2024;15(5):1508–1514. doi: 10.1039/D3MD00593C.</cite> [<a href="https://doi.org/10.1039/D3MD00593C" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11110794/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38784462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RSC%20Med.%20Chem.&amp;title=PDE-Stable%202%E2%80%B23%E2%80%B2-CGAMP%20Analogues,%20Containing%205%E2%80%B2-S-Phosphorothioester%20Linkage,%20as%20STING%20Agonists&amp;author=S.%20K.%20Yeboah&amp;author=H.%20O.%20Sintim&amp;volume=15&amp;issue=5&amp;publication_year=2024&amp;pages=1508-1514&amp;pmid=38784462&amp;doi=10.1039/D3MD00593C&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref31">
<cite>Yeboah S. K., Zigli A., Sintim H. O.. 2’,4’-LNA-Functionalized
5′-S-Phosphorothioester CDNs as STING Agonists. ChemBioChem. 2024;25(13):e202400321.  doi: 10.1002/cbic.202400321.</cite> [<a href="https://doi.org/10.1002/cbic.202400321" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38720428/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ChemBioChem&amp;title=2%E2%80%99,4%E2%80%99-LNA-Functionalized%205%E2%80%B2-S-Phosphorothioester%20CDNs%20as%20STING%20Agonists&amp;author=S.%20K.%20Yeboah&amp;author=A.%20Zigli&amp;author=H.%20O.%20Sintim&amp;volume=25&amp;issue=13&amp;publication_year=2024&amp;pages=e202400321&amp;pmid=38720428&amp;doi=10.1002/cbic.202400321&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref32">
<cite>Kong X., Zuo H., Huang H.-D., Zhang Q., Chen J., He C., Hu Y.. STING as an Emerging Therapeutic Target for Drug Discovery: Perspectives
from the Global Patent Landscape. J. Adv. Res. 2023;44:119–133. doi: 10.1016/j.jare.2022.05.006.</cite> [<a href="https://doi.org/10.1016/j.jare.2022.05.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9936525/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35636721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Adv.%20Res.&amp;title=STING%20as%20an%20Emerging%20Therapeutic%20Target%20for%20Drug%20Discovery:%20Perspectives%20from%20the%20Global%20Patent%20Landscape&amp;author=X.%20Kong&amp;author=H.%20Zuo&amp;author=H.-D.%20Huang&amp;author=Q.%20Zhang&amp;author=J.%20Chen&amp;volume=44&amp;publication_year=2023&amp;pages=119-133&amp;pmid=35636721&amp;doi=10.1016/j.jare.2022.05.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref33">
<cite>Kodra J. T., Kehler J., Dahl O.. Stability
of Oligodeoxynucleoside
Phosphorodithioates and Phosphorothioates in Aqueous Ammonia. Nucleic Acids Res. 1995;23(16):3349. doi: 10.1093/nar/23.16.3349.</cite> [<a href="https://doi.org/10.1093/nar/23.16.3349" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC307200/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7667115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res.&amp;title=Stability%20of%20Oligodeoxynucleoside%20Phosphorodithioates%20and%20Phosphorothioates%20in%20Aqueous%20Ammonia&amp;author=J.%20T.%20Kodra&amp;author=J.%20Kehler&amp;author=O.%20Dahl&amp;volume=23&amp;issue=16&amp;publication_year=1995&amp;pages=3349&amp;pmid=7667115&amp;doi=10.1093/nar/23.16.3349&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref34">
<cite>Habuchi T., Terao Y., Utsugi M.. A Robust Method
Using Reducing Inorganic
Salts for Preventing the Desulfurization of Phosphorothioate Oligonucleotides
during the Cleavage and Deprotection Step. Tetrahedron
Lett. 2023;133:154843. doi: 10.1016/j.tetlet.2023.154843.</cite> [<a href="https://doi.org/10.1016/j.tetlet.2023.154843" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tetrahedron%20Lett.&amp;title=A%20Robust%20Method%20Using%20Reducing%20Inorganic%20Salts%20for%20Preventing%20the%20Desulfurization%20of%20Phosphorothioate%20Oligonucleotides%20during%20the%20Cleavage%20and%20Deprotection%20Step&amp;author=T.%20Habuchi&amp;author=Y.%20Terao&amp;author=M.%20Utsugi&amp;volume=133&amp;publication_year=2023&amp;pages=154843&amp;doi=10.1016/j.tetlet.2023.154843&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref35">
<cite>Wang J., Zhou J., Donaldson G. P., Nakayama S., Yan L., Lam Y., Lee V. T., Sintim H. O.. Conservative Change to the Phosphate
Moiety of Cyclic Diguanylic Monophosphate Remarkably Affects Its Polymorphism
and Ability To Bind DGC, PDE, and PilZ Proteins. J. Am. Chem. Soc. 2011;133(24):9320–9330. doi: 10.1021/ja1112029.</cite> [<a href="https://doi.org/10.1021/ja1112029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21612220/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Am.%20Chem.%20Soc.&amp;title=Conservative%20Change%20to%20the%20Phosphate%20Moiety%20of%20Cyclic%20Diguanylic%20Monophosphate%20Remarkably%20Affects%20Its%20Polymorphism%20and%20Ability%20To%20Bind%20DGC,%20PDE,%20and%20PilZ%20Proteins&amp;author=J.%20Wang&amp;author=J.%20Zhou&amp;author=G.%20P.%20Donaldson&amp;author=S.%20Nakayama&amp;author=L.%20Yan&amp;volume=133&amp;issue=24&amp;publication_year=2011&amp;pages=9320-9330&amp;pmid=21612220&amp;doi=10.1021/ja1112029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref36">
<cite>Zhou J., Sayre D. A., Wang J., Pahadi N., Sintim H. O.. Endo-S-c-Di-GMP
Analogues-Polymorphism and Binding Studies with Class I Riboswitch. Molecules. 2012;17:13376–13389. doi: 10.3390/molecules171113376.</cite> [<a href="https://doi.org/10.3390/molecules171113376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6269045/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23143150/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecules&amp;title=Endo-S-c-Di-GMP%20Analogues-Polymorphism%20and%20Binding%20Studies%20with%20Class%20I%20Riboswitch&amp;author=J.%20Zhou&amp;author=D.%20A.%20Sayre&amp;author=J.%20Wang&amp;author=N.%20Pahadi&amp;author=H.%20O.%20Sintim&amp;volume=17&amp;publication_year=2012&amp;pages=13376-13389&amp;pmid=23143150&amp;doi=10.3390/molecules171113376&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref37">
<cite>Karanja C. W., Yeboah K. S., Ong W. W. S., Sintim H. O.. A STING-Based Fluorescent
Polarization Assay for Monitoring Activities of Cyclic Dinucleotide
Metabolizing Enzymes. RSC Chem. Biol. 2021;2(1):206–214. doi: 10.1039/D0CB00187B.</cite> [<a href="https://doi.org/10.1039/D0CB00187B" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8341399/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34458783/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RSC%20Chem.%20Biol.&amp;title=A%20STING-Based%20Fluorescent%20Polarization%20Assay%20for%20Monitoring%20Activities%20of%20Cyclic%20Dinucleotide%20Metabolizing%20Enzymes&amp;author=C.%20W.%20Karanja&amp;author=K.%20S.%20Yeboah&amp;author=W.%20W.%20S.%20Ong&amp;author=H.%20O.%20Sintim&amp;volume=2&amp;issue=1&amp;publication_year=2021&amp;pages=206-214&amp;pmid=34458783&amp;doi=10.1039/D0CB00187B&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref38">
<cite>Lioux T., Mauny M.-A., Lamoureux A., Bascoul N., Hays M., Vernejoul F., Baudru A.-S., Boularan C., Lopes-Vicente J., Qushair G., Tiraby G.. Design, Synthesis, and Biological
Evaluation of Novel Cyclic Adenosine–Inosine Monophosphate
(CAIMP) Analogs That Activate Stimulator of Interferon Genes (STING) J. Med. Chem. 2016;59(22):10253–10267. doi: 10.1021/acs.jmedchem.6b01300.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.6b01300" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27783523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Design,%20Synthesis,%20and%20Biological%20Evaluation%20of%20Novel%20Cyclic%20Adenosine%E2%80%93Inosine%20Monophosphate%20(CAIMP)%20Analogs%20That%20Activate%20Stimulator%20of%20Interferon%20Genes%20(STING)&amp;author=T.%20Lioux&amp;author=M.-A.%20Mauny&amp;author=A.%20Lamoureux&amp;author=N.%20Bascoul&amp;author=M.%20Hays&amp;volume=59&amp;issue=22&amp;publication_year=2016&amp;pages=10253-10267&amp;pmid=27783523&amp;doi=10.1021/acs.jmedchem.6b01300&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref39">
<cite>Pimková
Polidarová M., Břehová P., Kaiser M. M., Smola M., Dračínský M., Smith J., Marek A., Dejmek M., Šála M., Gutten O., Rulíšek L., Novotná B., Brázdová A., Janeba Z., Nencka R., Boura E., Páv O., Birkuš G.. Synthesis
and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs
of STING Agonist 3′,3′-c-Di­(2′F,2′dAMP) J. Med. Chem. 2021;64(11):7596–7616. doi: 10.1021/acs.jmedchem.1c00301.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.1c00301" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34019405/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Synthesis%20and%20Biological%20Evaluation%20of%20Phosphoester%20and%20Phosphorothioate%20Prodrugs%20of%20STING%20Agonist%203%E2%80%B2,3%E2%80%B2-c-Di%C2%AD(2%E2%80%B2F,2%E2%80%B2dAMP)&amp;author=M.%20Pimkov%C3%A1%20Polidarov%C3%A1&amp;author=P.%20B%C5%99ehov%C3%A1&amp;author=M.%20M.%20Kaiser&amp;author=M.%20Smola&amp;author=M.%20Dra%C4%8D%C3%ADnsk%C3%BD&amp;volume=64&amp;issue=11&amp;publication_year=2021&amp;pages=7596-7616&amp;pmid=34019405&amp;doi=10.1021/acs.jmedchem.1c00301&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref40">
<cite>Ritchie C., Cordova A. F., Hess G. T., Bassik M. C., Li L.. SLC19A1 Is
an Importer of the Immunotransmitter cGAMP. Mol. Cell. 2019;75(2):372–381. doi: 10.1016/j.molcel.2019.05.006.</cite> [<a href="https://doi.org/10.1016/j.molcel.2019.05.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6711396/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31126740/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cell&amp;title=SLC19A1%20Is%20an%20Importer%20of%20the%20Immunotransmitter%20cGAMP&amp;author=C.%20Ritchie&amp;author=A.%20F.%20Cordova&amp;author=G.%20T.%20Hess&amp;author=M.%20C.%20Bassik&amp;author=L.%20Li&amp;volume=75&amp;issue=2&amp;publication_year=2019&amp;pages=372-381&amp;pmid=31126740&amp;doi=10.1016/j.molcel.2019.05.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref41">
<cite>Cordova A. F., Ritchie C., Böhnert V., Li L.. Human SLC46A2 Is the
Dominant CGAMP Importer in Extracellular CGAMP-Sensing Macrophages
and Monocytes. ACS Cent. Sci. 2021;7(6):1073–1088. doi: 10.1021/acscentsci.1c00440.</cite> [<a href="https://doi.org/10.1021/acscentsci.1c00440" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8228594/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34235268/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ACS%20Cent.%20Sci.&amp;title=Human%20SLC46A2%20Is%20the%20Dominant%20CGAMP%20Importer%20in%20Extracellular%20CGAMP-Sensing%20Macrophages%20and%20Monocytes&amp;author=A.%20F.%20Cordova&amp;author=C.%20Ritchie&amp;author=V.%20B%C3%B6hnert&amp;author=L.%20Li&amp;volume=7&amp;issue=6&amp;publication_year=2021&amp;pages=1073-1088&amp;pmid=34235268&amp;doi=10.1021/acscentsci.1c00440&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref42">
<cite>Lahey L. J., Mardjuki R. E., Wen X., Hess G. T., Ritchie C., Carozza J. A., Böhnert V., Maduke M., Bassik M. C., Li L.. LRRC8A:C/E Heteromeric
Channels Are Ubiquitous Transporters of cGAMP. Mol. Cell. 2020;80(4):578–591. doi: 10.1016/j.molcel.2020.10.021.</cite> [<a href="https://doi.org/10.1016/j.molcel.2020.10.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33171122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cell&amp;title=LRRC8A:C/E%20Heteromeric%20Channels%20Are%20Ubiquitous%20Transporters%20of%20cGAMP&amp;author=L.%20J.%20Lahey&amp;author=R.%20E.%20Mardjuki&amp;author=X.%20Wen&amp;author=G.%20T.%20Hess&amp;author=C.%20Ritchie&amp;volume=80&amp;issue=4&amp;publication_year=2020&amp;pages=578-591&amp;pmid=33171122&amp;doi=10.1016/j.molcel.2020.10.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref43">
<cite>Yin L., Adraina J. A., Bernadette M., Dan Y., Suzanne E. R., Gina A. M. S., Klaus T., Helmut W.. et al. Activated
STING in a Vascular and Pulmonary Syndrome. N. Engl. J. Med. 2024;371(6):507–518. doi: 10.1056/NEJMoa1312625.</cite> [<a href="https://doi.org/10.1056/NEJMoa1312625" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4174543/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25029335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Activated%20STING%20in%20a%20Vascular%20and%20Pulmonary%20Syndrome&amp;author=L.%20Yin&amp;author=J.%20A.%20Adraina&amp;author=M.%20Bernadette&amp;author=Y.%20Dan&amp;author=E.%20R.%20Suzanne&amp;volume=371&amp;issue=6&amp;publication_year=2024&amp;pages=507-518&amp;pmid=25029335&amp;doi=10.1056/NEJMoa1312625&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref44">
<cite>Liu J., Li F., Ping Y., Wang L., Chen X., Wang D., Cao L., Zhao S., Li B., Kalinski P., Thorne S. H., Zhang B., Zhang Y.. Local Production of the Chemokines
CCL5 and CXCL10 Attracts CD8 + T Lymphocytes into Esophageal Squamous
Cell Carcinoma. Oncotarget. 2015;6(28):24978. doi: 10.18632/oncotarget.4617.</cite> [<a href="https://doi.org/10.18632/oncotarget.4617" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4694808/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26317795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Local%20Production%20of%20the%20Chemokines%20CCL5%20and%20CXCL10%20Attracts%20CD8%20+%20T%20Lymphocytes%20into%20Esophageal%20Squamous%20Cell%20Carcinoma&amp;author=J.%20Liu&amp;author=F.%20Li&amp;author=Y.%20Ping&amp;author=L.%20Wang&amp;author=X.%20Chen&amp;volume=6&amp;issue=28&amp;publication_year=2015&amp;pages=24978&amp;pmid=26317795&amp;doi=10.18632/oncotarget.4617&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref45">
<cite>Tokunaga R., Zhang W., Naseem M., Puccini A., Berger M. D., Soni S., McSkane M., Baba H., Lenz H.-J.. CXCL9,
CXCL10, CXCL11/CXCR3 Axis for Immune Activation – A Target
for Novel Cancer Therapy. Cancer Treat. Rev. 2018;63:40–47. doi: 10.1016/j.ctrv.2017.11.007.</cite> [<a href="https://doi.org/10.1016/j.ctrv.2017.11.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5801162/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29207310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Treat.%20Rev.&amp;title=CXCL9,%20CXCL10,%20CXCL11/CXCR3%20Axis%20for%20Immune%20Activation%20%E2%80%93%20A%20Target%20for%20Novel%20Cancer%20Therapy&amp;author=R.%20Tokunaga&amp;author=W.%20Zhang&amp;author=M.%20Naseem&amp;author=A.%20Puccini&amp;author=M.%20D.%20Berger&amp;volume=63&amp;publication_year=2018&amp;pages=40-47&amp;pmid=29207310&amp;doi=10.1016/j.ctrv.2017.11.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref46">
<cite>Larkin B., Ilyukha V., Sorokin M., Buzdin A., Vannier E., Poltorak A.. Cutting Edge: Activation
of STING in T Cells Induces
Type I IFN Responses and Cell Death. J. Immunol. 2017;199(2):397–402. doi: 10.4049/jimmunol.1601999.</cite> [<a href="https://doi.org/10.4049/jimmunol.1601999" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5525333/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28615418/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunol.&amp;title=Cutting%20Edge:%20Activation%20of%20STING%20in%20T%20Cells%20Induces%20Type%20I%20IFN%20Responses%20and%20Cell%20Death&amp;author=B.%20Larkin&amp;author=V.%20Ilyukha&amp;author=M.%20Sorokin&amp;author=A.%20Buzdin&amp;author=E.%20Vannier&amp;volume=199&amp;issue=2&amp;publication_year=2017&amp;pages=397-402&amp;pmid=28615418&amp;doi=10.4049/jimmunol.1601999&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref47">
<cite>Gaffney B. L., Veliath E., Zhao J., Jones R. A.. One-Flask Syntheses
of c-Di-GMP and the [Rp,Rp] and [Rp,Sp] Thiophosphate Analogues. Org. Lett. 2010;12(14):3269–3271. doi: 10.1021/ol101236b.</cite> [<a href="https://doi.org/10.1021/ol101236b" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2905038/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20572672/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Org.%20Lett.&amp;title=One-Flask%20Syntheses%20of%20c-Di-GMP%20and%20the%20%5BRp,Rp%5D%20and%20%5BRp,Sp%5D%20Thiophosphate%20Analogues&amp;author=B.%20L.%20Gaffney&amp;author=E.%20Veliath&amp;author=J.%20Zhao&amp;author=R.%20A.%20Jones&amp;volume=12&amp;issue=14&amp;publication_year=2010&amp;pages=3269-3271&amp;pmid=20572672&amp;doi=10.1021/ol101236b&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref48">
<cite>Smietana M., Johnson R. B., Wang Q. M., Kool E. T.. Solid-Phase Synthesis
and Screening of Macrocyclic Nucleotide-Hybrid Compounds Targeted
to Hepatitis C NS5B. Chem. Eur. J. 2004;10(1):173–181. doi: 10.1002/chem.200305402.</cite> [<a href="https://doi.org/10.1002/chem.200305402" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14695562/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chem.%20Eur.%20J.&amp;title=Solid-Phase%20Synthesis%20and%20Screening%20of%20Macrocyclic%20Nucleotide-Hybrid%20Compounds%20Targeted%20to%20Hepatitis%20C%20NS5B&amp;author=M.%20Smietana&amp;author=R.%20B.%20Johnson&amp;author=Q.%20M.%20Wang&amp;author=E.%20T.%20Kool&amp;volume=10&amp;issue=1&amp;publication_year=2004&amp;pages=173-181&amp;pmid=14695562&amp;doi=10.1002/chem.200305402&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref49">
<cite>Xie W., Lama L., Yang X., Kuryavyi V., Bhattacharya S., Nudelman I., Yang G., Ouerfelli O., Glickman J. F., Jones R. A., Tuschl T., Patel D. J.. Arabinose-
and Xylose-Modified Analogs of 2′,3′-CGAMP Act as STING
Agonists. Cell Chem. Biol. 2023;30(11):1366–1376. doi: 10.1016/j.chembiol.2023.07.002.</cite> [<a href="https://doi.org/10.1016/j.chembiol.2023.07.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10808274/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37536341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Chem.%20Biol.&amp;title=Arabinose-%20and%20Xylose-Modified%20Analogs%20of%202%E2%80%B2,3%E2%80%B2-CGAMP%20Act%20as%20STING%20Agonists&amp;author=W.%20Xie&amp;author=L.%20Lama&amp;author=X.%20Yang&amp;author=V.%20Kuryavyi&amp;author=S.%20Bhattacharya&amp;volume=30&amp;issue=11&amp;publication_year=2023&amp;pages=1366-1376&amp;pmid=37536341&amp;doi=10.1016/j.chembiol.2023.07.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref50">
<cite>Jekle A., Thatikonda S. K., Jaisinghani R., Ren S., Kinkade A., Stevens S. K., Stoycheva A., Rajwanshi V. K., Williams C., Deval J., Mukherjee S.. et al. Tumor regression upon intratumoral and subcutaneous
dosing of the
STING agonist ALG-031048 in mouse efficacy models. Int. J. Mol. Sci. 2023;24(22):16274. doi: 10.3390/ijms242216274.</cite> [<a href="https://doi.org/10.3390/ijms242216274" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10671074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38003463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=Tumor%20regression%20upon%20intratumoral%20and%20subcutaneous%20dosing%20of%20the%20STING%20agonist%20ALG-031048%20in%20mouse%20efficacy%20models&amp;author=A.%20Jekle&amp;author=S.%20K.%20Thatikonda&amp;author=R.%20Jaisinghani&amp;author=S.%20Ren&amp;author=A.%20Kinkade&amp;volume=24&amp;issue=22&amp;publication_year=2023&amp;pages=16274&amp;pmid=38003463&amp;doi=10.3390/ijms242216274&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref51">
<cite>Meric-Bernstam F., Sweis R. F., Hodi F. S., Messersmith W. A., Andtbacka R. H., Ingham M., Lewis N., Chen X., Pelletier M., Chen X., Wu J.. et al. Phase
I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING
agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clin. Cancer Res. 2022;28(4):677–688. doi: 10.1158/1078-0432.ccr-21-1963.</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-21-1963" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34716197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Phase%20I%20dose-escalation%20trial%20of%20MIW815%20(ADU-S100),%20an%20intratumoral%20STING%20agonist,%20in%20patients%20with%20advanced/metastatic%20solid%20tumors%20or%20lymphomas&amp;author=F.%20Meric-Bernstam&amp;author=R.%20F.%20Sweis&amp;author=F.%20S.%20Hodi&amp;author=W.%20A.%20Messersmith&amp;author=R.%20H.%20Andtbacka&amp;volume=28&amp;issue=4&amp;publication_year=2022&amp;pages=677-688&amp;pmid=34716197&amp;doi=10.1158/1078-0432.ccr-21-1963&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref52">
<cite>Meric-Bernstam F., Sweis R. F., Hodi F. S., Messersmith W. A., Andtbacka R. H., Ingham M., Lewis N., Chen X., Pelletier M., Chen X., Wu J.. et al. Correction:
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral
STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or
Lymphomas. Clin. Cancer Res. 2023;29(12):2336. doi: 10.1158/1078-0432.CCR-23-1170.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-23-1170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37309603/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Correction:%20Phase%20I%20Dose-Escalation%20Trial%20of%20MIW815%20(ADU-S100),%20an%20Intratumoral%20STING%20Agonist,%20in%20Patients%20with%20Advanced/Metastatic%20Solid%20Tumors%20or%20Lymphomas&amp;author=F.%20Meric-Bernstam&amp;author=R.%20F.%20Sweis&amp;author=F.%20S.%20Hodi&amp;author=W.%20A.%20Messersmith&amp;author=R.%20H.%20Andtbacka&amp;volume=29&amp;issue=12&amp;publication_year=2023&amp;pages=2336&amp;pmid=37309603&amp;doi=10.1158/1078-0432.CCR-23-1170&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref53">
<cite>Chin E. N., Yu C., Vartabedian V. F., Jia Y., Kumar M., Gamo A. M., Vernier W., Ali S. H., Kissai M., Lazar D. C., Nguyen N.. et al. Antitumor
activity of
a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020;369(6506):993–999. doi: 10.1126/science.abb4255.</cite> [<a href="https://doi.org/10.1126/science.abb4255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32820126/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Antitumor%20activity%20of%20a%20systemic%20STING-activating%20non-nucleotide%20cGAMP%20mimetic&amp;author=E.%20N.%20Chin&amp;author=C.%20Yu&amp;author=V.%20F.%20Vartabedian&amp;author=Y.%20Jia&amp;author=M.%20Kumar&amp;volume=369&amp;issue=6506&amp;publication_year=2020&amp;pages=993-999&amp;pmid=32820126&amp;doi=10.1126/science.abb4255&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref54">
<cite>Wang Q., Bergholz J. S., Ding L., Lin Z., Kabraji S. K., Hughes M. E., He X., Xie S., Jiang T., Wang W., Zoeller J. J.. et al. STING agonism reprograms
tumor-associated macrophages and overcomes resistance to PARP inhibition
in BRCA1-deficient models of breast cancer. Nat. Commun. 2022;13(1):3022. doi: 10.1038/s41467-022-30568-1.</cite> [<a href="https://doi.org/10.1038/s41467-022-30568-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9156717/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35641483/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=STING%20agonism%20reprograms%20tumor-associated%20macrophages%20and%20overcomes%20resistance%20to%20PARP%20inhibition%20in%20BRCA1-deficient%20models%20of%20breast%20cancer&amp;author=Q.%20Wang&amp;author=J.%20S.%20Bergholz&amp;author=L.%20Ding&amp;author=Z.%20Lin&amp;author=S.%20K.%20Kabraji&amp;volume=13&amp;issue=1&amp;publication_year=2022&amp;pages=3022&amp;pmid=35641483&amp;doi=10.1038/s41467-022-30568-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref55">
<cite>Ni H., Zhang H., Li L., Huang H., Guo H., Zhang L., Li C., Xu J. X., Nie C. P., Li K., Zhang X.. et al. T cell-intrinsic STING signaling promotes regulatory
T cell induction and immunosuppression by upregulating FOXP3 transcription
in cervical cancer. J. Immunother. Cancer. 2022;10(9):e005151.  doi: 10.1136/jitc-2022-005151.</cite> [<a href="https://doi.org/10.1136/jitc-2022-005151" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9490630/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36126994/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=T%20cell-intrinsic%20STING%20signaling%20promotes%20regulatory%20T%20cell%20induction%20and%20immunosuppression%20by%20upregulating%20FOXP3%20transcription%20in%20cervical%20cancer&amp;author=H.%20Ni&amp;author=H.%20Zhang&amp;author=L.%20Li&amp;author=H.%20Huang&amp;author=H.%20Guo&amp;volume=10&amp;issue=9&amp;publication_year=2022&amp;pages=e005151&amp;pmid=36126994&amp;doi=10.1136/jitc-2022-005151&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref56">
<cite>Gulen M. F., Koch U., Haag S. M., Schuler F., Apetoh L., Villunger A., Radtke F., Ablasser A.. Signalling strength
determines proapoptotic functions of STING. Nat. Commun. 2017;8(1):427. doi: 10.1038/s41467-017-00573-w.</cite> [<a href="https://doi.org/10.1038/s41467-017-00573-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5585373/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28874664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Signalling%20strength%20determines%20proapoptotic%20functions%20of%20STING&amp;author=M.%20F.%20Gulen&amp;author=U.%20Koch&amp;author=S.%20M.%20Haag&amp;author=F.%20Schuler&amp;author=L.%20Apetoh&amp;volume=8&amp;issue=1&amp;publication_year=2017&amp;pages=427&amp;pmid=28874664&amp;doi=10.1038/s41467-017-00573-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref57">
<cite>Cerboni S., Jeremiah N., Gentili M., Gehrmann U., Conrad C., Stolzenberg M. C., Picard C., Neven B., Fischer A., Amigorena S., Rieux-Laucat F.. et al. Intrinsic antiproliferative
activity of the innate sensor STING in T lymphocytes. J. Exp. Med. 2017;214(6):1769–1785. doi: 10.1084/jem.20161674.</cite> [<a href="https://doi.org/10.1084/jem.20161674" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5461003/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28484079/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Exp.%20Med.&amp;title=Intrinsic%20antiproliferative%20activity%20of%20the%20innate%20sensor%20STING%20in%20T%20lymphocytes&amp;author=S.%20Cerboni&amp;author=N.%20Jeremiah&amp;author=M.%20Gentili&amp;author=U.%20Gehrmann&amp;author=C.%20Conrad&amp;volume=214&amp;issue=6&amp;publication_year=2017&amp;pages=1769-1785&amp;pmid=28484079&amp;doi=10.1084/jem.20161674&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref58">
<cite>Li C., Zhang Y., Liu J., Kang R., Klionsky D. J., Tang D.. Mitochondrial DNA stress triggers autophagy-dependent ferroptotic
death. Autophagy. 2021;17(4):948–960. doi: 10.1080/15548627.2020.1739447.</cite> [<a href="https://doi.org/10.1080/15548627.2020.1739447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8078708/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32186434/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Autophagy&amp;title=Mitochondrial%20DNA%20stress%20triggers%20autophagy-dependent%20ferroptotic%20death&amp;author=C.%20Li&amp;author=Y.%20Zhang&amp;author=J.%20Liu&amp;author=R.%20Kang&amp;author=D.%20J.%20Klionsky&amp;volume=17&amp;issue=4&amp;publication_year=2021&amp;pages=948-960&amp;pmid=32186434&amp;doi=10.1080/15548627.2020.1739447&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref59">
<cite>Li C., Liu J., Hou W., Kang R., Tang D.. STING1 promotes
ferroptosis
through MFN1/2-dependent mitochondrial fusion. Front. Cell Dev. Biol. 2021;9:698679. doi: 10.3389/fcell.2021.698679.</cite> [<a href="https://doi.org/10.3389/fcell.2021.698679" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8236825/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34195205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Cell%20Dev.%20Biol.&amp;title=STING1%20promotes%20ferroptosis%20through%20MFN1/2-dependent%20mitochondrial%20fusion&amp;author=C.%20Li&amp;author=J.%20Liu&amp;author=W.%20Hou&amp;author=R.%20Kang&amp;author=D.%20Tang&amp;volume=9&amp;publication_year=2021&amp;pages=698679&amp;pmid=34195205&amp;doi=10.3389/fcell.2021.698679&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ol></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12371493/bin/bg5c00070_si_001.pdf" data-ga-action="click_feat_suppl" class="usa-link">bg5c00070_si_001.pdf</a><sup> (10.7MB, pdf) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from ACS Bio &amp; Med Chem Au are provided here courtesy of <strong>American Chemical Society</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1021/acsbiomedchemau.5c00070"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/bg5c00070.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (10.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12371493/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12371493/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12371493%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371493/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12371493/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12371493/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12371493/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12371493/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12371493/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="ioV9WEpOcXlAq0Qzz1EPbFfcsxIWJytytWowR4pwLjQGCPaolDbjYMAaVhgfGkye">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-574fdcc6.js"></script>
    
    

    </body>
</html>
